

**MONDAY, DECEMBER 5, 2016**

<b>P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</b>	
TOBACCO, RADON, AIR POLLUTION, OTHER RISK FACTORS	P1.01-001 - P1.01-014
PROTECTIVE FACTORS, RISK REDUCTION, SMOKING CESSATION	P1.01-015 - P1.01-026
LUNG CANCER SCREENING, DIAGNOSIS	P1.01-027 - P1.01-034
PROGNOSTIC FACTORS, TREATMENT	P1.01-035 - P1.01-051
DESCRIPTIVE EPIDEMIOLOGY	P1.01-052 - P1.01-059
<b>P1.02 BIOLOGY/PATHOLOGY</b>	
DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER	P1.02-001 - P1.02-061
OTHER MUTATIONS IN THORACIC MALIGNANCIES	P1.02-062 - P1.02-086
MISCELLANEOUS	P1.02-087
<b>P1.03 RADIOLOGY/STAGING/SCREENING</b>	
BIOLOGY	P1.03-001 - P1.03-007
PNEUMONOLOGY	P1.03-008 - P1.03-011
RADIOLOGY	P1.03-012 - P1.03-032
SCREENING	P1.03-033 - P1.03-064
STAGING	P1.03-065 - P1.03-084
<b>P1.04 PULMONOLOGY</b>	
PULMONOLOGY	P1.04-001 - P1.04-028
<b>P1.05 EARLY STAGE NSCLC</b>	
TRANSLATIONAL RESEARCH & BIOMARKERS	P1.05-001 - P1.05-028
SBRT	P1.05-029 - P1.05-035
SURGERY	P1.05-036 - P1.05-044
NEOADJUVANT AND ADJUVANT CHEMOTHERAPY	P1.05-045 - P1.05-054
RECURRENCE	P1.05-055 - P1.05-059
MISCELLANEOUS	P1.05-060 - P1.05-079
<b>P1.06 ADVANCED NSCLC &amp; CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</b>	
ADVANCED GENERAL	P1.06-001 - P1.06-045
ADVANCED ELDERLY	P1.06-046 - P1.06-047
<b>P1.07 SCLC/NEUROENDOCRINE TUMORS</b>	
DRUG TREATMENT ALONE AND IN COMBINATION WITH RADIOTHERAPY	P1.07-001 - P1.07-015
LOCAL TREATMENT	P1.07-016 - P1.07-022
MOLECULAR CHANGES	P1.07-023 - P1.07-035
PATHOLOGY	P1.07-036 - P1.07-039
PROGNOSTIC FACTORS	P1.07-040 - P1.07-043
SCLC/NEUROENDOCRINE TUMORS IN GENERAL	P1.07-044 - P1.07-055
<b>P1.08 SURGERY</b>	
RISK ASSESSMENT & PROGNOSTIC FACTORS	P1.08-001 - P1.08-024
EPIDEMIOLOGIC STUDIES IN SURGERY FOR NSCLC	P1.08-025 - P1.08-031
TRANSLATIONAL STUDIES	P1.08-032 - P1.08-035
MINIMAL INVASIVE SURGERY	P1.08-036 - P1.08-058
SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC	P1.08-059 - P1.08-083
MISCELLANEOUS	P1.08-084

## **Monday, December 5, 2016**

Poster Setup Time: Monday, December 5, 08:30 - 10:15

Poster Takedown Time: Monday, December 5, 15:45 - 18:00

(Posters not taken down by 18:00 will be discarded by management)

### **POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)**

Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.

Monday, December 5, 14:30 - 15:45 (Hall B - Poster Area)

## **P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION**

### **P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - TOBACCO, RADON, AIR POLLUTION, OTHER RISK FACTORS**

#### **P1.01-001: Reduction of Cigarette Consumption through a National Policy for Tobacco Control in Brazil**

Ana Paula Teixeira, National Cancer Institute-Ministry of Health, Brazil

#### **P1.01-002: Environmental Tobacco Smoke Exposure and EGFR Mutations/ALK Translocation in Never Smokers. A Multicentre Study in Spanish Never-Smokers**

Mónica Pérez-Ríos, University of Santiago de Compostela, Spain

#### **P1.01-003: Novel Associations between Lung Cancer-Related Genes and Indoor Radon Exposure**

Jung Ran Choi, Yonsei University Wonju College of Medicine, South Korea

#### **P1.01-004: Is There Any Role of Residential Radon in Non Small Cell Lung Cancer (NSCLC) Patients Harboring Molecular Alterations?**

Laura Mezquita, Gustave Roussy, France

#### **P1.01-005: First of Its Kind Study in India Finds That Government's Ban on Gutka (Highly Popular Smokeless Tobacco Product) DID NOT Increase Smoking at All**

Gaurav Kumar, GMERS Medical College, India

#### **P1.01-006: Interstitial Lung Diseases Are an Antecedent of Lung Cancer**

Wonil Choi, Keimyung University School of Medicine, South Korea

#### **P1.01-007: A Cross-Sectional Study on Tobacco Consumption Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India**

Delfin Lovelina Francis, Tagore Dental College and Hospital, India

#### **P1.01-008: Knowledge, Attitudes, and Smoking Behaviours among Dental and Medical Students in Chennai, Tamil Nadu, India**

Delfin Lovelina Francis, Tagore Dental College and Hospital, India

#### **P1.01-009: Smoking and Lung Cancer: Data from the Single Center in Albania**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

#### **P1.01-010: Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians**

Laurent Greillier, Hôpital Nord, France

**P1.01-011: Roflumilast Attenuates Benzo(a)Pyrene-Induced Lung Cancer via Suppression of Airway Inflammation in Murine Model**

Chang Dong Yeo, Catholic University of Korea, South Korea

**P1.01-012: Kava Effects on the Metabolism of Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Humans**

Drew Oostra, University of Minnesota, USA

**P1.01-013: Emphysematous Changes and Pulmonary Function for Asbestos-Related Lung Cancer in Japan**

Takumi Kishimoto, Okayama Rosai Hospital, Japan

**P1.01-014: The Role of Hereditary Factor, Profession and the Habit of Cigarette Smoking in Developing Lung Cancer**

Irina Pavlovska, Institute of Epidemiology and Biostatistics, Macedonia

**P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - PROTECTIVE FACTORS, RISK REDUCTION, SMOKING CESSATION**

**P1.01-015: Polyphenols-Rich Fruit Extracts Prevent Tobacco Specific Nitrosamine-Induced DNA Damage in Lung Epithelial Cells**

D.I.M. Amaratilaka, Dalhousie University, Canada

**P1.01-016: An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJov - CLICaP)**

Luis Corrales-Rodriguez, CIMCA / Hospital San Juan de Dios, Costa Rica

**P1.01-017: The Dramatic Shift of Lung Cancer toward Young in Prisons**

Luc Renault, Hospices Civils de Lyon, Hôpital Lyon Sud, France

**P1.01-018: Tobacco Use and Perceptions about Cessation Training among Health Professions Students: Estimates by Countries and WHO Regions**

Chandrashekhara Sreeramareddy, International Medical University, Malaysia

**P1.01-019: Integration of Tobacco Cessation Counseling in a Lung Screening Program**

Matthew Steliga, University of Arkansas for Medical Sciences, USA

**P1.01-020: Chemopreventive Effect of Catechin Hydrates against Benzo(a)Pyrene Induced Lung Carcinogenesis in Mice: Plausible Role of ALDH1**

Ayaz Shahid, Jamia Hamdard University, India

**P1.01-021: The Impact of Smoking Status on Overall Survival in a Population-Based Non-Small Cell Lung Cancer (NSCLC) Surgical Resection Cohort**

Nicholas Faris, Baptist Cancer Center, USA

**P1.01-022: Smoking Cessation Related to Lung Resection**

Tanel Laisaar, Tartu University, Estonia

**P1.01-023: Smoking Cessation before Initiation of Chemotherapy in Metastatic Non-Small Lung Cancer: Influence on Prognosis**

Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

**P1.01-024: University Students' Perceptions about Effectiveness of MPOWER Policies on Tobacco Control in Panama City Panama**

Omar Castillo-Fernandez, Instituto Oncologico Nacional, Panama

**P1.01-025: Mass Media and Tobacco in Bangladesh: An Investigation on the Role of Mass Media in the Light of Tobacco Control**

Tahsina Sadeque, Somoy Television, Bangladesh

**P1.01-026: Tobacco Use, Awareness and Cessation among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India**

Delfin Lovelina Francis, Tagore Dental College and Hospital, India

**P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - LUNG CANCER SCREENING, DIAGNOSIS**

**P1.01-027: Increased Risk of Lung Cancer among Women with Superficial TCC: A Potential Risk Cohort for Lung Cancer Screening**

Yaakov Tolwin, Tel Aviv University, Israel

**P1.01-028: High Risk Older Smokers' Perceptions, Attitudes and Beliefs About Lung Cancer Screening**

Janine Cataldo, University of California, San Francisco, USA

**P1.01-029: Personal and Hospital Factors Associated with Limited Surgical Resection, In-Hospital Mortality and Complications in New York State**

Wil Lieberman-Cribbin, Icahn School of Medicine at Mount Sinai, USA

**P1.01-030: Factors Associated with Margin Positive Resections for Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Region of the US**

Matthew Smeltzer, University of Memphis School of Public Health, USA

**P1.01-031: Does Malignant Pleural Mesothelioma (MPM) Behaviour Differ among Decades?**

Fatma Abou Elkasem, National Cancer Institute, Egypt

**P1.01-032: Emergency Department Visits by Lung Cancer Patients in Korea**

Dong Won Park, Hanyang University College of Medicine, South Korea

**P1.01-033: EGFR Mutation and ALK: Are Patients Being Adequately Tested in Brazil?**

Gilberto Lopes, Núcleo de Oncologia da Bahia, Brazil

**P1.01-034: ECOG Scale of Performance Status in Lung Cancer at the First Consultation at a National Cancer Institute in a Developing Country in Latin America**

Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

**P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - PROGNOSTIC FACTORS, TREATMENT**

**P1.01-035: Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis**

Madhusmita Behera, Winship Cancer Institute of Emory University, USA

**P1.01-036: Lung Cancer Screening Program Is Cost Effective in French Setting: A Model Based Study**

Christos Chouaid, GRC OncoEst Creteil, France

**P1.01-037: Baseline Demographics and Comorbidities of Patients with Advanced NSCLC Compared to the General Population from Two Regions in Sweden**

Patrice Verpillat, Boehringer Ingelheim, Germany

**P1.01-038: Prognosis Value of Body Mass Index (BMI) and Weight Loss at Diagnosis in Primary Lung Cancer: Results of KBP-2010-CPHG Study**

Didier Debievre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) - Hôpital Emile Muller, France

**P1.01-039: Does Distance between Chest and Surgery Departments Impact Outcome in Lung Cancer Patients? Results of KBP-2010-CPHG Study**

Didier Debievre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) - Hôpital Emile Muller, France

**P1.01-040: Long-Term Survival in Metastatic Non-Small-Cell Lung Cancer: An Investigation Using Surveillance, Epidemiology and End Results Data**

Eva Szabo, National Cancer Institute, USA

**P1.01-041: Quantitative Imaging Features Predict Response of Immunotherapy in Non-Small Cell Lung Cancer Patients**

Ilke Tunali, Namik Kemal University, Turkey

**P1.01-042: Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer**

Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

**P1.01-043: Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution**

Bahar Laderian, University of Miami, Miller School of Medicine, USA

**P1.01-044: Accelerometer-Determined Physical Activity and Sedentary Time among Lung Cancer Survivors**

Adrijana D'Silva, University of Calgary, Canada

**P1.01-045: Patient to Hospital Distance in Access to Care and Lung Cancer Surgical Treatment**

Wil Lieberman-Cribbin, Icahn School of Medicine at Mount Sinai, USA

**P1.01-046: Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients**

Jian Zhou, Peking University People's Hospital, China

**P1.01-047: Clinical Presentation and Outcome of Neuroendocrine Lung Tumors in a Brazilian Cohort from 2000 to 2016**

Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

**P1.01-048: Factors Contributing Delays during Management of Lung Cancer: A Study from Tertiary Level Hospital in Nepal**

Sandhya Acharya, National Academy Of Medical Sciences, Bir Hospital, Nepal

**P1.01-049: Predictors of High Grade Toxicity of Chemotherapy among Malignant Pleural Mesothelioma Patients**

Fatma Abou Elkasem, National Cancer Insitute, Egypt

**P1.01-050: Overall Survival in Advanced Lung Cancer Patients Treated at Oncosalud-AUNA**  
Alfredo Aguilar, Oncosalud - AUNA, Peru

**P1.01-051: Predictor Variables to ECOG Scale of Performance Status in Lung Cancer at a Developing Country in Latin America**  
Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

**P1.01**      **EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION - DESCRIPTIVE EPIDEMIOLOGY**

**P1.01-052: Lung Cancer Mortality in Mexico, 1990-2014**  
Oscar Arrieta, Instituto Nacional de Cancerología, Mexico

**P1.01-053: Lung Cancer in Brazil: Men and Women Differences**  
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

**P1.01-054: Lung Cancer: Histology, Gender and Age Changes Over Past 30 Years in Brazil**  
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

**P1.01-055: Clinicoepidemiological Trends of Lung Cancer from a Premier Regional Cancer Centre in South India**  
Abhijit Das, Cancer Institute (WIA), India

**P1.01-056: Lung Cancer Epidemiology in Croatia**  
Robert Zorica, University Hospital "Split", Croatia

**P1.01-057: Metastatic Lung Cancer at a Tertiary Cancer Centre in South India**  
Govind Babu, Kidwai Memorial Institute Of Oncology, India

**P1.01-058: Demographic Profile of Lung Cancer from Eastern India**  
Prasanta Mohapatra, All India Institute of Medical Sciences, India

**P1.01-059: Lung Cancer Epidemiology among the Bahraini Population, 2000-2011**  
Randah Hamadeh, Arabian Gulf University, Bahrain

**P1.02**      **BIOLOGY/PATHOLOGY**

**P1.02**      **BIOLOGY/PATHOLOGY - DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER**

**P1.02-001: Expressions of Resistance EGFR TKIs in Non Small Cell Lung Cancer At Pham Ngoc Thach Hospital - Viet Nam**  
Nguyen Lam, Pham Ngoc Thach Hospital, Vietnam

**P1.02-002: Is T790M Mutation A "Regulator" for EGFR Signal Pathway Not an Oncogene?**  
Zheng Wang, Beijing Hospital, China

**P1.02-003: ROS1 (D4D6) is Reliable for Immunohistochemistry Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignant Pleural Effusion**  
Zheng Wang, Beijing Hospital, China

**P1.02-004: A Retrospective Analysis of Frequency of ALK Gene Rearrangement in Saudi Lung Patients**  
Fouad Al Dayel, King Faisal Specialist Hospital and Research Centre, Saudi Arabia

**P1.02-005: Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)**

Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

**P1.02-006: Interlaboratory Variation in Molecular Testing (EGFR, KRAS and ALK) in Stage IV Non-Squamous Non-Small Cell Lung Cancer in the Netherlands in 2013**

Chantal Kuijpers, University Medical Center Utrecht, Netherlands

**P1.02-007: Alk Translocated NSCLC in the West of Scotland: Patient Demographics and Outcomes**

Nicola Steele, Beatson West of Scotland Cancer Centre, UK

**P1.02-008: 2-Year Single Institution Experience with EGFR Plasma Testing in Advanced NSCLC**

Izidor Kern, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia

**P1.02-009: High Concordance of ALK Rearrangement Testing between ALK RNA-In Situ Hybridization and IHC/FISH in Patients with Lung Adenocarcinoma**

Akihiko Yoshizawa, Kyoto University Hospital, Japan

**P1.02-010: Frequency of Uncommon EGFR Mutations in NSCLC in an Argentinean University Institution**

Carolina Gabay, Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

**P1.02-011: Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity**

Ying Wang, BC Cancer Agency, Canada

**P1.02-012: Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-013: Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-014: HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-015: A Multicenter Study of EGFR and EML4-ALK Detection in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-016: HER4 Expression Was Related to the Sensitivity of EGFR-TKI in Non-Small Cell Lung Cancer**

Masaaki Inoue, Shimonoseki City Hospital, Japan

**P1.02-017: Relative Abundance of EGFR Mutations Predict Tumor Metastasis and EGFR-TKIs Prognosis in Patients with Non-Small Cell Lung Cancer**

Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

**P1.02-018: Osteosarcomatous Differentiation in the Rebiopsy Specimens of Patients Harboring Pulmonary Adenocarcinoma with EGFR-TKI Resistance**

Hyun Jung Kwon, Seoul National University Bundang Hospital, South Korea

**P1.02-019: Complex Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non-Small Lung Cancer**

Hiromasa Arai, Kanagawa Cardiovascular and Respiratory Center, Japan

**P1.02-020: The Effect of EGF-Pathway Targeted Immunization (EGF PTI) on STAT3 and Cancer Stem Cells in EGFR Mutant NSCLC Cells**

Jordi Codony Servat, Pangaea Biotech SL, IOR Quirón-Dexeus University Institute, Spain

**P1.02-021: Review of Clinical Outcomes Attributable to Next Generation Sequencing Based Broad Mutation Panel Testing in Lung Adenocarcinoma**

Cathal O'Brien, St James's Hospital, Ireland

**P1.02-022: Establishing Reflex NGS Testing in NSCLC in a Regional Network of County Hospitals in Central Sweden**

Johan Isaksson, Gävle Hospital, Sweden

**P1.02-023: Application of an Amplicon-Based NGS Strategy in the Molecular Diagnosis of NSCLC: Comparable Performance with FISH and ARMS-PCR**

Dongmei Lin, Peking University Cancer Hospital & Institute, China

**P1.02-024: The Molecular Breakdown: A Comprehensive Look at Non-Small-Cell Lung Cancer with ALK Rearrangement**

Ka-Won Noh, Sungkyunkwan University, South Korea

**P1.02-025: Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project**

Stephen Finn, St James's Hospital, Ireland

**P1.02-026: Detection of Low-Abundant EGFR Somatic Mutations by PNA Clamping-Assisted Fluorescence Melting Curve Analysis**

Jihye Yoon, PANAGENE Inc., South Korea

**P1.02-027: A Comparative Analysis of Different Cytological Samples for the Assessment of ALK Gene Rearrangements in NSCLC Patients**

Maria Lozano Escario, University of Navarra, Spain

**P1.02-028: Detection of Oncogenic Drivers in Pleural Effusions and Archived FNA Smears of Pulmonary Adenocarcinoma**

Deepali Jain, All India Institute of Medical Sciences, India

**P1.02-029: Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis**

Paola De La Iglesia, Hospital Italiano de Buenos Aires, Argentina

**P1.02-030: Performance Evaluation of ALK/ROS1 Dual Break Apart FISH Probe Kit (RUO) in Non-Small-Cell Lung Cancer**

Hyun Chang, Catholic Kwandong University International St. Mary's Hospital, South Korea

**P1.02-031: Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes**

Paul Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, USA



**P1.02-032: Diagnosis and Treatment of EGFR Mutated NSCLC among Arabic Patients**

Abed Agbaria, Bnay Zion Medical Center, Israel

**P1.02-033: Mesenchymal Transformation is the Most Common Histomorphologic Changes in the Rebiopsy of Lung Cancer Patients with EGFR-TKI Resistance**

Hyein Ahn, Seoul National University Bundang Hospital, South Korea

**P1.02-034: EGFR Mutations and ALK Translocations in Lung Cancer - A National Study**

Erik Jakobsen, Odense University Hospital, Denmark

**P1.02-035: Concomitant Driver Mutation Determines Tumor Growth in EGFR Mutation-Positive Lung Adenocarcinoma**

Kazuhiro Nagayama, The University of Tokyo Hospital, Japan

**P1.02-036: An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations**

Hirotsugu Notsuda, Ontario Cancer Institute, Canada

**P1.02-037: Mutations of EGFR and KRAS Genes in Belorussian Patients With Non-Small Cell Lung Cancer**

Alena Mikhalenka, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Belarus

**P1.02-038: Over- Expression of Epidermal Growth Factor Receptor 1 (EGFR1) Gene in Serum of Adenocarcinoma Lung at a Tertiary Level Centre in North India**

Ashraf Ansari, All India Institute of Medical Sciences, India

**P1.02-039: Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients**

Álvaro Taus, Hospital del Mar, Spain

**P1.02-040: Heterogeneity of the EGFR / KRAS Gene Mutation in Multifocal Lung Adenocarcinoma and the Clinical Significance**

Lin Li, Cancer Hospital, Chinese Academy of Medical Sciences, China

**P1.02-041: Characterization of MET-N375S as an Activating Mutation in Squamous Cell Carcinoma of the Lung**

Li Ren Kong, Cancer Science Institute Singapore, Singapore

**P1.02-042: Detection of ALK Protein Expression in Lung Adenocarcinomas, a Consecutive Series of Cases from Northeastern Brazil**

Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

**P1.02-043: Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System**

Susana Hernandez, Hospital Universitario HM Sanchinarro, Spain

**P1.02-044: EGFR Status in a Previously Untested Population from Northeastern Brazil**

Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

**P1.02-045: Discordance (FISH+, IHC-) between FISH and IHC Analysis of ALK Status in Advanced Non Small Cell Lung Cancer (NSCLC): A Unexpected Issue in 7 Cases**

Annamaria Catino, National Cancer Research Centre, Istituto Tumori "Giovanni Paolo II" Bari, Italy, Italy

**P1.02-046: ALK IHC is Highly Sensitive to Fixation Parameters**

Isabell Loftin, Ventana Medical Systems Inc., a member of the Roche Group, USA

**P1.02-047: Effect of Dasatinib on EMT-Mediated-Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells**

Yuichi Sesumi, Kindai University Faculty of Medicine, Japan

**P1.02-048: MET Exon 14 Skipping Mutations and Gene Amplifications Are Not Simultaneous Events in NSCLC**

Sergi Clavé, Hospital del Mar, Spain

**P1.02-049: EGFR, KRAS and ALK Gene Alterations in Lung Cancer Patients in Croatia**

Marko Jakopovic, University Hospital Centre Zagreb, Croatia

**P1.02-050: Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP)**

Andrés Cardona, Clinical and Traslational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

**P1.02-051: Concomitant Driver Mutations in Advanced Stage Non-Small-Cell Lung Cancer of Adenocarcinoma Subtype with Activating EGFR-Mutation**

Jens Benn Sørensen, Finsen Centre/National University Hospital, Denmark

**P1.02-052: Signal Regulatory Protein a (SIRPA): A Key Regulator of the EGFR Pathway Demonstrates Both Tumor Suppressive and Oncogenic Properties**

Erin Marshall, BC Cancer Research Centre, Canada

**P1.02-053: Comparison of Two Different Commercially Available Probes for the Detection of ALK Rearrangements in Cytological Smears**

Maria Lozano Escario, University of Navarra, Spain

**P1.02-054: Genomic Complexity in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) by Smoking Status with Comparison to EGFR Mutant NSCLC**

Amanda Redig, Dana-Farber Cancer Institute, USA

**P1.02-055: Synthetic Lethality Dictates the Mutual Exclusivity of Oncogenic Mutations in Lung Adenocarcinoma**

William Lockwood, British Columbia Cancer Research Centre, Canada

**P1.02-056: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma**

Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P1.02-057: Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort**

Robert Doebele, University of Colorado, USA

**P1.02-058: EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP)**

Andrés Cardona, Clinical and Traslational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

**P1.02-059: Evaluation of Plasma DNA Extraction, Droplet PCR and Droplet next Generation Sequencing Methods for Liquid Biopsy Analysis**

Lina Salleh, National University of Singapore, Singapore

**P1.02-060: EGFR Mediates Activation of RET in Lung Adenocarcinoma with Neuroendocrine Differentiation Characterized by ASCL1 Expression**

Farhad Kosari, Mayo Clinic, USA

**P1.02-061: Kinase Fusions in Non-Small Cell Lung Carcinoma Identified by Hybrid Capture Based ctDNA Assay**

Lauren Young, Foundation Medicine, USA

**P1.02 BIOLOGY/PATHOLOGY - OTHER MUTATIONS IN THORACIC MALIGNANCIES**

**P1.02-062: Consensus of Gene Expression Phenotypes and Prognostic Risk Predictors in Primary Lung Adenocarcinoma**

Johan Staaf, Lund University, Sweden

**P1.02-063: Mutation Profiling by Targeted Next-Generation Sequencing of an Unselected NSCLC Cohort**

Linnea La Fleur, Uppsala University, Sweden

**P1.02-064: MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer**

Chiara Lazzari, Istituto Europeo di Oncologia - IEO, Italy

**P1.02-065: Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC**

Gillian Moore, Trinity College Dublin/St. James's Hospital, Ireland

**P1.02-066: Genomic Profiling in the Differential Diagnostics of Pulmonary Tumours: A Case Series**

Hans Brunnström, Lund University, Sweden

**P1.02-067: Repeated Biopsy for Immunohistochemical and Mutational Analysis of Non Small Cell Lung Cancer: Feasibility and Safety**

Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

**P1.02-068: The Impact of TP53 Overexpression on EMT and the Prognosis in Lung Adenocarcinoma Harboring Driver Mutations**

Shigeto Nishikawa, Graduate School of Medicine, Kyoto University, Japan

**P1.02-069: Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-070: Gene Spectrum and Survival Analyses of Pathologic Subtypes in Resected Lung Squamous Cell Carcinoma**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.02-071: Detection of Multiple Low-Frequency Mutations by Molecular-Barcode Sequencing**

Kei Namba, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

**P1.02-072: Comprehensive Genomic Alterations Identified by Next-Generation Sequencing of Lung Adenocarcinoma in Japanese Population**

Seijiro Sato, Niigata University Graduate School of Medical and Dental Sciences, Japan

**P1.02-073: Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumour Suppressor Gene**

Tanya De Silva, British Columbia Cancer Research Centre, Canada

**P1.02-074: The Gene Expression Signatures of Pulmonary Adenocarcinoma with Micropapillary Features**

Yuki Sata, Chiba University Graduate School of Medicine, Japan

**P1.02-075: Analysis of Driver Genes Alteration and Clinicopathological Features in Pulmonary Marker-Null Large Cell Carcinoma**

Likun Hou, Tongji University School of Medicine, China

**P1.02-076: DNA Methylation Profiling Unravels a TGF- $\beta$  Hyperresponse in Tumor Associated Fibroblasts from Lung Cancer Patients**

Jordi Alcaraz, Facultat de Medicina, Universitat de Barcelona, Spain

**P1.02-077: Whole-Transcriptome Gene Expression Analysis of Pulmonary Sarcomatoid Carcinomas**

Greta Alì, University Hospital of Pisa, Italy

**P1.02-078: Expression Profiling of LKB1 Pathway in Young and Old Lung Adenocarcinoma Patients**

Mirella Giordano, University of Pisa, Italy

**P1.02-079: DNA Ploidy, CPA4 and Rel B Expression in Non Small Cell Lung Cancer: Correlation with Clinicopathologic Parameter**

Eleftheria Haini, Corfu General Hospital, Greece

**P1.02-080: Genomic Relationship between Lung Adenocarcinoma and Synchronous AIS/AAH Lesions in the Same Lobe**

Laura Tafe, Dartmouth-Hitchcock Medical Center, USA

**P1.02-081: The Relationship of CDH3 Expression and DNA Methylation in Thymic Epithelial Tumors**

Koichiro Kajjura, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

**P1.02-082: The Feasibility of Cell-Free DNA Sequencing for Mutation Detection in Non-Small Cell Lung Cancer Was Determined by Tumor Volume**

Tatsuo Ohira, Tokyo Medical University, Japan

**P1.02-083: Gene Fusion Profile in Lung Adenocarcinoma Patients in Brazil**

Tatiane Montella, Neotorax, Brazil

**P1.02-084: Polo-Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens**

Daniel Merrick, University of Colorado, Anschutz Medical Campus, USA

**P1.02-085: Molecular Profile in NSCLC Biopsy Samples: A Multicenter Local Study**

Norma Pilnik, School Of Medicine Cordoba University, Argentina

**P1.02-086: ATM Mutations in Lung Cancer Correlate to Higher Mutation Rates**

Lars Petersen, University of Calgary, Canada

**P1.02 BIOLOGY/PATHOLOGY - MISCELLANEOUS**

**P1.02-087: Sensitive Detection of Rare Cancer Cells by Preprogrp-Specific RT-PCR and Its Correlation with Clinicopathological Data and Survival**

Fatma Abou Elkasem, National Cancer Insititute, Egypt

**P1.03 RADIOLOGY/STAGING/SCREENING**

**P1.03 RADIOLOGY/STAGING/SCREENING - BIOLOGY**

**P1.03-001: The Utility of Liquid-Biopsy for Detecting EGFR Mutation in Clinical Practice: 169 Cases in a Single Institution Research Study**

Kentaro Ito, Matsusaka Municipal Hospital, Japan

**P1.03-002: Can We Discriminate between Different Subtypes of Non-Small Cell Cancer Patients Based on Plasma Metabolic Fingerprint?**

Michal Ciborowski, Medical University of Bialystok, Poland

**P1.03-003: The Warburg Effect: Persistence of Stem Cell Metabolism in Lung Cancer as Failure of Differentiation**

Robert Downey, Memorial Sloan Kettering Cancer Center, USA

**P1.03-004: Percutaneous Lung Biopsy for Genomic Assessment: Comparison between Two Different next Generation Sequencing Platforms**

Livia Maria Frota Lima, MD Anderson Cancer Center, USA

**P1.03-005: High Resolution Metabolomics in Discovering Plasma Biomarkers of Lung Cancer Patients with EGFR Common Mutations (Exon 19 or 21)**

Sung Yong Lee, College of Medicine, Korea University, South Korea

**P1.03-006: Quantification of PD-L1 Expression on Tumor Cells in Non-Small Cell Lung Cancer Using Non-Enzymatic Tissue Dissociation and Flow Cytometry**

Amanda Chargin, IncellDx, USA

**P1.03-007: Improvement in Performance of an Autoantibody Panel Test for Detection of Lung Cancer by Addition of a Single Novel Biomarker (EDB1)**

Caroline Chapman, Queen's Medical Centre, UK

**P1.03 RADIOLOGY/STAGING/SCREENING - PNEUMONOLOGY**

**P1.03-008: Clinical Importance of Indolent Lung Cancers**

Gunnar Hillerdal, Gavle Hospital, Sweden

**P1.03-009: Venous Thromboembolism (VTE) in Lung Cancer - Associations and Prognostic Role: Results of a Prospective Cohort Study from North India**

R Lakshmi Narasimhan, Postgraduate Institute of Medical Education and Research (PGIMER), India

**P1.03-010: Characteristics of Lung Cancer Patients Diagnosed Following Emergency Admission**

Neal Navani, University College London, UK

**P1.03-011: Clinical Characters of 19 Bronchial Asthmatic Patients with Lung Cancer**  
Jie Zhang, Second Affiliated Hospital of Jilin University, China

**P1.03 RADIOLOGY/STAGING/SCREENING - RADIOLOGY**

**P1.03-012: Experience with BioSentry<sup>TM</sup> Tract Sealant System for Percutaneous CT-Guided Lung Nodule Biopsies in an Oncology Population**  
Patricia de Groot, UT MD Anderson Cancer Center, USA

**P1.03-013: Diagnosis, Assessment and Prediction of Early Response to Chemotherapy by Using Diffusion-Weighted MRI in Lung Cancer**  
Jian Zhang, Department of Pulmonary Medicine, Xijing Hospital, Fourth Military Medical University, China

**P1.03-014: Value of Performing Fine Needle Aspiration with Core Biopsy for Genomic Mutation Assessment in Percutaneous Lung Biopsies**  
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

**P1.03-015: Assessment of Response of FDG-PET Using Total Lesion Glycolysis (TLG) in NSCLC Patients Treated with Nivolumab: Results of a Pilot Study**  
Hector Soto Parra, A.O.U. Policlinico Vittorio Emanuele, Italy

**P1.03-016: Diagnostic Accuracy of Visual Assessment on Growth of Non-Measurable Target Pulmonary Nodules According to RECIST Criteria**  
Jeong Min Ko, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, South Korea

**P1.03-017: Does PET/CT SUVmax Value Correlate with Long-Term Survival in Patients with Surgically Treated Stage I Non-Small Cell Lung Cancer**  
Akif Turna, Istanbul University Cerrahpasa Medical School, Turkey

**P1.03-018: FDG-PET/CT in Patients with EGFR-Mutated NSCLC Treated with TKI. Can We Identify Early Lesions at Higher Risk of Progression?**  
Alexis Cortot, Lille University Hospital, France

**P1.03-019: Imaging of Anti-PD1 Therapy Response in Advanced Non-Small Lung Cancer**  
Sharyn Katz, Hospital of the University of Pennsylvania, USA

**P1.03-020: FDG-PET SUVmax Does Not Correlate with Glucose Metabolism in Non-Small Cell Lung Cancer**  
Kemp Kernstine, University of Texas Southwestern, USA

**P1.03-021: Initial Results from A Novel and Low Cost Method For Measuring CT Image Quality**  
Ricardo Avila, Accumetra, LLC, USA

**P1.03-022: Possibility of FDG-PET Predicting the Clinicopathological Characteristics and Prognosis of Lung Adenocarcinoma: Multicenter Study**  
Kumi Matsuura, Tokyo Medical University, Japan

**P1.03-023: Ground-Glass Opacity (GGO) with Semi-Consolidation: Clinicopathological and Radiological Correlations Compared to Pure-GGOs of the Lung**  
Jun Suzuki, Juntendo University School of Medicine, Japan

**P1.03-024: Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype**

Andrea Bille, Guys' & St. Thomas' Hospitals, UK

**P1.03-025: Serum KL-6 Levels in Patients with Lung Cancer**

Tatsuya Yoshimasu, Wakayama Medical University, Japan

**P1.03-026: Measurement of Pulmonary Artery on CT to Predict Acute Exacerbation of Interstitial Pneumonia after Pulmonary Resection for Lung Cancer**

Akiko Ui, Tokyo Medical and Dental University, Japan

**P1.03-027: Clinical and Histological Features Associated with SUV in FDG-PET-CT in Patients with Adenocarcinoma of the Lung**

Amanda Tufman, Ludwig Maximilian University of Munich, Germany

**P1.03-028: Wolf in Sheep's Clothing - Primary Lung Cancer Mimicking Benign Diseases**

Annemie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium

**P1.03-029: A Useful Algorithmatic Model in Predicting the Likelihood of Lung Cancer in Solitary Pulmonary Nodules**

Lin Gen, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, China

**P1.03-030: FDG-PET/CT Might Be a Predictor for Residual Disease in Advanced NSCLC after Chemoradiotherapy**

Toru Sawada, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

**P1.03-031: Gynecological Malignancies and Imaging Patterns. An Interesting Case Report and Literature Surveillance**

Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

**P1.03-032: In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis**

Akihiro Nishiyama, Kanazawa University, Japan

**P1.03 RADIOLOGY/STAGING/SCREENING - SCREENING**

**P1.03-033: Analysis of T0 Lung-RADS Scores in UI Health's Minority-Based Lung Cancer Screening Program and Comparison to the NLST**

Mary Pasquinelli, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

**P1.03-034: Implementing Smartphone Application in Early Lung Cancer Detection and Screening**

Zalan Szanto, University of Pécs, Hungary

**P1.03-035: Does Screening with Low-Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?**

Gianpiero Fasola, University hospital of Udine, Italy

**P1.03-036: Adherence to Eligibility Criteria for Low-Dose CT Screening in an Academic Center**

Jacob Bloom, Fred Hutchinson Cancer Research Center, USA

**P1.03-037: Radio-Guided Localization and Resection of Small or Ill-Defined Pulmonary Lesions**

Domenico Galetta, European Institute of Oncology, Italy

**P1.03-038: Appropriateness of Lung Cancer Screening with Low Dose Computed Tomography**  
M Rivera, The University of North Carolina, USA

**P1.03-039: Is It Necessary to Repeat Lung Cancer Screening with Low-Dose CT(LDCT) in Female Never Smokers?**  
Hyae Young Kim, National Cancer Center, South Korea

**P1.03-040: Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey**  
Alexis Cortot, Hôpital Calmette, France

**P1.03-041: Do Several Rounds of Negative Screening Low Dose CT Scans Influence the Risk to Develop Lung Cancer?**  
Heidi Schmidt, University Health Network, Canada

**P1.03-042: Nodule Size is Poorly Represented by Nodule Diameter in Low-Dose CT Lung Cancer Screening**  
Marjolein Heuvelmans, University of Groningen, University Medical Center Groningen, Netherlands

**P1.03-043: Practical Difficulty of Low Dose Computerized Tomography as a Lung Cancer Screening Tool in an Endemic Area of Tuberculosis**  
Natthaya Triphuridet, Chulabhorn Hospital, Thailand

**P1.03-044: EUS-Guided Sampling of Mediastinal Lymph Nodes and Abdominal Lesions in Lung Cancer**  
Toyoaki Hida, Aichi Cancer Center Hospital, Japan

**P1.03-045: Screening for Lung Cancer with Early CDT-Lung Blood Biomarkers and Computed Tomography**  
James Finigan, National Jewish Health, USA

**P1.03-046: Selection of Subjects at High-Risk for LDCT Lung Cancer Screening Using a Molecular Panel: Results by the ITALUNG Biomarker Study**  
Eugenio Paci, Institute for Cancer Prevention and Research (ISPO), Italy

**P1.03-047: Community-Based Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in the US Histoplasmosis Belt: One Year Followup**  
Emilia Porubcin, Rivermont Collegiate, USA

**P1.03-048: A Structured Lung Cancer Screening Program Facilitates Patient and Provider Compliance**  
Thomas D'Amico, Duke University Medical Center, USA

**P1.03-049: Smoking Patterns in a Predominantly African American Population Undergoing Lung Cancer Screening**  
Cherie Erkmen, Temple University Hospital, USA

**P1.03-050: Outcomes after the Decision to Biopsy: Results from a Nurse Practitioner Run Multidisciplinary Lung Cancer Screening Program**  
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA

**P1.03-051: Medically Underserved and Geographically Remote Individuals May Be Underrepresented in Current Lung Cancer Screening Programs**  
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA



**P1.03-052: The Effect of Rounding on Rate of Positive Results on CT Screening for Lung Cancer**  
Kunwei Li, Icahn School of Medicine, USA

**P1.03-053: The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low Dose CT**  
Dan Raz, City of Hope, USA

**P1.03-054: Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening**  
Ivan Tham, National University Cancer Institute Singapore, Singapore

**P1.03-055: LuCaS DA: A Lung Cancer Screening Decision Aid to Improve Screening Decisions**  
Jamie Studts, University of Kentucky, USA

**P1.03-056: Implementation of a Prospective Biospecimen Collection Study in an Established Lung Cancer Screening Program**  
Jacob Sands, Lahey Hospital & Medical Center, USA

**P1.03-057: Assessment of Lung Cancer Risk- Regional Respiratory Disease Screening Report in Jilin, China**  
Jie Zhang, Second Affiliated Hospital of Jilin University, China

**P1.03-058: Cost-Effectiveness of CT Screening in the Early Detection of Lung Cancer**  
Tomasz Szczęśny, Franciszek Łukaszczyk Memorial Oncological Center in Bydgoszcz, Poland

**P1.03-059: Organized High Risk Lung Cancer Screening in Ontario, Canada: A Multi-Centre Prospective Evaluation**  
Martin Tammemägi, Brock University, Canada

**P1.03-060: Lung Cancer Screening: A Qualitative Study Exploring the Decision to Opt Out of Screening**  
Lisa Carter-Harris, Indiana University, USA

**P1.03-061: Patient Motivations for Pursuing Low-Dose CT Lung Cancer Screening in an Integrated Healthcare System: A Qualitative Evaluation**  
Joshua Roth, Fred Hutchinson Cancer Research Center, USA

**P1.03-062: Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm**  
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P1.03-063: Quantitative Imaging Features Predict Incidence Lung Cancer in Low-Dose Computed Tomography (LDCT) Screening**  
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

**P1.03-064: Chest X-Ray (CXR) Screening Improves Lung Cancer (LC) Survival in the Prostate Lung Colon and Ovary (PLCO) Randomized Population Trial (RPT)**  
John Paul Flores, Tufts Medical Center, USA

**P1.03 RADIOLOGY/STAGING/SCREENING - STAGING**

**P1.03-065: Comparison of the Proposed IASLC 8th TNM Lung Cancer Staging System to the 7th Edition**

Kwun Fong, University of Queensland Thoracic Research Centre, Australia

**P1.03-066: Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging**

Gavitt Woodard, University of California, USA

**P1.03-067: Validation of the IASLC 8th Edition (8E) TNM Classification for Non-Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort**

Matthew Smeltzer, University of Memphis School of Public Health, USA

**P1.03-068: Impact of Positive Pleural Lavage Cytology or Malignant Effusion on Survival in Patients Having Lung Resection for NSCLC**

Tomohiro Obata, Nagasaki Graduate School of Medicine, Japan

**P1.03-069: EGFR Mutations Have Greater Influence on Survival Than Proposed M Descriptors of New TNM Classification for Lung Cancer**

Karmen Stanic, Institute of Oncology, Slovenia

**P1.03-070: The Impact of Advances in Systemic Staging on the Rate of Metachronous and Synchronous Metastases in Patients Lung Cancer**

Kyle Wang, University of North Carolina Hospitals, USA

**P1.03-071: Impact of Visceral Plural Invasion to T Descriptors: Based on the Forthcoming Eighth Edition of TNM Classification for Lung Cancer**

Mikiko Suzuki, Juntendo University School of Medicine, Japan

**P1.03-072: Mediastinal Lymphnodes Staging by PET CT for Resectable Non-Small Cell Lung Cancer in a Tuberculosis Endemic Country**

VinayaKumar J R, IRCH, All India institute of Medical Sciences(AIIMS), India

**P1.03-073: Predictors for Pathological N1 and N2 Disease in Clinical N1 Non-Small-Cell Lung Cancer**

Takayuki Fukui, Nagoya University, Japan

**P1.03-074: Combined Use of PET/CT and Clinical Features Yields a Higher Diagnostic Rate of Mediastinal Lymph Node Metastasis in Lung Adenocarcinoma**

Miao Huang, Peking University Cancer Hospital and Institute, China

**P1.03-075: Predictive Factors for Minimal Pleural Disease Detected at Thoracotomy or Positive Lavage Cytology**

Akira Sakurada, Institute of Development, Aging and Cancer, Japan

**P1.03-076: Nodal Staging of Patients with Pulmonary Malignancies - The Predictive Value of Different Patterns of Mediastinal 18FDG-PET Activity**

Socrates Angelides, Westmead Hospital, Australia

**P1.03-077: Analysis of the Early CDT-Blood Biomarker for Lung Cancer in Higher vs. Lower Risk Cohorts**

James Finigan, National Jewish Health, USA

**P1.03-078: Size Matters...but Don't Underestimate the Power of Morphology**

Annemie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium

**P1.03-079: Adequacy of Percutaneous Lung Biopsy for Assessing Clinically Requested Genetic Mutations in Lung Cancer**

Livia Maria Frota Lima, MD Anderson Cancer Center, USA

**P1.03-080: The SUVmax Ratio of Two Tumors on PET/CT May Differentiate Separate Primary Lung Cancers and Intrapulmonary Metastases**

Yi Liu, The Chinese People's Liberation Army General Hospital, China

**P1.03-081: Synchronous Triple Malignant Tumors of the Lung: A Case Report of Two Lung Adenocarcinomas, and Mucosa-Associated Lymphoid Tissue Lymphoma**

Xun Wang, Nanjing Medical University Wuxi No.2 People's Hospital, China

**P1.03-082: 18F-FDG PET/CT Value Staging NSCLC Extension to the Lymph Nodes, Single Center Experience**

Ruta Vosyliute, Vilnius University, Lithuania

**P1.03-083: Advances in Surgical Staging of NSCLC**

Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

**P1.03-084: Implications of 8th Edition TNM Proposal: Invasive vs. Total Size for T Descriptor in pT1a-2bN0M0 Lung Adenocarcinoma**

Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA

**P1.04 PULMONOLOGY**

**P1.04 PULMONOLOGY - PULMONOLOGY**

**P1.04-001: EGFR, EML4-ALK, ROS 1 and BRAF Testing in Austrian Patients with NSCLC: A Multicentre Study**

Sophia Holzer, Otto Wagner Hospital, Austria

**P1.04-002: Positive Airway Pressure-Enhanced CT to Improve Virtual Bronchoscopic Navigation**

Marta Diez-Ferrer, Hospital Universitari de Bellvitge, Spain

**P1.04-003: Incidence of Non-Caseating Granulomas Diagnosed in PET Avid Mediastinal/Hilar Nodes in Patients with Known Breast Cancer**

Rabih Bechara, Cancer Treatment Centers of America, USA

**P1.04-004: Bronchoscopic Cryosurgery with Carbon Dioxide; Experience in an Oncology Clinic in Colombia**

Jaime Echeverri, Oncólogos del Occidente S.A., Colombia

**P1.04-005: Efficacy of Photodynamic Therapy Combined with a Guide Sheath Method in Lung Cancer Patients with Endobronchial Stenosis**

Masafumi Misawa, Kameda Medical Center, Japan

**P1.04-006: Second Primary Lung Cancer: Five Years of a Single Center Experience in Its Diagnosis and Treatment**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

**P1.04-007: Y Stents in Malignant Tumours - Long Time Follow up and Survival**

Vitezslav Kolek, University Hospital, Czech Republic

**P1.04-008: Tumor Pentaplicity - Case Report**

Petra Smičková, The University Hospital of Olomouc, Czech Republic

**P1.04-009: Bacterial Population Dynamics in Colonization of Airway Stents in Patients with Cancer**

Antoni Rosell, Hospital Universitari de Bellvitge, Spain

**P1.04-010: Neutrophil to Lymphocyte, Platelet to Lymphocyte Ratios and Systemic Inflammation in Lung Cancer Stages**

Erhan Ionela Mihaela, Marius Nasta Institute of Pulmonology, Romania

**P1.04-011: Demographic, Clinical and Survival Characteristics of Lung Cancer among Elderly Patients in Turkey**

Guntulu Ak, ESOGU, Turkey

**P1.04-012: Single Center Experience with Nivolumab Administration in NSCLC Patients from EAP Program**

Milos Pesek, Charles University in Prague, Czech Republic

**P1.04-013: Diagnostics and Treatment of ALK-Positive NSCLC Patients - A Single Center Experience**

Milos Pesek, Charles University in Prague, Czech Republic

**P1.04-014: Diagnostic Yield in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnosis of Lung Cancer**

Sunkaru Touray, University of Massachusetts Medical School, USA

**P1.04-015: Clinical Application of Virtual Navigated Bronchial Intervention**

Naohiro Kajiwara, Tokyo Medical University, Japan

**P1.04-016: EBUS plus Fluoroscopy-Guided Biopsy Compared to Fluoroscopy-Guided TBB for Obtaining Samples of Peripheral Pulmonary Lesions**

Jian Ye, Affiliated Hangzhou Hospital of Nanjing Medical University, China

**P1.04-017: The Survival of Our Patients Diagnosed with Lung Cancer in 2013**

Sedat Altin, Yedikule Chest Diseases and Chest Surgery Hospital, Turkey

**P1.04-018: Occurrence of Triple Multiple Malignancies with Last Lung Squamous Cell Carcinoma - Case Reports**

Anna Romaszko, University of Warmia and Mazury, Poland

**P1.04-019: Final Analysis of Lung Microbiome from Patients Undergoing Bronchoscopy**

Glen Weiss, Western Regional Medical Center, Cancer Treatment Centers of America, USA

**P1.04-020: Management of Lung Cancer in Patients with past Pulmonary Tuberculosis and Their Possible Causative Link**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

**P1.04-021: Medical Thoracoscopy for the Diagnosis and Management of Pleural Effusions: Results of a Retrospective Analysis**

Sofia Tsagouli, Medical School, University of Athens, Greece

**P1.04-022: Use of Alternative Therapy in Patients with Lung Cancer**

Kristina Krpina, KBC Rebro, Croatia

**P1.04-023: Thrombomodulin Inhibits the Growth and Angiogenesis of Human Lung Cancer via Blocking VEGFR2-Mediated JAK/STAT3 Signaling Pathway**

Shun Lu, Shanghai Chest Hospital, China

**P1.04-024: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P1.04-025: The Impact of Emergency Presentation on Survival of Lung Cancer Patients**

Marko Jakopovic, University Hospital Center, Croatia

**P1.04-026: Coexisting Lung Cancer and Interstitial Lung Disease: A Challenge in Clinical Practice**

Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

**P1.04-027: Changes in Pulmonary Function in Lung Cancer Patients after Thoracic Surgery**

Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

**P1.04-028: Collection of ICHOM-Defined Patient-Reported Outcome Measures (PROMs) during Routine Lung Cancer Treatment: A Pilot Study**

Jan van Meerbeeck, Antwerp University Hospital, Belgium

**P1.05 EARLY STAGE NSCLC**

**P1.05 EARLY STAGE NSCLC - TRANSLATIONAL RESEARCH & BIOMARKERS**

**P1.05-001: Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium**

David Harpole, Duke University Medical Center, USA

**P1.05-002: The Prognostic Impact of EGFR Mutation Status and Mutation Subtypes in Patients with Surgically Resected Lung Adenocarcinomas**

Kazuya Takamochi, Juntendo University School of Medicine, Japan

**P1.05-003: Coexpression of CD8a and PD-L1 Frequently Observed in Resected NSCLC Tumors from Smokers**

Aaron Lisberg, UCLA Medical Center, USA

**P1.05-004: Surfactant Protein C is a Prognostic Marker in Resected Non-Small Cell Lung Cancer**

Ivan Macía, Hospital Universitari de Bellvitge. IDIBELL, Institut d'Investigació Biomèdica de Bellvitge, Spain

**P1.05-005: Programmed Death-Ligand 1 (PD-L1) in Resected Lung Adenocarcinomas (LA) in a University Hospital**

María Álvarez, Hospital Universitario Miguel Servet, Spain

**P1.05-006: Identification of miRNAs and mRNAs Associated with Metastasis in Early-Stage Non-Small Cell Lung Cancer (NSCLC)**

Shirley Tam, University Health Network, Canada

**P1.05-007: Analysis of RNA Sequencing Data along with PET SUV-max Can Discover Novel Gene Sets Which Can Predict Surgical Outcome of NSCLC**

Young Tae Kim, Seoul National University Hospital, South Korea

**P1.05-008: Detection of EGFR Mutations in Pulmonary Vein and Peripheral Blood Plasma Cell-Free DNA for Analysis of Surgical Treatment in Early-Stage NSCLC**

Chengliang Yang, Shenyang tenth People's Hospital & Shenyang Chest Hospital, China

**P1.05-009: Clinical Value of Circulating Tumor Cell in the Differential Diagnosis of Solitary Pulmonary Nodule**

Lin Wang, Shanghai Chest Hospital, China

**P1.05-010: Aberrant Promoter Methylation of ESR1 and CDH13 Gene Are an Independent Prognostic Marker in Surgically Resected Non-Small Cell Lung Cancer**

Milica Kontic, Clinical Centre of Serbia, Serbia

**P1.05-011: Comparative Analysis of TTF-1 Copy Number Alterations and Protein Expression in Patients with Non-Small Cell Lung Cancer**

Katsuhiko Yoshimura, Hamamatsu University School of Medicine, Japan

**P1.05-012: The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma**

Jiro Kitamura, Massachusetts General Hospital, USA

**P1.05-013: Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer**

Eloisa Jantus-Lewintre, Fundación Investigación Hospital General Universitario, Spain

**P1.05-014: Stemness Gene Expression Profile of Tumorspheres from Non-Small Cell Lung Cancer**

Eloisa Jantus-Lewintre, Fundación Investigación Hospital General Universitario, Spain

**P1.05-015: Genomic Characterisation of Non-Small Cell Lung Cancer in an Australian Population**

Brielle Parris, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia

**P1.05-016: Circulating BARD1 Antibodies for Early Detection of Lung Cancer**

Irmgard Irminger-Finger, University Hospitals Geneva, Switzerland

**P1.05-017: The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas**

Bonnie Gould Rothberg, Yale University School of Medicine, USA

**P1.05-018: LncRNA16 is a Potential Biomarker for Early-Stage Lung Cancer That Promotes Cell Proliferation by Regulating the Cell Cycle**

Xing Wang, Peking University Cancer Hospital & Institute, China

**P1.05-019: Two Inflammatory Biomarkers MDC/CCL22 and BLC/CXCL13 Are Independently Associated with the Significant Risk of Early Stage Lung Adenocarcinoma**

Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P1.05-020: Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non-Small-Cell Lung Cancer**

Yusuke Inoue, Hamamatsu University School of Medicine, Japan

**P1.05-021: circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer**  
Steven Gray, LabMed Directorate, Ireland

**P1.05-022: Circulating Tumor Cell Isolation to Monitor NSCLC Patients over the Course of Treatment**  
Julia Herrmann, SRH Wald-Klinikum Gera, Germany

**P1.05-023: Induction of Patient-Derived Xenograft Formation and Clinical Significance for PD-L1 in Lung Cancer Patients**  
Jiahui Si, Peking University Cancer Hospital & Institute, China

**P1.05-024: Preoperative Neuron-Specific Enolase to Albumin Ratio is a Prognostic Biomarker for Patients with Operable Non-Small-Cell Lung Cancer**  
Hong Ren, The First Affiliated Hospital of Xi'an Jiaotong University, China

**P1.05-025: Prognostic Significance of Hepatitis B Virus to Stage IB Non-Small Cell Lung Cancer Patients in China**  
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P1.05-026: High Resolution Metabolomics on Exhaled Breath Condensate to Discover Lung Cancer's Biomarker**  
Sung Yong Lee, Korea University Medical Center, South Korea

**P1.05-027: Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium**  
William Richards, Brigham and Women's Hospital, USA

**P1.05-028: Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC)**  
Lorenzo Federico, MD Anderson Cancer Center, USA

#### **P1.05 EARLY STAGE NSCLC - SBRT**

**P1.05-029: SABRTOOTH-A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery**  
Kevin Franks, Leeds Teaching Hospitals/University of Leeds, UK

**P1.05-030: Lung SABR for Early Stage Lung Cancer: Outcomes and Toxicity of 803 Patients Treated at the Leeds Cancer Centre**  
Patrick Murray, St James' University Hospital, UK

**P1.05-031: Primary Results of Dose Escalated Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer**  
Takafumi Komiyama, University of Yamanashi School of Medicine, Japan

**P1.05-032: Quality of Life after Stereotactic Body Radiotherapy and Surgery in Patients with Early Stage Non-Small Cell Lung Cancer**  
Elisabeth Kastelijn, St. Antonius Hospital, Netherlands

**P1.05-033: Comparison of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Central Lung Tumors**  
Sung Jun Ma, Roswell Park Cancer Institute, USA

**P1.05-034: Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR**

Stephen McKay, Beatson West of Scotland Cancer Centre, UK

**P1.05-035: SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity**

Stephen McKay, Beatson West of Scotland Cancer Centre, UK

**P1.05 EARLY STAGE NSCLC - SURGERY**

**P1.05-036: A Propensity-Matched Study of Multi-Port versus Single-Port Video-Assisted Thoracoscopic Surgery for Early Lung Cancer**

Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan

**P1.05-037: Histopathologic Results of Surgically Resected Pure Ground-Glass Opacity Lung Nodules**

Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

**P1.05-038: Patterns of Recurrence in Curatively Resected Stage I Lung Cancer**

Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P1.05-039: Recurrence and Survival Outcome after Segmentectomy for Non-Small Cell Lung Cancer: A Long-Term Follow-Up Study at a Single Institute**

Takamasa Koga, Kumamoto University Hospital, Japan

**P1.05-040: Prognostic Factor of Node Involvement Pattern in Completely Resected pN1 Squamous Cell Carcinoma Patients**

Kenta Tane, Hyogo Cancer Center, Japan

**P1.05-041: Dynamics of Brain Metastasis for Curatively Resected Stage I or II Non-Small Cell Lung Cancer Patients**

Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P1.05-042: Treatment Strategy of Limited Surgery for Early Lung Cancer**

Katsuo Kojima, Musashino Red-Cross Hospital, Japan

**P1.05-043: Survival Following Surgical Resection of Lung Adenocarcinoma Stratified According to Morphological Sub-Type**

Haval Balata, University Hospitals of South Manchester, UK

**P1.05-044: The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort**

Matthew Smeltzer, University of Memphis School of Public Health, USA

**P1.05 EARLY STAGE NSCLC - NEOADJUVANT AND ADJUVANT CHEMOTHERAPY**

**P1.05-045: Adjuvant Chemotherapy for Patients with Stage IB Non Small Cell Lung Cancer**

Jia Wang, Beijing Cancer Hospital, China

**P1.05-046: Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years' Median Follow-Up**

Wen-zhao Zhong, Department of Pulmonary Oncology; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China



**P1.05-047: Early Mortality in Patients with Non-Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy**

Daniel Morgensztern, Washington University School of Medicine, USA

**P1.05-048: Effect of Adjuvant Chemotherapy on the Patterns and Dynamics of Recurrences in Resected Stage II(N1) Lung Adenocarcinoma**

Byung Jo Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P1.05-049: Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma**

Matthijs Van Gool, NKI-AVL, Netherlands

**P1.05-050: External Validation of a Prognostic Model for Squamous-Cell Lung Cancer and Impact of Adjuvant Treatment in >1,300 Patients**

Emilio Bria, University Oncology Unit, Department of Medicine, Italy

**P1.05-051: Safety and Compliance Data of the Phase III Study of Adjuvant Chemotherapy in Completely Resected P-Stage I Non Small Cell Lung Cancer: JCOG0707**

Hiroyuki Sakurai, National Cancer Center Hospital, Japan

**P1.05-052: An Exploratory Analysis of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival for Lung Adenocarcinoma**

Masahiro Tsuboi, National Cancer Center Hospital East, Japan

**P1.05-053: Impact of Gender Difference on Adjuvant Chemotherapy after Radical Resection in Patients with Non-Small Cell Lung Cancer**

Lu Yang, Peking Union Medical College, China

**P1.05-054: Adjuvant Chemotherapy Uptake in Patients with NSCLC after Complete Resection: Single Institution/Single Area Experience**

Vitezslav Kolek, University Hospital, Czech Republic

**P1.05 EARLY STAGE NSCLC - RECURRENCE**

**P1.05-055: Risk Factors of Postoperative Recurrence in Stage IA and IB Patients**

Fumihiko Hoshi, Tohoku University Hospital, Japan

**P1.05-056: Increased Risk of Postoperative Recurrence in EGFR-Positive Stage IA to IB Invasive Lung Adenocarcinoma**

Masaaki Ito, Hiroshima University Hospital, Japan

**P1.05-057: Prediction of Early Recurrence in Patients with Stage I and II Non-Small Cell Lung Cancer Using FDG PET Quantification**

Sven Hillinger, University Hospital, Switzerland

**P1.05-058: Prognostic Factors of Post-Recurrence Survival in Resected Stage I Non-Small Cell Lung Cancer**

Yasuaki Kubouchi, Tottori University, Faculty of Medicine, Japan

**P1.05-059: Factors Associated with Recurrence and Survival in Patients with Curatively Resected Stage IA Adenocarcinoma of the Lung**

Masahiko Harada, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

## **P1.05 EARLY STAGE NSCLC - MISCELLANEOUS**

### **P1.05-060: Adherence to Surveillance Guidelines in Resected NSCLC: Physician Compliance and Impact on Outcomes**

Cheryl Ho, BC Cancer Agency, Canada

### **P1.05-061: Increased Treatment-Related Toxicity in Patients with Early-Stage Non-Small Cell Lung Cancer and Co-Existing Interstitial Lung Disease**

Hanbo Chen, London Health Sciences Centre, Canada

### **P1.05-062: Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis**

Paolo Mendogni, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

### **P1.05-063: Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial**

Tomoyuki Hishida, National Cancer Center Hospital East, Japan

### **P1.05-064: Global Practice Patterns of Multifocal Lung Cancer**

Aaron Mansfield, Mayo Clinic, USA

### **P1.05-065: Usage of Chest Radiography or Computed Tomography in Post-Treatment Surveillance for Stage I and II NSCLC: Influence on Survival**

Leonie Alberts, St. Antonius hospital, Netherlands

### **P1.05-066: Impact of Micropapillary Pattern in Nodal Upstaging of Lung Adenocarcinoma 2cm or Less**

Hirotsugu Yamazaki, Kitasato University School of Medicine, Japan

### **P1.05-067: Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer**

Gail Darling, Cancer Care Ontario, Canada

### **P1.05-068: Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist**

Gail Darling, University of Toronto, Canada

### **P1.05-069: Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes**

Shaan Dudani, University of Ottawa, Canada

### **P1.05-070: Diagnostic Yield and Efficacy of EBUS TBNA in Molecular Testing for NSCLC Mutations**

Shashank Nuguru, IU Health, USA

### **P1.05-071: A Review of Quality of Life Measures Used in Lung Cancer Surgical Outcomes**

Rowena Yip, Icahn School of Medicine, USA

### **P1.05-072: Predictors and Patterns of Lymph Node Metastasis in Small Peripheral Non Small Cell Lung Cancer**

Jun-tao Lin, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, China

**P1.05-073: Evaluation of Stage 1 Sub-Solid Lung Nodules Using PET Imaging**  
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

**P1.05-074: Factors Predicting Discordance between Clinical and Surgical-Pathologic Staging in Operable Non-Small Cell Lung Cancer**  
Kostas Syrigos, Medical School, University of Athens, Greece

**P1.05-075: The Correlation between the Prognoses of Patients with Non-Small Cell Lung Cancer and Preoperative Platelet- Lymphocyte Ratio**  
Shunta Ishihara, Ayabe City Hospital, Japan

**P1.05-076: Risk Factors in Patients with Pathological Stage I Non-Small Cell Lung Cancer**  
Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan

**P1.05-077: Outcome of N2 Disease in NSCLC - A Single Institution Experience**  
Marko Jakopović, University hospital center Zagreb, Croatia

**P1.05-078: The Relationship between IASLC/ATS/ERS Grading System of Adenocarcinoma of the Lung and Quantitative PET Parameters**  
Kyle Wang, University of North Carolina Hospitals, USA

**P1.05-079: Lung Cancer in the Elderly: Factors Affecting Long-Term Survival Following Resection**  
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

## **P1.06           ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

### **P1.06           ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ADVANCED GENERAL**

**P1.06-001: Sluga R, Roepman P, Kummer A, vd Bosch W, vd Borne BEEM, Schramel FMNH**  
Romina Sluga, St. Antonius Hospital, Netherlands

**P1.06-002: Contralateral Axillary Lymph Node Metastasis of a Lung Cancer: A Case Report**  
Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

**P1.06-003: Anamorelin in Cachectic Patients with Advanced NSCLC, a Post-Hoc Pooled Efficacy Data Analysis of Two Phase 3 Trials**  
David Currow, Flinders University, Australia

**P1.06-004: Evaluating the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Preliminary Results from the Quantitative Pilot Study**  
Astra Liepa, Eli Lilly and Company, USA

**P1.06-005: An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted**  
Matteo Giaj Levra, Michallon University Hospital, France

**P1.06-006: Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP)**  
Frederico Cappuzzo, AUSL Romagna, Italy

**P1.06-007: Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Cancer (NSCLC)**  
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

**P1.06-008: Non-Small Cell Lung Cancer in Octogenarians: Real-Life Clinical Practice; Characteristics, Therapy and Survival**  
Hirsh Koyi, Gävle Hospital, Sweden

**P1.06-009: Determining Optimal Array Layouts for Delivering TTFIELDS to the Lungs Using Computer Simulations**  
Zeev Bomzon, Novocure Ltd., Israel

**P1.06-010: Analysis of the Incidence of Cancer Cachexia in Patients with Advanced Lung Cancer at Referral to a Dietitian**  
Adele Hug, Royal Surrey County Hospital, UK

**P1.06-011: Altered Body Composition and Fat Loss in Advanced Non-Small Cell Lung Cancer**  
Anant Mohan, All India Institute of Medical Sciences, India

**P1.06-012: Central and Peripheral Lung Adenocarcinomas Exhibit Different Timing and Predilection for Distant Metastasis**  
Judit Moldvay, National Koranyi Institute of Pulmonology, Hungary

**P1.06-013: Patient Characteristics and Survival: A Real-World Analysis of US Veterans With Stage IV Adenocarcinoma vs Squamous NSCLC**  
Monika Parisi, Celgene Corporation, USA

**P1.06-014: What Factors Determine Treatment Satisfaction in Patients with Advanced NSCLC Receiving Chemotherapy?**  
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

**P1.06-015: Designing Transducer Arrays for the Delivery of TTFIELDS Whilst Maximizing Patient Comfort and Field Intensity in the Thorax**  
Zeev Bomzon, Novocure Ltd., Israel

**P1.06-016: Pulmonary Tuberculosis among Newly Diagnosed-Therapy Naive Advanced NSCLC in Persahabatan Hospital Jakarta Indonesia**  
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

**P1.06-017: Observational Study on Prolonged Disease Stabilization in Advanced NSCLC EGFR WT/Unknown Patients Treated with Erlotinib in Second Line**  
Francesco Grossi, IRCCS AOU San Martino - IST, Italy

**P1.06-018: Treatment Patterns and Clinical Practices of Advanced (Stage IV) Non-Small Cell Lung Cancer (NSCLC) in Europe - A Structured Literature Review**  
Thomas Brodowicz, Medical University Vienna - General Hospital, Austria & Central European Cooperative Oncology Group, Austria

**P1.06-019: The Possibility of the Additional Local Therapy to Systemic Chemotherapy in Advanced Lung Cancer Cases with Multiple Metastases**  
Takeshi Honda, Teikyo University, Japan

**P1.06-020: Prevalence of Autoimmune Disease in US Veterans With Non-Small Cell Lung Cancer (NSCLC)**

Monika Parisi, Celgene Corporation, USA

**P1.06-021: Treatment Patterns and Healthcare Resource Use from a Retrospective Cohort of Japanese Patients with Advanced Non-Small Cell Lung Cancer**

Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Japan

**P1.06-022: Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients**

Andrea Fung, University of Calgary, Canada

**P1.06-023: Clinicopathological Characteristics of Axillary Lymph Node Metastasis in Lung Cancer**

Yue Kong, Zhejiang Cancer Hospital, China

**P1.06-024: Distinctive Patterns of Primary Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer**

Dong Soo Lee, College of Medicine, The Catholic University of Korea, South Korea

**P1.06-025: Analysis of Risk Factors for Development of Skeletal-Related Events in Women with Bone Metastases from NSCLC and Breast Cancer**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P1.06-026: Adenosquamous Carcinoma of the Lung: A Single Institution Experience in the Era of Molecular Testing**

Kamal Kishore Mandalapu, Merit Health Biloxi., USA

**P1.06-027: Retrospective Study of Treatment for Postoperative Local Recurrence of Lung Cancer**

Kenjiro Tsuruoka, Osaka Medical College Hospital, Japan

**P1.06-028: Description of the Patients with Advanced Squamous NSCLC Treated in a Single Institution**

Irene Torres, Hospital Universitario Miguel Servet, Spain

**P1.06-029: Epidemiologic, Clinical Characteristics and Therapeutic Strategy of Elderly NSCLC Patients Treated in a Single Institution**

Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

**P1.06-030: Extended Lymph Node Dissection through Median Sternotomy in N3 Left NSCLC Surgical Results and Anatomical Findings**

Shingo Ikeda, Mitsui Memorial Hospital, Japan

**P1.06-031: A North Malaysia Pulmonology Center Experience in Management of Advanced Non-Small Cell Lung Cancer**

Syazatul Syakirin Sirol Aflah, Hospital Sultanah Bahiyah, Malaysia

**P1.06-032: The Humanistic Burden of Advanced Non-Small Cell Lung Cancer Patients in Europe - A Real World Survey**

Oana Chirita, Bristol-Myers Squibb, UK

**P1.06-033: Non-Small Cell Lung Cancer in Young Patients; Clinico-Pathologic Criteria and Prognostic Factors**

Hala Aziz, National Cancer Institute, Egypt

**P1.06-034: Outcomes after Pulmonary Metastasectomy for Metastatic Cancer**

Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

**P1.06-035: Frequency and Clinical Relevance of EGFR-Mutations and EML4-ALK-Translocations in Octagenarians with NSCLC**

Amanda Tufman, Ludwig Maximilian University of Munich, Germany

**P1.06-036: Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment**

Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P1.06-037: Non-Small Cell Lung Cancer Invading the Diaphragm: Outcome and Prognostic Factors**

Domenico Galetta, European Institute of Oncology, Italy

**P1.06-038: Survival and Prognostic Factors of Oligometastatic Non-Small Cell Lung Carcinoma: A Single Center Experience**

Ugur Yilmaz, Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

**P1.06-039: Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant**

Kelvin Young, Princess Margaret Cancer Centre, Canada

**P1.06-040: Home-Based Pulmonary Rehabilitation in Advanced Non Small Cell Lung Cancer Patients Treated by Oral Targeted Therapy: A Feasibility Study**

Caroline Pagniez, Hospital of the University (CHRU) of Lille, France

**P1.06-041: Overall Survival and Intermediate Outcomes among Scandinavian Non-Small Cell Lung Cancer Patients: The SCAN-LEAF Study**

Maria Planck, Lund University, Sweden

**P1.06-042: The Importance of Medication Related Osteonecrosis of the Jaws (MRONJ)**

Mark Krasnik, Rigshospitalet, Denmark

**P1.06-043: A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINTHER) - The Sheba Experience in Lung Cancer Patients**

Amir Onn, Sheba Medical Center, Israel

**P1.06-044: Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France**

Christos Chouaid, Centre Hospitalier Intercommunal Créteil, France

**P1.06-045: Multiple Neoplasms Consist of Lung Cancer and Hematological Malignancies**

Kazuhiko Natori, Toho University Medical Center Oomori Hospital, Japan

**P1.06 ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ADVANCED ELDERLY**

**P1.06-046: Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study**

Tindara Franchina, Department of Human Pathology, University of Messina and Medical Oncology Unit, A.O. Papardo, Italy

**P1.06-047: Management of Patients Aged over 70 Years with Newly Diagnosed Lung Cancer**  
Haider Abbas, Birmingham Heartlands Hospital, UK

## **P1.07 SCLC/NEUROENDOCRINE TUMORS**

### **P1.07 SCLC/NEUROENDOCRINE TUMORS - DRUG TREATMENT ALONE AND IN COMBINATION WITH RADIOTHERAPY**

**P1.07-001: A Phase II Study of Etirinotecan Pegol (NKTR-102), a Topoisomerase-I Inhibitor Polymer Conjugate, in Small Cell Lung Cancer**  
Hongbin Chen, Roswell Park Cancer Institute, USA

**P1.07-002: G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results**  
Lowell Hart, Florida Cancer Specialists, USA

**P1.07-003: A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC**  
Christian Grohé, Evangelische Lungenklinik, Germany

**P1.07-004: Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer**  
Muhammad Alamgeer, Monash Cancer Centre, Australia

**P1.07-005: A Retrospective Study of Sequential Chemoradiotherapy for LD-SCLC Patients in Whom Concurrent Therapy is Not Indicated**  
Sayaka Ohara, NTT Medical Center Tokyo, Japan

**P1.07-006: Preclinical Support for Evaluation of Irinotecan Liposome Injection (nal-IRI, MM-398) in Small Cell Lung Cancer**  
Bart Hendriks, Merrimack Pharmaceuticals, Inc., USA

**P1.07-007: Clinical Outcomes of Patients with LS-SCLC Treated with Chemoradiotherapy. Can We Find Candidates for Salvage Surgery?**  
Junichi Shimizu, Aichi Cancer Center Hospital, Japan

**P1.07-008: Lomustine Endoxan VP16 as Second or Further Line for Recurrent or Progressive Brain Metastases from SCLC**  
Pascal Dô, Baclesse, France

**P1.07-009: Outcomes of Patients with Relapsed Small-Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year-Analysis**  
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

**P1.07-010: Influence of Creatinine Clearance on Survival Parameters in Small Cell Lung Cancer Treated with Cisplatin-Based Chemotherapy Regimen**  
Fatih Kose, Baskent University, Turkey

**P1.07-011: Extensive-Stage Small Cell Lung Cancer in a 13-Year-Old Male Patient Treated with Bevacizumab Followed by High-Dose Chemotherapy**  
Michihiro Yano, Akita University Hospital, Japan

**P1.07-012: Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort**

Matteo Giaj Levra, Michallon Hospital - University Hospital, France

**P1.07-013: Treatment Related Side Effects of Oral Topotecan in Small Cell Lung Cancer**

Marko Jakopovic, University Hospital Center, Croatia

**P1.07-014: Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis**

Taofeek Owonikoko, Emory University Winship Cancer Institute, USA

**P1.07-015: STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC**

Penella Woll, University of Sheffield, UK

**P1.07 SCLC/NEUROENDOCRINE TUMORS - LOCAL TREATMENT**

**P1.07-016: Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer**

Elliot Wakeam, University of Toronto, Canada

**P1.07-017: Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer**

Elliot Wakeam, University of Toronto, Canada

**P1.07-018: Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice**

Giannis Mountzios, University of Athens School of Medicine, Greece

**P1.07-019: Large Cell Neuroendocrine Carcinoma of the Lung: Prognostic Factors of Survival and Recurrence after R0 Surgical Resection**

Maria Cattoni, Swedish Cancer Institute, USA

**P1.07-020: Surgical Resected Small Cell Lung Cancers (SCLCs): A Monocentric Retrospective Analysis**

Laura Bonanno, Istituto Oncologico Veneto, Italy

**P1.07-021: Impact on Survival of High Dose Consolidative Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer**

Josep Jové, Institut Catala Oncologia, Spain

**P1.07-022: The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer**

Aleksei Aksarin, Surgut District Clinical Hospital, Russia

**P1.07 SCLC/NEUROENDOCRINE TUMORS - MOLECULAR CHANGES**

**P1.07-023: NGS May Discriminate Extreme Long-Term versus Short-Term Survival in Patients with Stage IV Small-Cell Lung Cancer (SCLC)**

Zoltan Lohinai, Medical University Vienna, Austria

**P1.07-024: EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact**

Huarong Tang, Zhejiang Cancer Hospital, China



**P1.07-025: MiR-495 Promotes Chemoresistance of SCLC through Epithelial-Mesenchymal Transition via Etk/BMX**

Linlang Guo, Zhujiang Hospital, Southern Medical University, China

**P1.07-026: Activin A is Associated with Poor Prognosis and Promotes Metastatic Growth in Small Cell Lung Cancer**

Anita Rozsas, Medical University Vienna, Austria

**P1.07-027: 13-Genes Signature of EMT Reveals Impact on Invasion and Metastasis of Neuroendocrine Carcinomas of the Lung: A Preliminary Study**

Tabatha Prieto, Faculdade de Medicina da USP, Brazil

**P1.07-028: Dual Role of the Focal Adhesion Kinase in Small-Cell Lung Cancer**

Frank Aboubakar Nana, Université Catholique de Louvain, Belgium

**P1.07-029: In Vitro Effects of Pegylated Arginase in Small Cell Lung Cancer**

Shi Xu, The University of Hong Kong, Hong Kong

**P1.07-030: Gene Signature of EMT in Neuroendocrine Lung Carcinoma: A Comparative Analysis with Adenocarcinoma and Squamous Cell Carcinoma**

Tabatha Prieto, Faculdade de Medicina da USP, Brazil

**P1.07-031: Clinical Evaluation of Folate Receptor-Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer**

Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P1.07-032: Most Common Genomic Alterations in SCLC**

Patricia Thompson, Cancer Treatment Centers of America, USA

**P1.07-033: Trastuzumab Emtansine (T-DM1) Suppresses the Growth of HER2-Positive Small-Cell Lung Cancer in Preclinical Models**

Osamu Morimura, Osaka University Graduate School of Medicine, Japan

**P1.07-034: Somatostatin Receptors Expression in Small Cell Lung Cancer Patients**

Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

**P1.07-035: Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer**

Daniel Morgensztern, Washington University School of Medicine in St. Louis, USA

**P1.07 SCLC/NEUROENDOCRINE TUMORS - PATHOLOGY**

**P1.07-036: Large Cell Neuroendocrine Carcinoma of the Lung: The Mayo Clinic Experience**

Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand

**P1.07-037: Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung**

Masahiro Morise, Nagoya University Graduate School of Medicine, Japan

**P1.07-038: Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas**

Hao-ran Zhai, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China

**P1.07-039: Insulinoma-Associated 1 (INSM1) Immunohistochemical Expression in Lung Neuroendocrine Tumors**

Yasuyuki Shigematsu, The Cancer Institute, Japan

**P1.07 SCLC/NEUROENDOCRINE TUMORS - PROGNOSTIC FACTORS**

**P1.07-040: Prognostic Factors in Extensive Disease (ED) Small Cell Lung Cancer (SCLC): An ELCWP Phase III Randomised Trial**

Thierry Berghmans, Institut Jules Bordet, Belgium

**P1.07-041: Validation of Prognostic Scores in Small Cell Lung Cancer**

Sacha Rothschild, University Hospital Basel, Switzerland

**P1.07-042: Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Predict Prognosis in Early-Stage Resected Small-Cell Lung Cancer Patients**

Virag Hollosi, National Koranyi Institute of Pulmonology, Hungary

**P1.07-043: Patterns of Failure and the Prognostic Factors of the Patients with LD SCLC according to the TNM Staging; TOG-TROD Study**

H Fazilet Dinçbaşı, Istanbul University, Cerrahpasa Medical Faculty, Turkey

**P1.07 SCLC/NEUROENDOCRINE TUMORS - SCLC/NEUROENDOCRINE TUMORS IN GENERAL**

**P1.07-044: Educational Level and Management in Small-Cell Lung Cancer (SCLC): A Population-Based Study**

Salomon Tendler, Karolinska University Hospital, Sweden

**P1.07-045: Characteristics of Exceptional Long Term Survivors in Extensive Stage Small Cell Lung Cancer**

Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand

**P1.07-046: Uptake of Recommended Treatment in Small Cell Lung Cancer: Trend over the Last 15 Years and Risk Factors**

KM Islam, University of Nebraska Medical Center, USA

**P1.07-047: Refusal of Chemoradiotherapy and Chemotherapy among SCLC Patients: Analysis of US National Facility-Based Data**

KM Islam, University of Nebraska Medical Center, USA

**P1.07-048: Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients**

Hisao Imai, Gunma Prefectural Cancer Center, Japan

**P1.07-049: Limited Stage Small Cell Lung Cancer: Patterns of Care and Outcomes of a Single Institution over 15 Years**

Eunji Hwang, Prince of Wales Hospital, Australia

**P1.07-050: Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center**

Abdulaziz Al Farsi, Juravinski Cancer Center, Canada

**P1.07-051: Incidence and Clinical Characteristics of Pulmonary Large-Cell Neuroendocrine Carcinoma: An Overview of Our Own Data**

Gordana Drpa, Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, Croatia

**P1.07-052: Pulmonary Neuroendocrine Tumors: Single Institution Experience in Brazil**

Maria Teresa Tsukazan, Universidade Federal do Rio Grande do Sul - UFRGS, Brazil

**P1.07-053: Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study**

Wei Hong, Zhejiang Cancer Hospital, China

**P1.07-054: Second Primary Small Cell Carcinoma of Lung in Previously Treated Carcinoma Breast**

Prasanta Mohapatra, All India Institute of Medical Sciences, India

**P1.07-055: Introducing the US National Cancer Institute's Small Cell Lung Cancer Consortium**

Peter Ujhazy, National Cancer Institute, USA

**P1.08 SURGERY**

**P1.08 SURGERY - RISK ASSESSMENT & PROGNOSTIC FACTORS**

**P1.08-001: Log Odds as a Novel Prognostic Indicator Superior to the Number-Based and Ratio-Based Category for Non-Small Cell Lung Cancer**

Dariusz Dziedzic, National Institute of Chest Diseases, Poland

**P1.08-002: The Prognostic Significance of Pleural Lavage Cytology before and after Lung Resection**

Yohei Yurugi, Tottori University, Japan

**P1.08-003: Survival of Lung Cancer Patients was Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System**

Oleg Kshivets, Saint-Petersburg Clinic, Russia

**P1.08-004: Prediction of Surgical Outcome by Modeling Based on Risk Factors of Morbidity Following Pulmonary Resection for Lung Cancer in the Elderly**

Yuzhao Wang, Peking University Cancer Hospital & Institute, China

**P1.08-005: Stratification of pStage I Lung Adenocarcinoma by the Scoring System Based on Prognostic Factors**

Naoya Kawakita, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan

**P1.08-006: Prognostic Impact of Incompletely Lobulated Fissures in Non-Small-Cell Lung Cancer**

Junichi Okamoto, Nippon Medical School Musashikosugi Hospital, Japan

**P1.08-007: The Significant Improvement of Lung Function after Preoperative Rehabilitation in Patients with Thoracic Tumors and Abnormal Spirometry**

Maciej Glogowski, The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Poland

**P1.08-008: Impact of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection**

Osamu Araki, Dokkyo Medical University, Japan

**P1.08-009: Does Body Mass Index (BMI) Affect Outcomes Post Lung Resection Surgery?**

Tomoyo Fujiwara, NHS Golden Jubilee National Hospital, UK

**P1.08-010: Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery**

Florian Kocher, Medical University Innsbruck, Austria

**P1.08-011: Feasibility of Surgical Resection for Lung Cancer Patients Aged over 85 Years**

Takehiro Ouchi, Juntendo University, Japan

**P1.08-012: Characterizing Time to Care for Lung Cancer Surgical Patients**

Michael Humer, Kelowna Thoracic Surgical Group, Canada

**P1.08-013: Preoperative Managements for Pulmonary Complications Using Inhalations in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease**

Kyoshiro Takegahara, Nippon Medical School Hospital, Japan

**P1.08-014: Usefulness of Chest CT in Follow-Up of Patients with Completely Resected Lung Cancer**

Jefferson Gross, AC Camargo Cancer Center, Brazil

**P1.08-015: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 80 Years or Older**

Osamu Kawamata, Onomichi Municipal Hospital, Japan

**P1.08-016: BMI in Patients with Operated Lung Cancer in Comparison with the Scottish Health Survey 2014. Is There a Democracy in BMI?**

Tomoyo Fujiwara, Golden Jubilee National Hospital, UK

**P1.08-017: Does Mediastinal Lymph Node Dissection Affect Prognosis of Early Stage NSCLC?**

Hye-seon Kim, Hanyang University Seoul Hospital, South Korea

**P1.08-018: Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer**

Jin Gu Lee, Yonsei University College of Medicine, South Korea

**P1.08-019: Risk Factors and Survival of Occult N2 Lymph Node Metastasis in NSCLC Patients with Clinical N0-1 Diagnosed by Preoperative PET-CT**

KS Park, DCMC, South Korea

**P1.08-020: The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)**

Nicholas Faris, Baptist Cancer Center, USA

**P1.08-021: Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US**

Matthew Smeltzer, University of Memphis School of Public Health, USA

**P1.08-022: Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables**

Haval Balata, University Hospitals of South Manchester, UK

**P1.08-023: Analysis of Prognostic Factors and Long-Term Results of Primary Pulmonary Pleomorphic Carcinoma**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08-024: Surgical Outcomes and Prognostic Factors in the Treatment of Adenosquamous Carcinoma of the Lung**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08 SURGERY - EPIDEMIOLOGIC STUDIES IN SURGERY FOR NSCLC**

**P1.08-025: Long-Term Survival of Lung Cancer in Chile**

Ruben Valenzuela, Clínica Santa María, Chile

**P1.08-026: LUNG CANCER - Early and Late Outcomes of Surgical Patients of a New District Hospital**

Paulo Calvino, Hospital de Santa Marta, Portugal

**P1.08-027: Evolution of Survival in a Regional Population-Based US Lung Cancer Resection Cohort**

Raymond Osarogiagbon, Baptist Cancer Center, USA

**P1.08-028: Nationwide Trends in Surgery for Lung Cancer in Finland from 2004 to 2014**

Jarmo Gunn, Turku University Hospital, Finland

**P1.08-029: Surgical Experience of Primary Salivary Gland Tumors of Lung: Experience from Tertiary Care Cancer Center in North India**

Ashish Jakhetiya, All India Institute of Medical Sciences, India

**P1.08-030: Female Lung Cancer and Our Five Year Experience**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

**P1.08-031: Non-Small Cell Lung Cancer in Patients Aged 40 Years or Younger: Clinical, Surgical, and Long-Term Outcomes**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08 SURGERY - TRANSLATIONAL STUDIES**

**P1.08-032: Impact of the Oncogenic Status on the Mode of Recurrence in Resected Non-Small Cell Lung Cancer**

Tetsuya Mizuno, Aichi Cancer Center Hospital, Japan

**P1.08-033: Effect of EGFR Mutations on Survival in Patients following Surgical Resection of Lung Adenocarcinoma**

Grace Laidlaw, Stanford University School of Medicine, USA

**P1.08-034: Prognostic Impact of EGFR Mutation in Patients with Surgically Resected Lung Adenocarcinoma; Analysis about Subtypes of EGFR Mutations**

Yohei Kawaguchi, Tokyo Medical University Hospital, Japan

**P1.08-035: Analysis of Post-Operative Recurrence in a Population with NSCLC Harboring an EGFR Mutation: A Single Institutional Retrospective Study**

Hayashi Kosuke, Matusaka Municipal Hospital, Japan

**P1.08 SURGERY - MINIMAL INVASIVE SURGERY**

**P1.08-036: Thoracotomy and VATS-Surgery in Local Non-Small Cell Lung Cancer: Differences in Long-Term Health Related Quality of Life**

Ville Rauma, Heart and Lung Center, Helsinki University Central Hospital, Finland

**P1.08-037: Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography-Assisted Bronchoscopic Metallic Coil Marking (2nd Version)**

Takanori Miyoshi, Tokushima Municipal Hospital, Japan

**P1.08-038: VATS Sub-Lobar Anatomical Pulmonary Resections: Indications and Outcomes in Thoracic Oncological Practice**

Bibhusal Thapa, Olivia Newton John Cancer Research Institute, Australia

**P1.08-039: Systematic Review and Updated Meta-Analysis of Uniportal versus Multiportal Video-Assisted Thoracoscopic Surgery for Lung Cancer**

Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

**P1.08-040: Lymph Node Sampling in 3-Port Video Assisted Thoracoscopic Surgery (VATS) vs Uniportal VATS**

Michael Klimatsidas, Golden Jubilee National Hospital, UK

**P1.08-041: Disease Free and Overall Survival is Equal in Open and VATS Resection for Early Lung Cancer in a Multivariate Analysis**

Caecilia Ng, Medical University Innsbruck, Austria

**P1.08-042: Overall Survival and Tumor Recurrence after VATS Lobectomy of N1 Positive NSCLC is Equal to Open Resection**

Herbert Maier, Medical University Innsbruck, Austria

**P1.08-043: Perioperative and Mid-Term Outcomes after Single Port versus Multi-Ports Thoracoscopic Lobectomy for Lung Cancer: A Propensity Matching Study**

Bong Soo Son, Pusan National University Yangsan Hospital, South Korea

**P1.08-044: Comparison of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Lobectomies versus Segmentectomies**

Eric Toloza, Moffitt Cancer Center, USA

**P1.08-045: Partial Lung Resection after Bronchoscopic Metallic Coil Marking Using Two Coins and C-Armed Shaped Fluoroscopic Guidance**

Koh Uyama, Tokushima Municipal Hospital, Japan

**P1.08-046: Survival Following Thoracoscopic Pulmonary Metastasectomy for Osteosarcoma**

Takashi Tojo, Nara medical university, Japan

**P1.08-047: Decreasing Use of Epidural Analgesia with Increasing Minimally Invasive Lobectomy: Impact on Postoperative Morbidity**

Masha Zeltsman, Memorial Sloan Kettering Cancer Center, USA

**P1.08-048: Comparison of Pulmonary Function after Robotic-Assisted Video-Thoracoscopic Lobectomies vs Segmentectomies**

Eric Toloza, Moffitt Cancer Center, USA

**P1.08-049: CT Guided Labeling with Indocyanine Green of Small Lung Nodules for Sublobar Resection Utilizing Robotic Assisted Thoracoscopic Surgery (RATS)**

K Adam Lee, Jupiter Medical Center, USA

**P1.08-050: VATS Lobectomy in Locally Advanced NSCLC: A Single Centre Experience**

Davide Tosi, Fondazione IRCCS Ca' Granda Policlinico, Italy

**P1.08-051: VATS Lobectomy Combined with Limited Thoracotomy for Treatment of Superior Sulcus Tumors**

Davide Tosi, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

**P1.08-052: Comparison Study of Perioperative Outcomes in Robotic, Video-Assisted Thoracic Surgery, and Thoracotomy Approaches for Lung Cancer**

Hiroshige Nakamura, Tottori University Hospital, Japan

**P1.08-053: Thoracoscopic Partial Resection for Peripheral Pulmonary Nodules without Using Stapler**

Toshiya Toyazaki, Tenri Hospital, Japan

**P1.08-054: Uniportal VATS Lobectomy in the Treatment of NSCLC**

Nenad Ilic, University Surgical Hospital, Croatia

**P1.08-055: Hand Assisted Thoracoscopic Surgery (HATS) for Metastatic Lung Tumors - Improved Technique for More Safety and Accuracy**

Shozo Fujino, University Hospital Mizonokuchi, Teikyo University School of Medicine, Japan

**P1.08-056: Surgical Results of Thoracoscopic Anatomical Sublobar Resections for Early-Stage Lung Cancer**

Fumiaki Watanabe, Matsusaka Municipal Hospital, Japan

**P1.08-057: Outcomes between Single Port, Two Port and Three Port VATS Pulmonary Resection**

Juwei Mu, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P1.08-058: VATS lung resection analysis from Brazilian Society of Thoracic Surgery Database**

Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

**P1.08 SURGERY - SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC**

**P1.08-059: Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC**

Huseyin Melek, Uludag University, Turkey

**P1.08-060: Survival of Patients with Unsuspected N2 (Stage IIIA) Non-Small Cell Lung Cancer**

Takashi Yamamichi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

**P1.08-061: Clinical Experience of Rib Resection for Lung Cancer with Chest Wall Invasion Using a Pneumatic High Speed Power Drill System**

Yuichiro Ueda, Tenri Hospital, Japan

**P1.08-062: The Short and Long-Term Outcomes of Completion Pneumonectomy Compared with Primary Pneumonectomy**

Takuya Ueda, National Cancer Center Hospital East, Japan

**P1.08-063: Double Primary Malignancies Involving Lung Cancer and Hepatocellular Carcinoma**

Han Pil Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P1.08-064: Surgery for Malignant Pulmonary Tumor Invading Proximal Left Main Pulmonary Artery**

Fumihiko Tanaka, University of Occupational and Environmental Health, Japan

**P1.08-065: Resection of Isolated Brain Metastasis Improves Outcome of Non Small-Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study**

Julia Fuchs, University Hospital Basel, Switzerland

**P1.08-066: Prognostic Factors of Post-Recurrence Survival in Patients with Completely Resected Stage III-N2 Non-Small Cell Lung Cancer**

Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

**P1.08-067: The Feasibility of Lung Second Surgery for 2nd Primary Lung Cancer**

Kazunori Hata, Juntendo University School of Medicine, Japan

**P1.08-068: Salvage Surgical Resection after Curative-Intent Concurrent Chemoradiotherapy for N2-Stage III Lung Cancer**

Motohiro Yamashita, Shikoku Cancer Center, Japan

**P1.08-069: One Surgeon's 30-Year Experience of Surgical Treatment for Pancoast Tumor**

Hiroshi Niwa, Seirei Mikatahara General Hospital, Japan

**P1.08-070: Salvage Lung Surgery: Difficulties and Results**

Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

**P1.08-071: Surgery for Lung Cancer with Mediastinal Lymph Node Metastasis - Effectiveness of Extended Bilateral Mediastinal Lymphadenectomy**

Toshiya Yokota, Mitsui Memorial Hospital, Japan

**P1.08-072: The Result of Completion Pneumonectomy for the Local Recurrent Lung Cancer after Radical Lobectomy**

Takeshi Shiraishi, Fukuoka University School of Medicine, Japan

**P1.08-073: Experience of Third Primary Lung Tumors after Treatment of First and Second Primary Lung Cancer**

Takehiro Watanabe, Nishi-Niigata Chuo National Hospital, Japan

**P1.08-074: Effect of Intrapleural Perfusion Hyperthermic Chemotherapy in Non-Small Cell Lung Cancer with Pleural Seeding**

Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

**P1.08-075: Salvage Surgery for Stage IV Non-Small Cell Lung Cancer**

Hideaki Kojima, Shizuoka Cancer Center, Japan

**P1.08-076: Recurrence Patterns in Lung Cancer Patients Treated with Protocol Based Multimodality Treatment at a Tertiary Care Cancer Center in India**

Ashish Jakhethiya, All India Institute of Medical Sciences, India

**P1.08-077: Comparison of Pulmonary Resection for Lung Cancer after Radical Chemoradiation with That after Induction Chemoradiation**

Yasuhiro Hida, Hokkaido University Hospital, Japan

**P1.08-078: Does Surgery Have Real Benefit in Resectable Oligometastatic NSCLC?**

Oleg Pikin, Hertzen Research Institute of Oncology, Russia

**P1.08-079: Salvage Surgery after Definitive Radiotherapy or Chemoradiotherapy for Lung Cancer**

Naoya Yamasaki, Nagasaki University, Japan



**P1.08-080: Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results and Long-term Outcomes**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08-081: Resection of T4 Non-Small Cell Lung Cancer Invading the Spine**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08-082: Surgical Techniques and Long-Term Results of the Pulmonary Artery Reconstruction in Patients with Lung Cancer**

Domenico Galetta, European Institute of Oncology, Italy

**P1.08-083: Hyperthermic Pleural Lavage for Pleural Metastases**

Patricia Thompson, Cancer Treatment Centers of America, USA

**P1.08 SURGERY - MISCELLANEOUS**

**P1.08-084: Treatment for Elderly Patients with Clinical Stage I Non-Small Cell Lung Cancer; Surgery or Stereotactic Body Radiotherapy?**

Takuro Miyazaki, Nagasaki Graduate School of Medicine, Japan

**TUESDAY, DECEMBER 6, 2016****P2.01 BIOLOGY/PATHOLOGY**

ANALYSIS OF BODY FLUIDS IN CANCER	P2.01-001 - P2.01-009
ANALYSIS OF RNA	P2.01-010 - P2.01-025
PROTEINS IN LUNG CANCER AND PROTEOMICS	P2.01-026 - P2.01-041
IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY	P2.01-042 - P2.01-068
MARKER FOR PROGNOSIS, PREDICTION	P2.01-069 - P2.01-085
TARGETS FOR TREATMENT PREDICTION	P2.01-086 - P2.01-093
MISCELLANEOUS	P2.01-094

**P2.02 LOCALLY ADVANCED NSCLC**

BIOLOGY	P2.02-001 - P2.02-006
CLINICAL OUTCOME	P2.02-007 - P2.02-022
MULTIMODALITY TREATMENT	P2.02-023 - P2.02-043
PROGNOSTIC FACTOR	P2.02-044 - P2.02-056
RT TECHNIQUES	P2.02-057 - P2.02-060
TOXICITIES	P2.02-061 - P2.02-062

**P2.03a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

CLINICAL TRIALS	P2.03a-001 - P2.03a-071
-----------------	-------------------------

**P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

BRAIN META	P2.03b-001 - P2.03b-020
BIOMARKERS	P2.03b-021 - P2.03b-098

**P2.04 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES**

THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL	P2.04-001 - P2.04-024
ESOPHAGEAL CANCER AND OTHER MALIGNANCIES	P2.04-025 - P2.04-054

**P2.05 RADIOTHERAPY**

BIOLOGY	P2.05-001 - P2.05-005
CLINICAL OUTCOME	P2.05-006 - P2.05-025
MULTIMODALITY TREATMENT	P2.05-026 - P2.05-032
RT TECHNIQUES	P2.05-033 - P2.05-048
TOXICITIES	P2.05-049 - P2.05-058

**P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS**

PHASE I TRIALS	P2.06-001 - P2.06-005
PHASE I/II TRIALS	P2.06-006 - P2.06-009
PHASE II + NK	P2.06-010 - P2.06-020
PHASE III	P2.06-021 - P2.06-024
MESOTHELIOMA AND SCLC	P2.06-025 - P2.06-029
SUPPORTIVE, PREVENTIVE	P2.06-030 - P2.06-033
RADIOTHERAPY, TT FIELDS	P2.06-034 - P2.06-037
LAB., OTHER	P2.06-038 - P2.06-047

**P2.07 NURSES**

INFORMATION FOR PATIENTS	P2.07-001 - P2.07-003
DIFFERENT ASPECTS OF SYMPTOMS	P2.07-004 - P2.07-006
RESEARCH, AUDITS	P2.07-007 - P2.07-010



**P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS**  
PATIENTS' VOICE, PATIENTS INFORMATION  
OTHER

P2.08-001 - P2.08-007  
P2.08-008 - P2.08-015

## **Tuesday, December 6, 2016**

Poster Setup Time: Tuesday, December 6, 08:30 - 10:15

Poster Takedown Time: Tuesday, December 6, 15:45 - 18:00

(Posters not taken down by 18:00 will be discarded by management)

### **POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)**

Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.

Tuesday, December 6, 14:30 - 15:45 (Hall B - Poster Area)

#### **P2.01 BIOLOGY/PATHOLOGY**

##### **P2.01 BIOLOGY/PATHOLOGY - ANALYSIS OF BODY FLUIDS IN CANCER**

**P2.01-001: Enrichment-Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Pheripheral Blood**

Qihui Shi, Shanghai Jiao Tong University, China

**P2.01-002: Serum Protein Signature in Lung Cancer Patients and in Patients with Chronic Obstructive Pulmonary Disease**

Janna Berg, Vestfold Hospital Trust, Norway

**P2.01-003: Serum VEGF, MMP-7 and CYFRA 21-1 as Predictive Markers of Lung Metastases from Colorectal Cancer**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P2.01-004: The Methylation Profiling of Multiple Tumor Suppressor Genes in Plasma Cell-Free DNA of Patients with NSCLC vs Benign Tumors**

Mateusz Florczuk, National Institute of Tuberculosis and Lung Diseases, Poland

**P2.01-005: Evaluation of Circulating Tumoral Microemboli (CTM) as a Prognostic Factor in Non-Small Cell Lung Cancer (NSCLC)**

Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

**P2.01-006: Sensitive Detection of CTCs in Thoracic Malignant Tumors With "Universal" CTC-Chip**

Kazue Yoneda, University of Occupational and Environmental Health, Japan

**P2.01-007: Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in Tissue Biopsy and Matched Serum of Advanced Stage Lung Cancer Patients**

Ashraf Ansari, All India Institute of Medical Sciences, India

**P2.01-008: SiRe Next Generation Sequencing Panel: Effective Diagnostic Tool for Circulating Free DNA Analysis**

Umberto Malapelle, University of Naples Federico II, Italy

**P2.01-009: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer**

Yue Zhao, Fudan University Shanghai Cancer Center, China

#### **P2.01 BIOLOGY/PATHOLOGY - ANALYSIS OF RNA**

**P2.01-010: Downregulation of PFTK1 by shRNA Inhibits Migration and Invasion of Human Non-Small Cell Lung Cancer Cell Lines**

Xiaoting Zhao, Beijing TB and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, China

**P2.01-011: Identification of Differentially Expressed Circulating miRNAs in the Serum of NSCLC Patients Using next Generation Sequencing**

Sachin Kumar, Amity University Uttar Pradesh, India

**P2.01-012: Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines**

Simon Haefliger, University of Sydney, Australia

**P2.01-013: HA-Liposome Nanocarrier Containing CD44 siRNA as a Targeted Chemotherapy to CD44 Related Chemoresistant Non-Small Cell Lung Cancer**

Hyun Koo Kim, Korea University Guro Hospital, South Korea

**P2.01-014: miR-3941: A Novel microRNA That Controls IGBP1 Expression and is Associated with Malignant Progression of Lung Adenocarcinoma**

Taiki Sato, University of Tsukuba, Japan

**P2.01-015: Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes**

Tomas Tokar, University Health Network, Canada

**P2.01-016: Analysis of 5 Differential miRNA Expression in NSCLC Patients**

Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

**P2.01-017: Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment**

Orazio Fortunato, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Italy

**P2.01-018: Differential microRNA Expression Profile between Young and Old Lung Adenocarcinoma Patients**

Mirella Giordano, University of Pisa, Italy

**P2.01-019: Three microRNAs Associated with Poor Prognosis Are Up-Regulated in Amplified Regions of Squamous Cell Lung Carcinoma**

Sana Yokoi, Chiba Cancer Center Research Institute, Japan

**P2.01-020: Identification of a Three-lncRNA Signature for Lung Cancer Diagnosis and Prognosis**

Changli Wang, Tianjin Medical University Cancer Institute and Hospital, China

**P2.01-021: miRNA Deep Sequencing of Early-Stage Lung Cancer Patients to Evaluate the Dynamic Change of Circulating Biomarkers in Response to Surgery**

Daniela Petriella, IRCCS, Istituto Tumori Giovanni Paolo II, Italy

**P2.01-022: A PIWI-Interacting RNAs Co-Expression Networks as a Prognostic Factor in Lung Cancer**

Brenda Minatel, British Columbia Cancer Research Centre, Canada

**P2.01-023: Deregulation of Small Non-Coding RNAs at the DLK1-DIO3 Imprinted Locus Predicts Lung Adenocarcinoma Patient Outcome**

John Enterina, BC Cancer Research Centre, Canada

**P2.01-024: Expression of miR-106 Paralogs Improves Prognostic Value of Mesenchymal Signatures but Only miR-106b Promotes Invasiveness**

Sonia Kung, British Columbia Cancer Research Centre, Canada

**P2.01-025: MiR-146b Functions as a Suppressor miRNA and Prognosis Predictor in Non-Small Cell Lung Cancer**

Jun Chen, Tianjin Medical University General Hospital, China

**P2.01 BIOLOGY/PATHOLOGY - PROTEINS IN LUNG CANCER AND PROTEOMICS**

**P2.01-026: A Mass Spectrometry Based Stem Cell-Oriented Phylogeny of Intra-Tumoral NSCLC Subclones**

Robert Downey, Memorial Sloan Kettering Cancer Center, USA

**P2.01-027: A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Samples**

Joey Lim, National University of Singapore, Singapore

**P2.01-028: Prognostic Significance of GLUT1 and CAIX Expression: Correlation with Volume-Based PET Parameters in Non-Small Cell Lung Cancer**

Young Wha Koh, Ajou University School of Medicine, South Korea

**P2.01-029: Tumor B7-H3 (CD276) Protein Expression, Smoking History, and Survival in Lung Adenocarcinoma Patients**

Kentaro Inamura, The Cancer Institute, JFCR, Japan

**P2.01-030: Prognostic Impact of Stathmin1 Expression in Patients with Non-Small Lung Cancer**

Kimihiko Shimizu, Gunma University Graduate School of Medicine, Japan

**P2.01-031: CCL Chemokines May Play an Important Role in Cisplatin Resistance**

Sarah-Louise Ryan, Queensland University of Technology, Australia

**P2.01-032: Impact of Preoperative Serum Anti-60S Ribosomal Protein L29 Levels on Prognosis in Patients Who Underwent Surgery for Non-Small Cell Lung Cancer**

Hiromasa Yamamoto, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

**P2.01-033: Exosomal Proteomics Analysis Reveal New Targets for Radiation-Induced Lung Toxicity Diagnosis**

Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

**P2.01-034: The Pregnancy Associated Endometrial Protein Glycodelin as a Biomarker for Malignant Pleural Mesothelioma**

Marc Schneider, Thoraxklinik at Heidelberg University Hospital, Germany

**P2.01-035: Protein and Molecular Alterations in EMT Pathways of Lung Cancer: A Comparative Analysis between NSCLCs**

Vera Capelozzi, University of São Paulo, Brazil

**P2.01-036: Identification of a Novel Oncogenic Ubiquitin Ligase from a Lung Cancer Epigenome-Wide Association Study (EWAS)**

Christian Faltus, Division of Epigenomics and Cancer Risk Factors, DKFZ - German Cancer Research Center; University of Salzburg, Austria

**P2.01-037: Molecular Biology Underlying COPD and Lung Cancer Converge on FOXM1 Network**  
Victor Martinez, British Columbia Cancer Research Centre, Canada

**P2.01-038: Discrimination of NSCLC Cases from Cancer-Free Controls and Adenocarcinoma from Squamous Cell Carcinoma Using Plasma Metabolomics Profiles**  
Michael Abdalmassih, University of Manitoba, Canada

**P2.01-039: Prognostic Significance of Claudin Protein Expression in Histological Subtypes of Non-Small Cell Lung Cancer**  
Judit Moldvay, National Korányi Institute of Pulmonology, Hungary

**P2.01-040: CXC Chemokine Receptor 3 and ELR Motif Negative CXC Chemokine Ligand Axis in Non-Small Cell Lung Cancer**  
Artjoms Spaks, Pauls Stradins Clinical University Hospital, Latvia

**P2.01-041: Integrated Proteo-Genomics Analyses Reveal Extensive Tumor Heterogeneity and Novel Somatic Variants in Lung Adenocarcinoma**  
Udayan Guha, Center for Cancer Research, NCI, NIH, USA

#### **P2.01 BIOLOGY/PATHOLOGY - IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY**

**P2.01-042: T Cells Subsets with INF-Gamma, TNF-Alpha and ADA in Distinguishing Tuberculous from Malignant Pleural Effusions**  
Abdellah Ali, Sohag University, Egypt

**P2.01-043: Pathologist Agreement Rates of PD-L1 Tumor and Immune Cell Quantitation Using Digital Read, Field-Of-View, and Whole Tumor Image Analysis**  
Christopher Guetter, Roche Diagnostics, USA

**P2.01-044: Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting**  
Antonio Passaro, European Institute of Oncology, Italy

**P2.01-045: Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition**  
Frank Hilberg, Boehringer Ingelheim RCV, Austria

**P2.01-046: Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC**  
Mehmet Altan, Yale Cancer Center, USA

**P2.01-047: Intra- and Inter-Observer Reproducibility Study of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC) - The DREAM STUDY**  
Wendy Cooper, Royal Prince Alfred Hospital, Australia

**P2.01-048: Paired Comparison of PDL1 Assessment on Cytology and Histology from Malignancies in the Lung**  
Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark

**P2.01-049: A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung**

Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark

**P2.01-050: Clinicopathological Characteristics of PD-L1 Expression in Lung Adenocarcinoma**

Xuan Zeng, Peking Union Medical College Hospital, China

**P2.01-051: Myeloid-Derived Suppressor Cell Expression within the Microenvironment of Lung Adenocarcinoma**

Yasuto Jin, Hiratsuka Kyosai Hospital, Japan

**P2.01-052: High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung**

Manuel Keller, Institute of Pathology, University of Bern, Switzerland

**P2.01-053: PD-L1 Expression in Patients with Small Cell Lung Cancer**

Haiyue Wang, Peking University Cancer Hospital, China

**P2.01-054: Lung Cancer PD-L1 mRNA Expression Profile and Clinical Outcomes - An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia**

Boris Sepesi, UT MD Anderson Cancer Center, USA

**P2.01-055: Lymphocytes' Subtypes Differentiation after Stimulation with Synthetic Antigen-Pulsed Dendritic Cells in Lung Adenocarcinoma Patients**

Pawel Krawczyk, Medical University, Poland

**P2.01-056: Distinct PD-L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation**

Janaki Sharma, Albert Einstein College of Medicine/Montefiore Medical Center, USA

**P2.01-057: Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma**

Wen Feng, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P2.01-058: Mutational Features Associated with Immunoreactivity in Non-Small Cell Lung Cancer**

Nicholas Syn, National University Cancer Institute, Singapore

**P2.01-059: Regulation of Glycodelin Expression - An Immunomodulatory and Pregnancy Associated Protein in NSCLC**

Rebecca Weber, Thoraxklinik at Heidelberg University Hospital, Germany

**P2.01-060: Comparative Analysis of PD-L1 Expression between Circulating Tumor Cells and Tumor Tissues in Patients with Lung Cancer**

Yasuhiro Koh, Wakayama Medical University, Japan

**P2.01-061: Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas**

Jaime Rodrigues-Canales, U.T.-M.D. Anderson Cancer Center, Translational Molecular Pathology, USA

**P2.01-062: Impact of the Tissue Distribution of Subpopulations of TILs and PD-L1 Expression on the Clinical Outcome of NSCLC**

Giovanni Bocchialini, University of Parma, Italy



**P2.01-063: PDL1, JAK2 and PTEN Copy Number Alterations Synergistically Upregulate PD-L1 Expression in NSCLC**

Sergi Clavé, Hospital del Mar, Spain

**P2.01-064: Molecular Context of Immune Microenvironment in Early-Stage Lung Squamous Cell Carcinoma**

Esther Conde, Hospital Universitario HM Sanchinarro, Spain

**P2.01-065: Quantification of Tumour-Immune Cell Spatial Relationships in the Lung Tumour Microenvironment Using Single Cell Profiling**

Katey Enfield, BC Cancer Research Centre, Canada

**P2.01-066: PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC)**

Jane Sui, St. James's Hospital, Ireland

**P2.01-067: The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients**

Giulia Barletta, San Martino Hospital - National Institute for Cancer Research, Italy

**P2.01-068: Analysis of Epithelial-Stromal Interactions and their Relevance to Lung Cancer**

César Márquez, Stanford University School of Medicine, USA

**P2.01 BIOLOGY/PATHOLOGY - MARKER FOR PROGNOSIS, PREDICTION**

**P2.01-069: Erythron Reaction Shows High Malignant Tumor Process in Lung Cancer Patients**

Yury Ragulin, Medical Radiological Research Center, Russia

**P2.01-070: Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**

Alastair Greystoke, Newcastle University, UK

**P2.01-071: Biological Implication of Cytoplasmic ECT2 in Malignant Progression of Lung Adenocarcinoma**

Zeinab Kosibaty, University of Tsukuba, Japan

**P2.01-072: Clinical Associations of MUC1 Expression in Human Lung Cancer and Precancerous Lesions**

Andreas Saltos, Moffitt Cancer Center, USA

**P2.01-073: The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma**

Hongyang Lu, Zhejiang Cancer Hospital, China

**P2.01-074: Increased AIMP2-DX2/AIMP2 Autoantibody Ratio is Associated with Poor Prognosis in Lung Cancer**

Eun Young Kim, Yonsei University College of Medicine, South Korea

**P2.01-075: Prognostic Value of Angiogenesis and Cell Adhesion Biomarkers in Non-small Cell Lung Cancer**

Kostas Syrigos, Medical School, University of Athens, Greece

**P2.01-076: Drebrin: A New Targetable Molecular Marker of Lung Adenocarcinoma**

Shinji Iyama, University of Tsukuba, Japan

**P2.01-077: Serum CYFRA 21-1 and CEA Level as a Predicting Marker for Advanced Non-Small Cell Lung Cancer**

Busyamas Chewaskulyong, Faculty of Medicine, Chiangmai university, Thailand

**P2.01-078: Frequent High TIM-3 (HAVCR2) Expression in Resected NSCLC Specimens, Most Notably in Adenocarcinoma Histology**

Aaron Lisberg, UCLA Medical Center, USA

**P2.01-079: The Serum Levels of Alpha-1 Antitrypsin Are Strongly Associated with Its Local Production by Tumor Cells in NSCLC Patients**

Adam Szpechcinski, National Institute of Tuberculosis and Lung Diseases, Poland

**P2.01-080: Mitosis Count of Lung Adenocarcinomas: Correlation between the Phosphorylated Histone 3, Number of Cancer Cells, Nuclear Grade, and Prognosis**

Takashi Inoue, Dokkyo Medical University, Japan

**P2.01-081: CDCA3 is a Novel Prognostic Cell Cycle Protein and Target for Therapy in Non-Small Cell Lung Cancer**

Mark Adams, Institute of Health and Biomedical Innovation, Australia

**P2.01-082: Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma**

Yuqing Lou, Shanghai Chest Hospital, Shanghai Jiaotong University, China

**P2.01-083: Prognostic Factors of Overall Survival in 150 Resected Lung Adenocarcinoma Patients**

Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China

**P2.01-084: Linker-Phosphorylated Smad2 and STAT3 Induce Resistance to Tyrosine Kinase Inhibition in Lung Cancer**

Yojiro Makino, Tokyo Medical University Hospital, Japan

**P2.01-085: Epigenetic Profile of Oligoprogressive versus Widespread Non-Small Cell Lung Cancer Patients**

Carolina Gabay, Instituto Angel H Roffo, Argentina

**P2.01 BIOLOGY/PATHOLOGY - TARGETS FOR TREATMENT PREDICTION**

**P2.01-086: Luteolin is a Novel Target of Axl Receptor Tyrosine Kinase to Inhibit Cell Proliferation and Circumvent Chemoresistance in Lung Cancer Cells**

Kyungchan Kim, Catholic University of Daegu Hospital, South Korea

**P2.01-087: Prognostic Significance of CA IX Overexpression in Stage III NSCLC Patients Received Neoadjuvant Treatment**

Sezer Saglam, Istanbul Bilim University, Turkey

**P2.01-088: Prenylation Inhibitors in Lung Adenocarcinoma: Comparison of Zoledronic Acid and a Novel Lipophilic Bisphosphonate**

Balazs Hegedus, Medical University of Vienna, Austria

**P2.01-089: Predictive Value of AEG-1 Expression on Tumor Response by Liquid Biopsy in NSCLC Patients Treated with Chemotherapy**

Chung-Yu Chen, National Taiwan University Hospital Yunlin Branch, Taiwan

**P2.01-090: Platin Induced Phosphorylation of ATM and ATM-Deficiency as a Predictive Marker of Platin Sensitivity in Non-Small Cell Lung Cancer**

Jarrett Moore, University of Calgary, Canada

**P2.01-091: The Anticancer Effect of Techoic Acids on Lewis Lung Carcinoma Model**

Viktoriia Nikulina, Taras Shevchenko National University of Kyiv, Ukraine

**P2.01-092: PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy**

Meng Welliver, The Ohio State University CCC, USA

**P2.01-093: Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients**

Christian Rolfo, Antwerp University Hospital & Antwerp University, Belgium

**P2.01 BIOLOGY/PATHOLOGY - MISCELLANEOUS**

**P2.01-094: Stromal Antigen 1 (SA-1), a Cohesin, is a Novel Proto-Oncogene Regulating Chromatin in Non-Small Cell Lung Cancer (NSCLC)**

Hemant Roy, Boston University Medical Center, USA

**P2.02 LOCALLY ADVANCED NSCLC**

**P2.02 LOCALLY ADVANCED NSCLC - BIOLOGY**

**P2.02-001: Advanced Large Cell Lung Cancer; Biological Behavior and Prognostic Factors**

Hala Aziz, National Cancer Institute, Egypt

**P2.02-002: Association between VEGF Gene Functional Polymorphisms and Clinical and Pathological Characteristics of Non-Small Cell Lung Cancer**

Anna Shchayuk, National Academy of Sciences of Belarus, Belarus

**P2.02-003: Increased Circulating Cytokeratin-19 (Cyfra 21-1) is Predictive of Poor Outcome of Locally Advanced Squamous Cell Carcinoma in Lung**

Jingbo Wang, Cancer Hospital, Chinese Academy of Medical Sciences, China

**P2.02-004: Real-time Monitoring of Circulating Tumor Cells to Evaluate Response of Neoadjuvant Chemotherapy in Locally Advanced NSCLC**

Miao Huang, Peking University Cancer Hospital and Institute, China

**P2.02-005: A Rare Clinical Presentation Of EGFR-Mutant Non-Small Cell Lung Cancer With Oligo-Acrometastasis**

Ugur Yilmaz, Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

**P2.02-006: Targeted Next Generation Sequencing Reveals Prognostic Recurrent Somatic Mutations in the GNAQ Oncogene in NSCLC**

Norma Hernández-Pedro, Instituto Nacional de Cancerología, Mexico

**P2.02 LOCALLY ADVANCED NSCLC - CLINICAL OUTCOME**

**P2.02-007: Treatment Outcomes of Combine Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Single Institution Study**

Pitchayaponne Klunklin, Chiangmai University, Thailand

**P2.02-008: How Do We Really Treat Patients with Stage III Non-Small Cell Lung Cancer (NSCLC)?**

Allan Price, Western General Hospital, UK

**P2.02-009: Clinical Outcomes of Induction Chemoradiotherapy with High Dose Chest Radiation for Locally Advanced Non-Small Cell Lung Cancer Patients**

Hidejiro Torigoe, Okayama University Hospital, Japan

**P2.02-010: Prognosis Impact of Oligoprogression Following Definitive Chemo-Radiotherapy in Stage III Non-Small Cell Lung Cancer**

Maria Saigi, Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet, Spain

**P2.02-011: Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries**

Milada Zemanová, Faculty of Medicine of Charles University in Prague, Czech Republic

**P2.02-012: Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin & Radiotherapy in Locally Advanced NSCLC**

Óscar Juan, Hospital Universitari i Politècnic La Fe, Spain

**P2.02-013: Costing Analysis of PROCLAIM Non-Small Cell Lung Cancer Trial Data**

Katherine Winfree, Eli Lilly and Company, USA

**P2.02-014: Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer - Analysis of the National Cancer Database**

Boris Sepesi, MD Anderson Cancer Center, USA

**P2.02-015: Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer**

Hiba Ahmed, Winship Cancer Institute, Emory University, USA

**P2.02-016: Real World Experience with Chemoradiotherapy in Locally Advanced NSCLC**

Irene Torres, Hospital Universitario Miguel Servet, Spain

**P2.02-017: A Clinical Outcome of Resected Small-Sized Non-Small Cell Lung Cancer 1 cm or Less in Diameter with N2 Lymph Node Metastasis**

Yasufumi Kato, Tokyo Medical University Ibaraki Medical Center, Japan

**P2.02-018: Chemoradiotherapy in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer**

Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

**P2.02-019: Lung Cancer in Young Adults (Age Group 18-50 yrs): Presentation, Clinical Features and Treatment**

Balaji Varadhan, Leicester Royal Infirmary, UK

**P2.02-020: Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals**

Marco Perna, Radiation Oncology Unit, Italy

**P2.02-021: Extracranial Progression (ePD) after Chemoradiotherapy (CRT) for Stage III NSCLC: Does the Chemotherapy Regimen Matter?**

Anne-Marie Dingemans, Maastricht University Medical Center, Netherlands

**P2.02-022: For down Staged Clinical N3 M0 Non-Small Cell Lung Cancer Patients Chemo-Radiotherapy Followed by Surgery Can Improve Survival**

Jitian Zhang, University of Hong Kong Shenzhen Hospital, China

**P2.02**                    **LOCALLY ADVANCED NSCLC - MULTIMODALITY TREATMENT**

**P2.02-023: Neoadjuvant Chemotherapy and Concurrent Full-Dose Radiation Therapy Followed by Surgery for Stage IIIB Non-Small Cell Carcinoma of the Lung**

Sherry Yan, Columbia University Medical Center, USA

**P2.02-024: Phase I and II Trial of Intrapleural Paclitaxel Injection for Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions**

Masato Sasaki, University of Fukui, Japan

**P2.02-025: Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage ? Non-Small-Cell Lung Cancer**

Hong Lian Ma, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China

**P2.02-026: Individualized Adjuvant Chemotherapy for Resected Lung Cancer According to Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test**

Masayoshi Inoue, Kyoto Prefectural University of Medicine, Japan

**P2.02-027: A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018**

Kazuhiko Yamada, Kurume University School of Medicine, Japan

**P2.02-028: A Phase I/II Study of Carboplatin, Pemetrexed, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC. CJLSG0912**

Naohiko Murata, Japanese Red Cross Nagoya Daini hospital, Japan

**P2.02-029: Concomitant ChemoRadiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group**

Joaquin Casal Rubio, Complejo Hospitalario Universitario de Vigo, Spain

**P2.02-030: Consolidation Chemotherapy Following Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: A Brazilian Multicentric Cohort**

Vladmir Cordeiro De Lima, A.C. Camargo Cancer Center, Brazil

**P2.02-031: Survival Data of Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine for Completely Resected NSCLC: A Retrospective Study**

Hirotsugu Kenmotsu, Shizuoka Cancer Center, Japan

**P2.02-032: Induction Histology-Based Combination Chemotherapy for Elderly Patients with Inoperable Non-Small Cell Lung Cancer (NSCLC)**

Giuseppe Banna, Cannizzaro Hospital, Italy

**P2.02-033: The Role of Surgery for Treating Occult N2 Non-Small Cell Lung Cancer**

Masashi Yanada, Japanese Red Cross Kyoto Daini Hospital, Japan

**P2.02-034: Both Induction and Adjuvant Treatment Improve Outcomes of Surgically-Resected IIIA(N2) NSCLC When Compared to Definitive Chemoradiotherapy**

Patrick Villeneuve, The Ottawa Hospital, Canada

**P2.02-035: The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non Small Cell Lung Cancer Accompanied with Central Disease Region**

Hiroki Sato, Okayama University Graduate School of Medicine, Japan

**P2.02-036: Double Plasty Operation; A Procedure with Pulmonary Arterioplasty and Bronchoplasty against Centrally Located Non-Small Cell Lung Cancer**

Koji Takahashi, Graduate School of Medicine, Kyoto University, Japan

**P2.02-037: Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer**

Ritsuko Komaki, MD Anderson Cancer Center, USA

**P2.02-038: Surgical Outcome of Stage III A-cN2/pN2 Non-Small Cell Lung Cancer**

Ryotaro Kamohara, Nagasaki University Graduate School of Biomedical Sciences, Japan

**P2.02-039: Intercalated EGFR and Chemotherapy in Locally Advanced NSCLC with EGFR Mutations: Data on 5 Patients and Clinical Study**

Frank Griesinger, Pius Hospital Oldenburg, Germany

**P2.02-040: Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer**

Yuhchyan Chen, University of Rochester, USA

**P2.02-041: The Impact of Surgical Resection after Concurrent Chemotherapy and High Dose (61 Gy) Radiation in Stage IIIA/N2 Non-Small Cell Lung Cancer**

Akif Turna, Istanbul University, Cerrahpasa Medical Faculty, Turkey

**P2.02-042: Surgical Management of Squamous Cell Carcinoma of the Lung: Survival and Functional Outcomes**

Jun Chen, Tianjin Medical University General Hospital, China

**P2.02-043: Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC**

Rachel Sanborn, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, USA

**P2.02**      **LOCALLY ADVANCED NSCLC - PROGNOSTIC FACTOR**

**P2.02-044: Impact of N2 Extent and Nodal Response on Survival after Trimodal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer**

Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P2.02-045: Prognostic Value of Metabolic FDG-PET Response in Locally Advanced NSCLC: A Literature Review**

Charlotte Van De Kerckhove, University Hospital KU Leuven, Belgium

**P2.02-046: Prognostic Value of Early Tumor Regression during Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer**

Alexander Sun, University of Toronto, Canada

**P2.02-047: Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumours Treated with Trimodality Therapy**  
Bibhusal Thapa, Austin Health, Australia

**P2.02-048: Predictive Factors of Outcome in Locally Advanced NSCLC Patients Treated with Neo-Adjuvant Chemotherapy in Resource-Constrained Settings**  
VinayaKumar J R, IRCH, All India institute of Medical Sciences(AIIMS), India

**P2.02-049: Gender and Risk of Cessation of Oral Vinorelbine in a Randomized Trial of Concurrent Chemoradiation of Locally Advanced NSCLC**  
Olfred Hansen, Odense University Hospital, Denmark

**P2.02-050: Gender and Smoking Influence on Non Small Cell Lung Cancer Histology and Tnm Stage in a Brazilian Population**  
Ricardo Terra, University of Sao Paulo Medical School, Brazil

**P2.02-051: Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non-Small Cell Lung Cancer**  
Marko Jakopovic, University Clinical Hospital Center Zagreb, Croatia

**P2.02-052: Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non Small Cell Lung Cancer**  
Jeremy Ruben, William Buckland Radiotherapy Centre and Monash University, Australia

**P2.02-053: Does the Method of Mediastinal Staging Cause the Mediastinal Nodal Clearance Following Trimodality Therapy?**  
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

**P2.02-054: Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers**  
Junichi Soh, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

**P2.02-055: Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA-N2 NSCLC after Neoadjuvant Chemotherapy**  
Christophe Doods, University Hospitals KU Leuven, Belgium

**P2.02-056: FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non-Small Cell Lung Cancer, and Associated with Lymph Node Metastasis**  
Wu Nan, Peking University Cancer Hospital & Institute, China

## **P2.02**      **LOCALLY ADVANCED NSCLC - RT TECHNIQUES**

**P2.02-057: The Importance of Adaptive Radiotherapy in the Radical Treatment of Locally Advanced Non Small Cell Lung Cancer**  
Slavica Maric, International Medical Centers Banja Luka, Bosnia and Herzegovina

**P2.02-058: Moderately Hypofractionated Radiotherapy in Locally Advanced Non Small Cell Lung Cancer: A Single Institution Retrospective Analysis**  
Alessio Bruni, Aou Policlinico Of Modena, Italy

**P2.02-059: New Treatment Strategy in Inoperable Locoregionally Advanced NSCLC: C Arm Cone Beam CT -Guided Selective Intraarterial Chemotherapy**

Mustafa Ozdogan, Mediterranean Integrative Oncology Group, Turkey

**P2.02-060: SBRT and Sequential Chemotherapy for Stage IIA to IIIA Non-Small Cell Lung Cancer - A Phase I Dose Escalation Study**

Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA

**P2.02**            **LOCALLY ADVANCED NSCLC - TOXICITIES**

**P2.02-061: Role of MMP-2-1306C/T in Onset of Hematological Toxicity in Lung Cancer Patients Receiving First Line Platinum Based Therapy**

Annamaria Catino, National Cancer Research Centre, Istituto Tumori "Giovanni Paolo II" Bari, Italy, Italy

**P2.02-062: Alterations in Pulmonary Function Tests Predict the Development of Radiation-Induced Pneumonitis in Advanced NSCLC**

Oscar Arrieta, National Cancer Institute, Mexico

**P2.03a**            **ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

**P2.03a**            **ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - CLINICAL TRIALS**

**P2.03a-001: A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**

Baohui Han, Shanghai Chest Hospital, China

**P2.03a-002: Patterns of Chemotherapy Use and Overall Survival (OS) of Patients with Stage IV Squamous Lung Cancer (SCC)**

Daniel Morgensztern, Washington University School of Medicine, USA

**P2.03a-003: Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC)**

Ramaswamy Govindan, Washington University School of Medicine, USA

**P2.03a-004: Second-line Therapy Improves Overall Survival in Primary Refractory Non Small-Cell Lung Cancer (NSCLC) Patients**

Sacha Rothschild, University Hospital Basel, Switzerland

**P2.03a-005: A Study of Endostar Combined with Gemcitabine in the First-Line Treatment of the Elderly Patients with Advanced Non-Small Cell Lung Cancer**

Qun Chen, Fuzhou Pulmonary Hospital of Fujian, China

**P2.03a-006: Frequency of 2 Year PFS Milestone in Stage IV NSCLC Patients Treated with First Line Pemetrexed/Platinum and Pemetrexed Maintenance**

Marta Batus, Rush University Medical Center, USA

**P2.03a-007: Pem/CBP/Bev Followed by Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to Combined Score of TS, ERCC1 and VEGF Expression**

Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia



**P2.03a-008: Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)**

Jeffrey Crawford, Duke University School of Medicine, USA

**P2.03a-009: Clinical Outcome of Node-Negative Oligometastatic Non-Small Cell Lung Cancer**

Masayuki Takeda, Kinki University Faculty of Medicine, Japan

**P2.03a-010: A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC**

David Ettinger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

**P2.03a-011: Population Pharmacokinetic/Pharmacodynamic Monitoring of Pemetrexed to Predict Survival in Patients with Advanced NSCLC**

Sabine Visser, Erasmus MC Cancer Institute, Netherlands

**P2.03a-012: Nephrotoxicity in Patients with Advanced NSCLC Receiving Pemetrexed-Based Chemotherapy**

Sabine Visser, Erasmus MC Cancer Institute, Netherlands

**P2.03a-013: Chemotherapy is Beneficial for Octogenarians with Non-Small Cell Lung Cancer (NSCLC)**

Hirsh Koyi, Gävle Hospital, Sweden

**P2.03a-014: A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non-Small Cell Lung Cancer (NSCLC)**

Giuseppe Giaccone, Georgetown University, USA

**P2.03a-015: Systemic Inflammation Alters Carboplatin Pharmacokinetics Explaining Poor Survival in Advanced Lung Cancer Patients**

Benjamin Harris, University of Sydney, Australia

**P2.03a-016: Weekly Paclitaxel with 4 Weekly Carboplatin as Salvage Treatment in Advanced Non-Small Cell Lung Cancer- HCG Centre Experience**

Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India

**P2.03a-017: Chemotherapy-Induced Nausea and Vomiting (CINV) in Italian Lung Cancer Patients: Assessment by Physician, Nurse and Patient**

Silvia Novello, Thoracic Oncology Unit, Italy

**P2.03a-018: A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC**

Hossein Borghaei, Fox Chase Cancer Center, USA

**P2.03a-019: A Retrospective Analysis Of Nanoparticle Albumin Bound Paclitaxel In Chinese Patients With Recurrent Advanced Non-small Cell Lung Cancer In A Single Center**

Yixiang Zhu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

**P2.03a-020: Metronomic Oral Vinorelbine Monotherapy in Elderly Patients with Advanced NSCLC**

Angeliki Rapti, Hospital of Chest Diseases of Athens, Greece

**P2.03a-021: Vinorelbine/Carboplatin vs Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer**

Ali Hasan, Damascus University, Syria

**P2.03a-022: QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC**

Yukie Omori, Eli Lilly Japan K.K., Japan

**P2.03a-023: Induction-Maintenance Treatment Sequence in Non-Squamous Non-Small Cell Lung Cancer (neNSCLC): Pemetrexed vs Vinorelbine-Based Induction**

Xabier Mielgo Rubio, Hospital Universitario Fundación Alcorcón, Spain

**P2.03a-024: The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis**

Xingsheng Hu, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

**P2.03a-025: Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC**

Vladimir Hanes, Amgen, USA

**P2.03a-026: Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)**

Jana Skrickova, University Hospital and Masaryk University Brno, Czech Republic

**P2.03a-027: A Phase I Study of the Non-Receptor Tyrosine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid Tumors**

Nagla Karim, The University of Cincinnati, USA

**P2.03a-028: Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part**

Satoshi Ikeo, Kurashiki Central Hospital, Japan

**P2.03a-029: Efficacy and Safety of Combined Carboplatin, Paclitaxel and Bevacizumab for Patients with Stage IIIb and IV Non-Squamous NSCLC**

Nektarios Alevizopoulos, Evangelismos General Hospital, Greece

**P2.03a-030: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm**

Michael Thomas, Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Germany

**P2.03a-031: Metronomic Oral Vinorelbine as First-Line Treatment in Elderly (>65 Year) Patients with Advanced NSCLC**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P2.03a-032: Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy**

Giuseppe Banna, Cannizzaro Hospital, Italy

**P2.03a-033: Prediction of Response to First Line Treatment for Metastatic Non-Small Cell Lung Cancer**

Ahmed Badawy, Alexandria University, Egypt

**P2.03a-034: RRM1 - A Prognostic Marker in Advanced NSCLC among Male Smokers Receiving Chemotherapy**

Maha Yehia, National Cancer Institute, Egypt

**P2.03a-035: Down-Regulation of BIII-Tubulin and bFGF Sensitizes Non-Small Cell Lung Carcinoma A549/Taxol Cells Lines to Taxol**

Qisen Guo, Shandong Cancer Hospital, China

**P2.03a-036: Response of Additional Chemotherapy, since First Line Chemotherapy in Non-Small Cell Lung Cancer**

Jung Hyun Chang, Ewha Womans University, South Korea

**P2.03a-037: Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy**

Hee Kyung Ahn, Gachon University Gil Medical Center, South Korea

**P2.03a-038: Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged  $\geq 70$**

Dae Ho Lee, University of Ulsan College of Medicine, Asan Medical Center, South Korea

**P2.03a-039: ABOUN.D.70+: Interim Quality of Life (QoL) Results of nab-Paclitaxel/Carboplatin Treatment of Elderly Patients With NSCLC**

Jared Weiss, Lineberger Comprehensive Cancer Center, USA

**P2.03a-040: Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer**

Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, USA

**P2.03a-041: Comparison between Combination and Mono Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Population-Based Study**

Joung Soon Jang, Chung-Ang University College of Medicine, South Korea

**P2.03a-042: Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy**

Danica Sazdanic-Velikic, Institute for pulmonary Diseases of Vojvodina, Serbia

**P2.03a-043: A Retrospective Analysis of the Chemotherapy for 'Very Old' Patients Aged 80 Years and Older with Advanced Lung Cancer**

Yosuke Tamura, Osaka Medical College Hospital, Japan

**P2.03a-044: Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy**

Hossein Borghaei, Fox Chase Cancer Center, USA

**P2.03a-045: Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study**

Óscar Juan, Hospital Universitari i Politècnic La Fe, Spain

**P2.03a-046: Safety and Efficacy Results From ABOUN.D.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC**

Corey Langer, Abramson Cancer Center, University of Pennsylvania, USA

**P2.03a-047: Clinical Trial Participation and Outcomes in Non-Small Cell Lung Cancer: Case-Control Study**

Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

**P2.03a-048: The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth**

John Heymach, The University of Texas M.D. Anderson Cancer Center, USA

**P2.03a-049: Response to Salvage Chemotherapy Following Exposure to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer**

Paul Leger, Vanderbilt University Medical Center, USA

**P2.03a-050: Elevated Expression of CCP Genes is Associated with Absolute Chemotherapy Benefit in Early Stage Lung Adenocarcinoma Patients**

Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA

**P2.03a-051: CMTM1\_v17 Promotes Chemotherapy Resistance and is Associated with Poor Prognosis in Non-Small Cell Lung Cancer**

Jiahui Si, Peking University Cancer Hospital & Institute, China

**P2.03a-052: Phase I Study and Pharmacokinetics of Paclitaxel Micelles for Injection in Chinese Patients with Advanced-Stage Malignancies**

Meiqi Shi, Jiangsu Cancer Hospital, China

**P2.03a-053: Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab**

Pierpaolo Correale, Azienda Ospedaliera Universitaria Senese, Italy

**P2.03a-054: A Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer**

Hisashi Tanaka, Hirosaki University, Japan

**P2.03a-055: Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials**

Herbert Pang, The University of Hong Kong, China

**P2.03a-056: Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: KTOSG Trial 1301**

Shinya Sakata, Kumamoto University Hospital, Japan

**P2.03a-057: Ligand Mediated Solid Lipid Nanoparticle of Paclitaxel for Effective Management of Bronchogenic Carcinoma**

Saurabh Bhargava, Manav Bharti University, India

**P2.03a-058: Is There a Place for Pemetrexed Rechallenge in Advanced Lung Adenocarcinoma?**

Shun Lu, Shanghai Chest Hospital, China

**P2.03a-059: LCL161 Increases Paclitaxel-Induced Apoptosis by Degrading cIAP1 and cIAP2 in NSCLC**

Chengcheng Yang, The First Affiliated Hospital of Xi'an Jiaotong University, China

**P2.03a-060: Favorable Survival of TTF-1 Expression in Pemetrexed Based Treated NSCLC Patients**

Claus Steppert, Klinikum Bayreuth, Germany

**P2.03a-061: Randomized Phase II Trial Comparing Intercalation of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy**  
Shinkyoo Yoon, Bundang Jesaeng General Hospital, South Korea

**P2.03a-062: Characterisation and Targeting of the DNA Repair Gene, XRCC6BP1, in Cisplatin Resistant NSCLC**  
Martin Barr, St. James's Hospital & Trinity College Dublin, Ireland

**P2.03a-063: Small Molecule Cancer Stemness Inhibitor, BBI608, Restores Cisplatin Sensitivity in Resistant NSCLC**  
Martin Barr, Trinity College Dublin/St. James's Hospital, Ireland

**P2.03a-064: Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC**  
Martin Barr, Trinity College Dublin/St. James's Hospital, Ireland

**P2.03a-065: Lack of Drug-Drug Interaction (DDI) between Necitumumab and Gemcitabine or Cisplatin: A Phase 2, Open-Label, Nonrandomized Study**  
James Lee, University of Pittsburgh Cancer Institute, USA

**P2.03a-066: Pemetrexed(P) in Third and Fourth Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (Non-Squamous)-aNSCLCs**  
Alexandru Calin Grigorescu, Institute of Oncology Bucharest, Romania

**P2.03a-067: Therapy-Related Leukemia after Lung Cancer Chemotherapy**  
Kazuhiko Natori, Toho University Medical Center Oomori Hospital, Japan

**P2.03a-068: Impact of Platinum/Pemetrexed versus Other Platinum-Based Regimens on Adjuvant Chemotherapy in Resected Adenocarcinoma Lung Cancer**  
Wang Ziping, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P2.03a-069: Effectiveness of Adjuvant Carboplatin-Based Chemotherapy Compared to Cisplatin in Resected Non-Small Cell Lung Cancer**  
Pierre-Yves Gagnon, IUCPQ, Canada

**P2.03a-070: A Feasibility Study of Adjuvant Chemotherapy with Modified Weekly Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC**  
Hisashi Saji, St. Marianna University School of Medicine, Japan

**P2.03a-071: Adjuvant Chemotherapy Following Resection of NSCLC: An Audit of 5 Years of Practice and Outcomes in South West Wales**  
Amy Case, Singleton Hospital, UK

## **P2.03b      ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

### **P2.03b      ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - BRAIN META**

**P2.03b-001: A Phase I Dose Expansion Study of Epatinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis**

Qing Zhou, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

**P2.03b-002: Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer**

Ruiguang Zhang, Union Hospital, China

**P2.03b-003: Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer**

Oscar Arrieta, National Cancer Institute, Mexico

**P2.03b-004: Factors Associated with Brain Metastasis in Patients with Lung Adenocarcinoma after Surgical Resection**

Jung-Jyh Hung, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan

**P2.03b-005: Correlation between Primary Tumor Location and Brain Metastasis Development or Peritumoral Brain Edema in Lung Cancer**

Katalin Fabian, Semmelweis University Department of Pulmonology, Hungary

**P2.03b-006: Distinct MR Imaging Features of Metastatic Lesions in Brain with Non-Small Cell Lung Cancer According to EGFR Mutation Status**

Yan Cheng, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P2.03b-007: Palliative Whole Brain Radiotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC), the University College London Hospital Experience**

Amy Ward, University College London, UK

**P2.03b-008: The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients**

Grainne O'Kane, Princess Margaret Cancer Centre, Canada

**P2.03b-009: Brain Metastasis and Epidermal Growth Factor Receptor Mutations in Croatian Caucasians with Lung Adenocarcinoma**

Katherina Sreter, University Hospital Centre "Sestre Milosrdnice", Croatia

**P2.03b-010: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases**

Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

**P2.03b-011: Screening for ALK Abnormalities in Central Nervous System Metastases of Non-Small-Cell Lung Cancer**

Pawel Krawczyk, Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

**P2.03b-012: A Phase II Study of Etrintotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer**

Joel Neal, Stanford Cancer Institute, USA

**P2.03b-013: Outcome of Patients with ALK+ NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management**

Luigi De Petris, Karolinska University Hospital, Sweden

**P2.03b-014: Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis**

Rimas Lukas, The University of Chicago Medicine, USA

**P2.03b-015: Efficacy of the Irreversible ErbB Family Blocker Afatinib in Treatment of an Intracerebral Non-Small Cell Lung Cancer in Mice**

Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P2.03b-016: Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)**

Davic Berz, Beverly Hills Cancer Center, USA

**P2.03b-017: Differences of Central Nerve System Metastasis during Gefitinib or Erlotinib Therapy in Patients with EGFR-Mutated Lung Adenocarcinoma**

Kazushi Yoshida, National Cancer Center Hospital, Japan

**P2.03b-018: Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK+ Non-Small Cell Lung Cancer and Brain Metastases**

Shouzheng Wang, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), China

**P2.03b-019: Comparison of the Efficacy of First-Generation EGFR-TKIs in Brain Metastasis**

Naoto Aiko, Yokohama Municipal Citizen's Hospital, Japan

**P2.03b-020: EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non-Small-Cell Lung Cancer Patient with Brain Metastases**

Xiao-Ling Xu, Zhejiang Province Cancer Hospital, China

**P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - BIOMARKERS**

**P2.03b-021: Screening for Major Oncogene Alterations in Adenosquamous Lung Carcinoma Using PCR Coupled with Next-Generation and Sanger Sequencing Methods**

Xiaohua Shi, Peking Union Medical College Hospital, China

**P2.03b-022: Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts**

Julia Roeper, Pius Hospital Oldenburg, Germany

**P2.03b-023: Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)**

Vincent Lam, The University of Texas M.D. Anderson Cancer Center, USA

**P2.03b-024: microRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer (NSCLC) by Activating MAPK/MEK/ERK Signaling Pathway**

Ruiguang Zhang, Union Hospital, China

**P2.03b-025: Mutation Profile and Histology Subtype According to IASLC/ERS/ATC as Risk Factors for Brain Metastases in Lung Adenocarcinoma**

Oscar Arrieta, Instituto Nacional de Cancerología, Mexico

**P2.03b-026: Next-Generation Sequencing for Molecular Diagnosis of Tumour Specimens from Patients with Advanced Lung Adenocarcinoma**

Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal

**P2.03b-027: Circulating Free DNA (cfDNA) Analysis from Patients with Advanced Lung Adenocarcinoma**

Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal

**P2.03b-028: Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM**

Anna Kostenko, University Hospital of Cologne, Germany

**P2.03b-029: Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next-Generation Sequencing**

Min Li, Xiangya Hospital, Central South University, China

**P2.03b-030: Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer**

Hai Tran, University of Texas M.D. Anderson Cancer Center, USA

**P2.03b-031: Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRAS<sup>m</sup> Advanced NSCLC**

Pasi Jänne, Dana-Farber Cancer Institute, USA

**P2.03b-032: The Peculiar Changing Pattern of Serum NSE Acts as an Indicator of Transformation from Adenocarcinoma to SCLC**

Jie Zhang, Shanghai Pulmonary Hospital, China

**P2.03b-033: Clinical Effectiveness of Hybrid Capture-Based Massive Parallel Sequencing in Therapeutic Strategy Planning in Lung Cancer**

Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

**P2.03b-034: Clinical Relevant Oncogenic Drivers in Advanced Adenocarcinoma Discloses New Therapeutic Targets in Negative EGFR/ALK/KRAS Patients**

Vera Capelozzi, University of São Paulo, Brazil

**P2.03b-035: EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE**

Carlo Genova, IRCCS AOU San Martino - IST, Italy

**P2.03b-036: Analysis of Potentially Targetable Mutations in 821 Patients with Squamouscell Lung Cancer Undergoing Routine NGS-Based Molecular Diagnostics**

Sophia Koleczko, Lung Cancer Group Cologne, Germany

**P2.03b-037: Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study**

Jacques Cadranel, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, France

**P2.03b-038: The Diagnostic and Prognostic Value of CSF Cyfra 21-1 in Patients with Leptomeningeal Metastasis of Non-Small Cell Lung Cancer**

Jae-Won Hyun, National Cancer Center, South Korea



**P2.03b-039: Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression**

Luis Raez, Memorial Cancer Institute, USA

**P2.03b-040: NANOG Predicts Poor Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy**

Seung Hyeun Lee, Kyung Hee University Medical Center, South Korea

**P2.03b-041: Cerebrospinal Fluid Tumor Cells for Diagnosis of Leptomeningeal Metastases in Non-Small Cell Lung Cancer**

Yang-si Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P2.03b-042: MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma**

Nir Peled, Rabin Medical Center, Israel

**P2.03b-043: Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients**

Shu-Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P2.03b-044: Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC**

Jose Carlos Ruffinelli, Medical Oncology Dept Catalan Institute of Oncology - ICO Hospitalet, Spain

**P2.03b-045: Assessment of microRNAs in FFPE Tissue for Prediction of the Effect of Palliative Chemotherapy for Squamous Cell Carcinoma of the Lung**

Martin Svaton, Charles University in Prague, Czech Republic

**P2.03b-046: Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P2.03b-047: The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer**

Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

**P2.03b-048: Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer**

Apar Ganti, Veteran's Affairs Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, USA

**P2.03b-049: Molecular & Clinical Status of Current Biomarkers: EGFR, ALK, ROS, MET of Lung Cancer in North Indian Patients**

Moushumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

**P2.03b-050: Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients**

Laura Mezquita, Gustave Roussy, France

**P2.03b-051: TrxR1: A Novel Biomarker Proved to Be Prognostic Factor and Evidence to Provide Newly Treatment Strategies in Metastatic EGFR Wild-Type NSCLC**

Yongchang Zhang, Hunan Cancer Hospital, China

**P2.03b-052: XRCC1 Arg399Gln and Rad51 G135C Gene Polymorphisms in Advanced Lung Adenocarcinoma in Serbia**

Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

**P2.03b-053: Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab**

Philipp Mack, UC Davis Comprehensive Cancer Center, USA

**P2.03b-054: Biomarker Predictors in NSCLC**

Maha Yahia, National Cancer Institute, Egypt

**P2.03b-055: Survival in Non-Small Cell Lung Cancer (NSCLC) Patients (pts) with Driver Mutations at Sandton Oncology Centre, South Africa**

Sze Wai Chan, Sandton Oncology Centre, South Africa

**P2.03b-056: Prognostic Value of Neutrophil to Lymphocyte Ratio Was Influenced by Albumin Level**

Zhen-Yu Ding, West China Hospital, China

**P2.03b-057: Diagnostic Value of Tumor Markers in Lung Adenocarcinoma-Associated Cytologically Positive and Negative Pleural Effusions**

Cheng-Chuan Su, Buddhist Dalin Tzu Chi Hospital, Taiwan

**P2.03b-058: Blood Cell Count Ratios at Diagnosis as Prognostic Markers in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)**

Eliza Ricardo, A.C. Camargo Cancer Center, Brazil

**P2.03b-059: Detection of Circulating Tumor Cells Using Multiple mRNA in Situ Hybridization Predicts Metastasis in Non-Small Cell Lung Cancer**

Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P2.03b-060: Baseline Skeletal Muscle Index (SMI) Values Are Associated with Biomarkers of Insulin Resistance in Stage IV Non-Small Cell Lung Cancer**

Marta Batus, Rush University Medical Center, USA

**P2.03b-061: Baseline Neutrophil-Lymphocyte Ratio is Related to Baseline Presence of Brain Metastases and Subsequent Brain Metastases in Stage IV NSCLC**

Young Wha Koh, Ajou University School of Medicine, South Korea

**P2.03b-062: Association of the FAACT Total Score and Subscales with Clinical Characteristics and Survival in Advanced Lung Cancer**

Oscar Arrieta, National Cancer Institute, Mexico

**P2.03b-063: Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study**

Silvia Novello, Department of Oncology, University of Turin, AOU San Luigi, Italy

**P2.03b-064: Genomic Profiling in Non Small Cell Lung Cancer: New Hope for Personalized Medicine**

Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India

**P2.03b-065: Serum and Bronchoalveolar Lavage Levels of Adiponectin in Advanced Non-Small Cell Lung Cancer: Results of a Prospective Study**

Kostas Syrigos, Medical School, University of Athens, Greece

**P2.03b-066: Diagnostic Value of Pleural Cytology Together with Pleural CEA and VEGF in Patients with NSCLC and Lung Metastases from Breast Cancer**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P2.03b-067: Predictors of Advanced Squamous Cell Lung Cancer Prior to Biopsy; Biological Behavior and Prognostic Factors**

Hala Aziz, National Cancer Institute, Egypt

**P2.03b-068: The Druggable Mutation Landscape of Lung Adenocarcinoma**

Siraj Ali, Foundation Medicine, USA

**P2.03b-069: LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling**

Tadaaki Yamada, Kanazawa University, Japan

**P2.03b-070: Establishment of Organoid Cell Lines from Lung Squamous Cell Carcinoma**

Ruoshi Shi, Ontario Cancer Institute, Canada

**P2.03b-071: Therapeutic Targeting of the Phosphatidylinositol-3 Kinase Pathway in Lung Squamous Cell Carcinoma**

Ruoshi Shi, Ontario Cancer Institute, Canada

**P2.03b-072: Resistance to BET Inhibitors in Lung Adenocarcinoma is Mediated through a MYC Independent Mechanism**

Jack Calder, BC Cancer Research Center, Canada

**P2.03b-073: High Concordance of Somatic SNVs between Tumor-Only and Tumor-Normal Testing: Implications for Clinical Practice**

Dongmei Lin, Peking University Cancer Hospital, China

**P2.03b-074: NSCLC Homing Nanoparticles Selectively Transfect Lung Cancer**

Gregory Holt, University of Miami, USA

**P2.03b-075: PD-1 Protein Expression Predicts Survival in Resected Adenocarcinomas of the Lung**

Martin Filipits, Medical University of Vienna, Austria

**P2.03b-076: MAP2K1 Mutations in NSCLC: Clinical Presentation and Co-Occurrence of Additional Genetic Aberrations**

Alessandra Holzem, Department I of Internal medicine University Hospital of Cologne, Germany

**P2.03b-077: EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study**

Michael Cabanero, University of Toronto, University Health Network, Canada

**P2.03b-078: MET Gene Amplification and Overexpression in Chinese NSCLC Patients without EGFR Mutations**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P2.03b-079: Decreased Expression of miR-125a-3p is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients**

Likun Hou, Tongji University School of Medicine, China

**P2.03b-080: A Comprehensive Test of Cancer Treatment-Related Genes for the Clinical Samples of Non-Small Cell Lung Cancer (NSCLC)**

Yoshiaki Inoue, Saitama Medical University Saitama Medical Center, Japan

**P2.03b-081: Comparison of Genomic Alterations Derived from Matched Tumor Tissue and Liquid Biopsy**

Judith Müller-Eisert, NEO New Oncology, Germany

**P2.03b-082: AQP11 as a Novel Factor of Lung Cancer Cell Resistance to Cisplatin**

David Carbone, The Ohio State University, USA

**P2.03b-083: Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC**

Denisse Lee-Cervantes, Instituto Nacional de Cancerología, Mexico

**P2.03b-084: Profiling of Eph Signaling in Malignant Pleural Effusions- Identification of Therapy Approaches and Associated Biomarkers**

Metka Novak, Karolinska Institutet, Sweden

**P2.03b-085: Programmed Cell Death Ligand 1 (PD-L1) Expression in Stage II and III Lung Adenocarcinomas**

Hironori Uruga, Toranomon Hospital, Japan

**P2.03b-086: High Expression of PDL-1 Correlates with Pleomorphic Features in Non-Small Cell Lung Carcinomas**

Francois Kwong, Royal Brompton and Harefield NHS Foundation Trust, UK

**P2.03b-087: PD-L1 Expression in Adenosquamous Lung Carcinoma and the Comparison with the Other Common Variants of Non-Small Cell Lung Cancer**

Xiaohua Shi, Peking Union Medical College Hospital, China

**P2.03b-088: PET-CT with <sup>68</sup>Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC**

Denisse Lee-Cervantes, Instituto Nacional de Cancerología, Mexico

**P2.03b-089: CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin**

Chang-Qi Zhu, University Health Network, Canada

**P2.03b-090: A CTLA-4 Antagonizing DNA Aptamer with Anti-Tumor Effect**

Bo-Tsang Huang, Institute of Biomedical Science, Academia Sinica, Taiwan

**P2.03b-091: CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer**

Hui Zhao, The Second Affiliated Hospital, Dalian Medical University, China

**P2.03b-092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy**

Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P2.03b-093: Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories**

Emma Green, Inivata Ltd., UK

**P2.03b-094: Prognostic Value of Serum Carcinoembryonic Antigen during Conventional Chemotherapy in Advanced (Non-)Small Cell Lung Cancer**  
C. De Jong, St Antonius Hospital, Netherlands

**P2.03b-095: Retrospective Analysis of Correlation between ACEIs/ARBs and Clinical Outcome in Lung Cancer Patients with Bevacizumab-Based Chemotherapy**  
Sachi Okawa, Kobe Red-Cross Hospital, Japan

**P2.03b-096: Utilisation of a Novel 3D Culture Technology for the Assessment of Chemo-Resistance in Non-Small Cell Lung Cancer**  
Sarah-Louise Ryan, Queensland University of Technology, Australia

**P2.03b-097: Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)**  
Katharina Verleger, Pharmerit International, Germany

**P2.03b-098: Comparison of Digital PCR, Ion Proton with ARMS-PCR in Tumor Tissue and Plasma of NSCLC Patients**  
WanChun Zang, Novogene Bioinformatics Institute, China

## **P2.04           MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES**

### **P2.04           MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL**

**P2.04-001: A Comparative Analysis of Long-Term Outcome of Thymoma between Video-Assisted Surgery and Open Resection from Multi-Center Study Data**  
Su Kyung Hwang, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P2.04-002: The Efficacy of Postoperative Radiotherapy against Thymic Epithelial Tumors According to Masaoka Staging and WHO Classification**  
Kai Obayashi, Gunma University Hospital, Japan

**P2.04-003: Chemotherapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort**  
Nicolas Girard, Hospices Civils de Lyon, France

**P2.04-004: Thymectomy without Definitive Diagnosis Could Be Feasible in Patients with Suspicious of Thymic Epithelial Tumor**  
Shuhei Hakiri, Nagoya University, Japan

**P2.04-005: WHO Classification and IASLC/ITMIG Staging Proposal in Thymic Tumors: Real-Life Assessment**  
Nicolas Girard, Hospices Civils de Lyon, France

**P2.04-006: Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis**  
Nicolas Girard, Louis Pradel Hospital, France

**P2.04-007: Role of F-18-Choline Petscan in Recurrence of Thymic Epithelial Tumors (TET)**  
Benjamin Besse, Gustave Roussy, France

**P2.04-008: Diagnostic Performance of PET-CT for Anterior Mediastinal Lesions - The DECiMaL Study**  
Chiara Proli, Royal Brompton & Harefield NHS Foundation Trust, UK

**P2.04-009: Tumor Size Did Not Affect Masaoka Staging as Predictors of Recurrence in Thymoma**  
Yen-Chiang Tseng, Kaohsiung Veterans General Hospital, Taiwan

**P2.04-010: Survival after Surgery and Radiotherapy for Thymic Epithelial Tumours: A Single-Centre Experience from the United Kingdom**  
Hemal Ariyaratne, University College London Hospital, UK

**P2.04-011: Tumours of the Thymus: Northern Ireland 11 Year Experience**  
Lynn Campbell, Belfast City Hospital, UK

**P2.04-012: A Risk of Death from a Second Cancer Following Complete Resection of Thymoma**  
Masatsugu Hamaji, Kyoto University, Japan

**P2.04-013: Prognosis Factors and Survival Analysis in Thymic Epithelial Tumors**  
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

**P2.04-014: Retrospective Study of Pleuropneumectomy for Thymoma with Dissemination**  
Shiaki Oh, Juntendo University School of Medicine, Japan

**P2.04-015: Thymoma and Thymic Carcinoma - Our Experience**  
Jana Kulísková, University hospital Olomouc, Czech Republic

**P2.04-016: Is FDG-PET Useful for Distinguishing between Thymic Epithelial Tumors and Malignant Lymphoma?**  
Hiroyuki Sakamaki, Keio University School of Medicine, Japan

**P2.04-017: Prognostic Relevance of PD-1/PD-L1 Pathway in Thymic Malignancies with Combined Immunohistochemical and Biomolecular Approach**  
Rossana Berardi, Università Politecnica delle Marche - AOU Ospedali Riuniti, Italy

**P2.04-018: Comprehensive Copy Number Alteration and Gene Expression Analysis of Surgically Resected Thymic Carcinoma**  
Takao Nakanishi, Graduate School of Medicine, Kyoto University, Japan

**P2.04-019: A Peripheral Immune Signature Associated with Clinical Activity of Sunitinib in Thymic Carcinoma**  
Arun Rajan, Center for Cancer Research, NCI, NIH, USA

**P2.04-020: Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma**  
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

**P2.04-021: Role of Adjuvant Radiotherapy and Prognostic Factor Analysis in Thymic Malignancies: A Retrospective Analysis of 129 Consecutive Patients**  
Alessio Bruni, Aou Policlinico Of Modena, Italy

**P2.04-022: Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors**  
Zhengbo Song, Zhejiang Cancer Hospital, China

**P2.04-023: Rare Frequency of Gene Variation and Survival Analysis in Thymic Epithelial Tumors**  
Zhengbo Song, Zhejiang Cancer Hospital, China

**P2.04-024: Thymic Epithelial Tumors and Radiotherapy Results**  
Sureyya Sarihan, Uludag University, Turkey

**P2.04 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - ESOPHAGEAL CANCER AND OTHER MALIGNANCIES**

**P2.04-025: Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study**  
Jun Liang, Beijing Cancer Hospital, China

**P2.04-026: Expression Patterns of PD-L1 in Esophageal Adenocarcinomas: Comparison between Primary Tumors and Metastases**  
Rupert Langer, Institute of Pathology, University of Bern, Switzerland

**P2.04-027: Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis**  
David Carbone, The Ohio State University, USA

**P2.04-028: Cone-Beam CT Virtual Navigation-Guided Percutaneous Needle Biopsy of Suspicious Pleural Metastasis: Initial Experience**  
Hyun-ju Lim, Seoul National University Hospital, South Korea

**P2.04-029: Primary Pulmonary Sarcoma: Risks and Optimal Surgical Treatment Options**  
Yoshito Yamada, Zurich University Hospital, Switzerland

**P2.04-030: Airway Intervention in the Management of Low Grade Malignant Bronchogenic Neoplasms**  
Anne Hsu, Singapore General Hospital, Singapore

**P2.04-031: Predictors of Pathological Complete Response (TRG=1) among Esophageal Cancer Cases; NCI Pooled Data**  
Fatma Abou Elkassem, National Cancer Institute, Egypt

**P2.04-032: Pulmonary Sarcomatoid Carcinoma (PSC): Experience of 45 Patients at a Comprehensive Cancer Center**  
Nabeela Khan, State University of New York Downstate, USA

**P2.04-033: Primary Salivary Gland Tumors of the Lung: A Systematic Review and Pooled Analysis**  
Pankaj Garg, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, India

**P2.04-034: SPARC/  $\beta$ -Tubulin III Expressions for Clinical Outcomes of ESCC Patients Receiving Nab-Paclitaxel plus DDP Neoadjuvant Chemotherapy**  
Yun Fan, Zhejiang Cancer Hospital, China

**P2.04-035: Surgical Perplexities in a Rare Case of Symptomatic Mediastinal Lymphangioma**  
Kingsfield Ong, Tan Tock Seng Hospital, Singapore

**P2.04-036: Giant Primary Dedifferentiated Liposarcoma of the Anterior Mediastinum: An Extremely Rare Occurrence**  
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

**P2.04-037: Solitary Fibrous Tumor of the Pleura Associated with Severe Hypoglycemia: The Doege-Potter Syndrome**

Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

**P2.04-038: Primary Pulmonary Meningioma: Rare Tumour with Malignant Potential**

Kingsfield Ong, Tan Tock Seng Hospital, Singapore

**P2.04-039: Long-Term Risk of Recurrence in Benign Pleural Solitary Fibrous Tumors: A Single Institution Review**

Gavitt Woodard, UCSF, USA

**P2.04-040: Pleural Effusion Characteristics and Relationship with Outcomes in Cancer Patients**

Patricia Thompson, Cancer Treatment Centers of America, USA

**P2.04-041: Two Cases of Pulmonary Schwannoma**

Tsunehiro Ii, Otsu Municipal Hospital, Japan

**P2.04-042: Epithelial-Myoepithelial Tumour of Unknown Origin: An Interesting Case Report with Unexpected Outcome**

Nektarios Alevizopoulos, Evangelismos General Hospital, Greece

**P2.04-043: Squamous Cell Carcinoma Arising from the Pleura. An Interesting Case Report**

Nektarios Alevizopoulos, Evangelismos General Hospital, Greece

**P2.04-044: Mediastinal Neurogenic Tumors: Histopathological Characteristics and Surgical Treatment in a Single-Institutional Experience**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

**P2.04-045: Management of Malignant Pleural Effusions: Ten Years Experience of a Single Center**

Fatmir Caushi, University Hospital of Lung Diseases, Albania

**P2.04-046: A Rare Case of Pleuro-Pulmonary Epithelioid Hemangioendothelioma**

Giulia Pacella, Ospedali Riuniti di Foggia, Italy

**P2.04-047: A Rare Case of Extramedullary Plasmacytoma Occurring in the Posterior Mediastinum**

Giulia Pacella, Ospedali Riuniti di Foggia, Italy

**P2.04-048: Sarcomatoid Carcinoma of Lung**

Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

**P2.04-049: Treatment for Three Cases Tracheal Carcinoma of Low-Grade Malignancy**

Yutaka Oshima, Showa University Hospital, Japan

**P2.04-050: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case**

Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

**P2.04-051: Palliative Treatment of Dysphagia Syndrome in Patients with Gastroesophageal Cancer**

Irina Schetkina, Ministry of Healthcare of Perm region State Budget Health Care Establishment "Ordена "Znak Pocheta" Perm Regional Clinical Hospital", Russia



**P2.04-052: Promoter Hypermethylation of DNA Mismatch Repair Gene hMLH1 of Lung Cancer in Chromate-Exposed Workers**

Mitsuhiro Tsuboi, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

**P2.04-053: Surgery of Multiple Lung Metastases in Patients with Sarcomas and Epithelial Tumors**

Yury Ragulin, Medical Radiological Research Center, Russia

**P2.04-054: Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P2.05 RADIOTHERAPY**

**P2.05 RADIOTHERAPY - BIOLOGY**

**P2.05-001:  $\alpha 7$ -nAChR Agonist GTS-21 Reduces Radiation-Induced Lung Injury by Inhibiting HMGB1/TLR-4/NF- $\kappa$ B Pathway**

Conghua Xie, Zhongnan Hospital of Wuhan University, China

**P2.05-002: CACNA2D1 Enhances Radio-Resistance in Cancer Stem-Like Cells in NSCLC**

Siyuan Zhang, Peking University Cancer Hospital and Institute, China

**P2.05-003: PIK3CA Mutation is Associated with Increased Local Failure in Lung Stereotactic Body Radiation Therapy (SBRT)**

Abraham Wu, Memorial Sloan Kettering Cancer Center, USA

**P2.05-004: ABT-737, a BH3 Mimetic, Enhances Therapeutic Effect of Ionizing Radiation in Murine Lung Cancer Model**

Jung Mo Lee, Yonsei University College of Medicine, South Korea

**P2.05-005: Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance**

Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P2.05 RADIOTHERAPY - CLINICAL OUTCOME**

**P2.05-006: Radiotherapy as Definitive Treatment in Patients Aged 70 Years and Older with Non-Small Cell Lung Cancer**

Sureyya Sarihan, Uludag University, Turkey

**P2.05-007: Outcomes after Stereotactic Body Radiotherapy/Proton Beam Therapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer**

Yasuhisa Ohde, Shizuoka Cancer Center, Japan

**P2.05-008: Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From "Radioresistant" Histologies?**

Davide Franceschini, Humanitas Clinical and Research Center, Italy

**P2.05-009: The Outcome and Adverse Event of Chemoradiation  $\pm$  Surgery for Stage III Non-Small Cell Lung Cancer**

Shigehiro Kudo, Saitama Cancer Center, Japan

**P2.05-010: Stereotactic Radioterapy (SBRT) for Primary and Metastatic Lung Tumors in Elderly Patients**

Luis Larrea, Hospital NISA Virgen del Consuelo, Spain

**P2.05-011: The Current Status of Radiotherapy in the Definitive Treatment of Lung Cancer in a Developing Country: Turkey**

Deniz Yalman, Ege University Faculty of Medicine, Turkey

**P2.05-012: Definitive Radiotherapy and Survival in Lung Cancer: Results from a Brazillian Cohort Study**

Matheus Leal, UFRGS, Brazil

**P2.05-013: Stereotactic Brain Radiosurgery in Lung Cancer Patients in the Era of Personalized Therapy: A Review of Outcomes and Prognostic Scores Evaluation**

Wai Kong Tsang, Prince of Wales Hospital, Hong Kong

**P2.05-014: Sites of Recurrent Disease in SCLC Patients Treated with Radiochemotherapy - Is Selective Nodal Irradiation Safe?**

Calogero Gumina, Medical Faculty and University Hospital Carl Gustav Carus, Germany

**P2.05-015: Long-Term Outcomes of Prospective Phase II Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC**

Joe Chang, The University of Texas MD Anderson Cancer Center, USA

**P2.05-016: Higher Dose of Radiotherapy Better for Outcome of Patients with Locally Advanced Non-Small Cell Lung Cancer**

Martina Vrankar, Institute of Oncology Ljubljana, Slovenia

**P2.05-017: Tumor Regression Gradient Predicts Disease Free Survival**

Yolande Lievens, Ghent University Hospital, Belgium

**P2.05-018: Re-Irradiation Using SBRT: A Good Option as a Salvage Treatment in Pulmonary Lesions**

Arturo Navarro-Martin, Catalan Institute of Oncology -ICO Hospitalet, Spain

**P2.05-019: Stereotactic Body Radiotherapy (SBRT) for Central Lung Tumors: The Experience of Florence University-Careggi Hospital Radiotherapy**

Vieri Scotti, Radiation Oncology Unit, Italy

**P2.05-020: Survival Outcomes in Stage 1 NSCLC Following Stereotactic Ablative Radiotherapy or Conventional Radiotherapy**

Gerard Hanna, Queen's University of Belfast, UK

**P2.05-021: Stereotactic Radiosurgery for Brain Metastasis in Non-Small Cell Lung Cancer: Predictor of Intracranial Progression**

Yeon Sil Kim, Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea

**P2.05-022: Is Post-Chemotherapy Tumor Volume Sufficient RT Target Volume in Patients with LD-SCLC?**

Jae Myoung Noh, Samsung Medical Center, South Korea

**P2.05-023: Patterns of Failure after Adjuvant Radiation Therapy Based On "Tumor Bed with Margin" for Stage III Thymic Epithelial Tumor**

Jae Myoung Noh, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P2.05-024: Current Status of Stereotactic Body Radiation Therapy (SBRT) in Japan**  
Yasushi Nagata, Hiroshima University, Japan

**P2.05-025: 9-Year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer**  
Denise Bernhardt, Heidelberg Institute of Radiation Oncology (HIRO), Germany

**P2.05 RADIOTHERAPY - MULTIMODALITY TREATMENT**

**P2.05-026: Postoperative Radiotherapy in Non-Small Cell Lung Cancer: 20 Years' Experience in a Single Centre**  
Deniz Yalman, Ege University Faculty of Medicine, Turkey

**P2.05-027: Effects of Thermo-Chemotherapy for Lung Cancer Induced by Nano-Paclitaxel Magnetic Fluid**  
Runlei Hu, Hangzhou First People's Hospital, China

**P2.05-028: Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA-Single Station N2**  
Jian Ni, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P2.05-029: Microwave Thermal Therapy Enhances Radiosensitivity of Highly Invasive Human Non-Small Cell Lung Cancer H460 Cells via Inhibiting DNA Repair**  
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P2.05-030: WBRT Prior EGFR TKIs is Effective Treatment Option for NSCLC Patients with CNS Metastases Harboring EGFR Mutation**  
Pawel Krawczyk, Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

**P2.05-031: The Clinical Impact of Different Chemotherapy Regimen Combined with Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer**  
Jiancheng Li, Fujian Cancer Hospital, China

**P2.05-032: CT-Based Surrogates of Pulmonary Ventilation in Lung Cancer: A Voxel-Level Comparison with HP Gas MRI**  
Matthew Hatton, Weston Park Hospital, UK

**P2.05 RADIOTHERAPY - RT TECHNIQUES**

**P2.05-033: Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer**  
Georgios Tsakonas, Karolinska Institute, Sweden

**P2.05-034: New 3D «All in 1» Device for Fiducial Tumor Marking: A Pilot Animal Study**  
Bruno Escarguel, Hopital Saint Joseph, France

**P2.05-035: Interim Analysis of the Phase II Trial Dose Risk Adapted FFF Using SBRT in Stage I NSCLC and Lung Metastases (NCT01823003)**  
Arturo Navarro-Martin, Catalan Institute of Oncology -ICO Hospitalet, Spain

**P2.05-036: Single Fraction of SBRT for Pulmonary Lesions**  
Arturo Navarro-Martin, Catalan Institute of Oncology -ICO Hospitalet, Spain

**P2.05-037: Higher Radiation Dose is Still Promising in Patients with Complete Response to 50 Gy of Early Thoracic Radiotherapy with Chemotherapy?**

Sung-Ja Ahn, Chonnam National University Hwasun Hospital, South Korea

**P2.05-038: Initial Clinical Experience of VMAT-SBRT with Flattening-Filter-Free Techniques in the University of Tokyo Hospital**

Shuri Aoki, University of Tokyo Hospital, Japan

**P2.05-039: Assessment of Lung Tumour Motion Comparing 4DCT, 4DCBCT and Motion of Implanted Beacons during Imaging and Irradiation**

Elisabeth Steiner, University of Sydney, Australia

**P2.05-040: Interobserver Variability in the Definition of the Primary Lung Cancer and Lymph Nodes on Different 4DCT Reconstructions**

Susan Mercieca, University of Malta, Malta

**P2.05-041: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Fractionations**

Stephen Robinson, Sheffield Teaching Hospitals, UK

**P2.05-042: Development of Thoracic Magnetic Resonance Imaging (MRI) for Radiotherapy Planning**

Fiona McDonald, Institute of Cancer Research & Royal Marsden Hospital, UK

**P2.05-043: Lung Tumour Motion Kilovoltage Intrafraction Monitoring (KIM): First Clinical Results**

Fiona Hegi-Johnson, University of Sydney, Australia

**P2.05-044: Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases**

Juliane Hoerner-Rieber, Universitätsklinikum Heidelberg, Germany

**P2.05-045: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Schedules in the Treatment of Elderly Patients**

Stephen Robinson, Sheffield Teaching Hospitals, UK

**P2.05-046: Is Delineating Clinical Target Volume a Must for Medium and Late Stages of Non-Small Cell Lung Cancer?**

Jiancheng Li, Fujian Cancer Hospital, China

**P2.05-047: Feasibility Study: Assessment of RT Dose Using Cardiac MRI Contouring Methodology on Retrospective Lung Planning CT Scans**

Nazia Mohammed, Beatson West of Scotland Cancer Centre, UK

**P2.05-048: Directional Characteristics of Motion Marker in CBCT for Target Localization for Lung Stereotactic Body Radiotherapy (SBRT)**

Kaile Li, Associates in Medical Physics, USA

**P2.05 RADIOTHERAPY - TOXICITIES**

**P2.05-049: Radical Treated NSCLC Radiotherapy Patients: A Prospective Study of Toxicities and Outcomes**

Nathaniel Hatton, University of Glasgow, UK

**P2.05-050: Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non-Small Cell Lung Cancer**

Yukinori Matsuo, Kyoto University, Japan

**P2.05-051: Safety of Lung Stereotactic Body Radiotherapy (SBRT): A Single Institution Prospective Study Based on RTOG 0915 Protocol Constraints**

Christine Seebacher, S. Maurizio Hospital, Italy

**P2.05-052: A Systematic Review and Meta-Analysis of Pneumonitis in Radically Treated NSCLC Patients: SABR. vs. Non-SABR Treatment**

Fiona Hegi-Johnson, University of Sydney, Australia

**P2.05-053: Discussion and Analysis of Pneumonitis Related to Stereotactic Radiotherapy in Our Hospital**

Keisuke Imasaka, Saiseikai Yokohamashi Tobu Hospital, Japan

**P2.05-054: Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients**

Samantha Aso, Bellvitge Hospital, Spain

**P2.05-055: 90 Day Mortality and Survival Following Radical Radiotherapy for Non-Small Cell Lung Cancer Treated in the Dorset Cancer Centre, UK**

Matthew Roberts, Poole Hospital, UK

**P2.05-056: Safety of Stereotactic Body Radiotherapy for Central, Ultracentral, and Paramediastinal Lung Tumors**

Megan Daly, University of California Davis Comprehensive Cancer Center, USA

**P2.05-057: Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy**

Pierpaolo Pastina, Azienda Ospedaliera Universitaria Senese, Italy

**P2.05-058: Blood Biomarkers of Inflammation, Tumour Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer**

Ahmed Salem, University of Manchester, UK

**P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS**

**P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE I TRIALS**

**P2.06-001: A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors**

Matteo Levisetti, Mirati Therapeutics, USA

**P2.06-002: Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene**

Kaname Nosaki, National Kyusyu Cancer Center, Japan

**P2.06-003: A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI**

Ji Soo Park, Yonsei Cancer Center, South Korea

**P2.06-004: A Phase 1b Study of Erlotinib and Mometinib for EGFR TKI Naïve EGFR Mutated Metastatic Non-Small Cell Lung Cancer**

Sukhmani Padda, Stanford Cancer Institute/Stanford University School of Medicine, USA

**P2.06-005: Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC**

David Planchard, Gustave Roussy, France

**P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE I/II TRIALS**

**P2.06-006: Phase I/II Dose Escalation Study of L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients**

Heman Chao, Helix BioPharma Corp., Canada

**P2.06-007: A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)**

Robert Doebele, University of Colorado Cancer Center, USA

**P2.06-008: Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)**

Matteo Levisetti, Mirati Therapeutics, USA

**P2.06-009: Combined PKC $\alpha$  and mTOR Inhibition in Advanced or Recurrent Lung Cancer, Preliminary Report of an Ongoing Phase I/II Trial**

Helen Ross, Mayo Clinic Arizona, USA

**P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE II + NK**

**P2.06-010: AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study**

Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón-Dexeus, Spain

**P2.06-011: Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC**

Arthur Kudla, Merrimack Pharmaceuticals, Inc., USA

**P2.06-012: Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer**

Julien Mazieres, Hôpital Rangueil, France

**P2.06-013: Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy**

Caicun Zhou, Shanghai Pulmonary Hospital, China

**P2.06-014: Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy**

Matteo Levisetti, Mirati Therapeutics, USA

**P2.06-015: The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer**

Takashi Niwa, Kurashiki Central Hospital, Japan

**P2.06-016: Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy**  
Martin Sebastian, University Hospital Frankfurt, Goethe University, Germany

**P2.06-017: Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET**  
Lyudmila Bazhenova, University of California San Diego, USA

**P2.06-018: Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426**  
Yasuko Ichikawa, Teikyo University School of Medicine, Japan

**P2.06-019: A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC)**  
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

**P2.06-020: A Open-Label Randomised Controlled Trial of First-Line Genexol-PM/ CrEL-Based Paclitaxel plus Cisplatin in Advanced NSCLC Patients**  
Baohui Han, Shanghai Chest Hospital, China

#### **P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - PHASE III**

**P2.06-021: Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC**  
Ronan Kelly, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, USA

**P2.06-022: First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study**  
Tony Mok, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

**P2.06-023: A Phase III Study Comparing Gefitinib and Inserted Cisplatin plus Pemetrexed with Gefitinib for EGFR-Mutated Advanced Non-Squamous NSCLC**  
Shintaro Kanda, National Cancer Center Hospital, Japan

**P2.06-024: Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1**  
Benjamin Besse, Gustave Roussy, France

#### **P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - MESOTHELIOMA AND SCLC**

**P2.06-025: DREAM - A Phase 2 Trial of DuRvalumab with First Line chemotherapy in Mesothelioma with a Safety Run In**  
Anna Nowak, Sir Charles Gairdner Hospital, Australia

**P2.06-026: A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress**  
Anna Nowak, University of Western Australia, Australia

**P2.06-027: Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma**  
Raffit Hassan, National Cancer Institute, USA

**P2.06-028: A Phase 2 Study of Prexasertib in Patients with Extensive Stage Small Cell Lung Cancer**  
Lauren Averett Byers, The University of Texas MD Anderson Cancer Center, USA

**P2.06-029: Pilot Window-Of-Opportunity Study of Pembrolizumab in Patients with Resectable Malignant Pleural Mesothelioma (MPM)**  
Hedy Kindler, University of Chicago, USA

#### **P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - SUPPORTIVE, PREVENTIVE**

**P2.06-030: Optimum Duration of Vitamin B12/Folate Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy: The PEMVITASTART Randomized Trial**  
Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India

**P2.06-031: QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets**  
Karen Zeman, Walter Reed National Military Medical Center, USA

**P2.06-032: Oral Pioglitazone for the Chemoprevention of Lung Cancer in Current and Former Smokers**  
Robert Keith, Denver Veteran Affairs Medical Center, USA

**P2.06-033: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy**  
Jesús Cárdenas Sánchez, Centro Medico de Colima, Mexico

#### **P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - RADIOTHERAPY, TT FIELDS**

**P2.06-034: METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC**  
Minesh Mehta, Miami Cancer Institute, USA

**P2.06-035: Exploring Recruitment Factors in a Feasibility Trial of SABR versus Surgery**  
Janine Bestall, Leeds Institute of Health Sciences, UK

**P2.06-036: LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)**  
Uri Weinberg, Novocure GmbH, Switzerland

**P2.06-037: A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer**  
Hiroyasu Yokomise, Kagawa University Hospital, Japan

#### **P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS - LAB., OTHER**

**P2.06-038: An RCT of the Detection of Autoantibodies to Tumour Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Scotland (ECLS) in 12 208 Study Subjects**  
Alistair Dorward, NHS Greater Glasgow & Clyde, UK

**P2.06-039: Searching for Standards: Multicenter Ring Trials to Evaluate Technologies for the Enrichment of Circulating Tumor Cells**  
Sebastian Bender, Bayer AG, Germany



**P2.06-040: WINNERS Study: Does a Formal Interactive Patient Education Program Positively Impact Patient Outcomes and Satisfaction after Thoracic Surgery**  
Melissa Culligan, University of Maryland Medical Center, USA

**P2.06-041: TeleNursing: A Thoracic Surgery Nursing Initiative Aimed at Decreasing Hospital Readmissions and Increasing Patient Satisfaction**  
Melissa Culligan, University of Maryland Medical Center, USA

**P2.06-042: Evaluate the Utility of the Computed Bioconductance Measurement in the Diagnosis of Lung Cancer**  
Dawei Yang, Zhongshan Hospital Fudan University, China

**P2.06-043: 3-Dimensional High Throughput Multi-Drug Screening Using Patient-Derived Tumor Cells (PDC) Established from Surgical Specimens of NSCLC**  
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P2.06-044: Frequency of Mutations and Related Factors in Lung Adenocarcinoma Cases in Turkey**  
Senay Yilmaz, Eskisehir Osmangazi University, Turkey

**P2.06-045: Initiative for Early Lung Cancer Research on Treatment (IELCART)**  
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

**P2.06-046: Shaping and Optimization of the Non-Small Cell Lung Cancer (NSCLC) Diagnostic Landscape in Australia and New Zealand (ANZ)**  
Anchit Khanna, Pfizer Oncology, Australia

**P2.06-047: LRRK2-In-1 Inhibit Proliferation of Doublecortin and CaM Kinase-Like-1 (DCLK1)-Positive Lung Cancer Cells**  
Hiroyuki Tao, Yamaguchi Ube Medical Center, Japan

## **P2.07 NURSES**

### **P2.07 NURSES - INFORMATION FOR PATIENTS**

**P2.07-001: Non-Negotiated Companion Influence on Information Exchange at Lung Cancer Clinic Consultations**  
Allison Smith, Greater Glasgow and Clyde Health Board, UK

**P2.07-002: Evaluation of Providing Healthcare Information for Lung Mass Patients after Surgery**  
Daowan Khunyothing, Chiang Mai University, Thailand

**P2.07-003: What Do People Living with and Surviving Lung Cancer and Mesothelioma Want and Need from a Recovery Care Package?**  
Josianne Roberts, The Rotherham NHS Foundation Trust, UK

### **P2.07 NURSES - DIFFERENT ASPECTS OF SYMPTOMS**

**P2.07-004: Social Support and Number of Symptoms One Month after Lung Cancer Surgery**  
Trine Oksholm, VID Specialized University, Norway

**P2.07-005: Narratives from High Risk Respiratory Patients Who Had Bronchoscopy with Limited Sedation and Analgesia**

Catherine Saxon, University of Queensland Thoracic Research Centre, Australia

**P2.07-006: Combined Application of Two Biological Medicines with Healthcare and Health Education in Systemic Therapy Clinic**

Irena Tominc, University Clinical Centre Maribor, Slovenia

**P2.07 NURSES - RESEARCH, AUDITS**

**P2.07-007: Thoracic Oncology Research from Concept to Home-run (TORCH): Building Research Capacity in Lung Cancer Nursing**

Mary Grace Coates, Barts Health NHS Trust, UK

**P2.07-008: Victorian Comprehensive Cancer Centre Lung Cancer Clinical Audit: Collecting the UK National Lung Cancer Audit data from hospitals in Australia**

Mark Shaw, Peter MacCallum Cancer Centre, Australia

**P2.07-009: Lung Function after Pulmonary Resection in Lung Cancer**

Pernille Mikkelsen, Odense University Hospital, Denmark

**P2.07-010: Hospital Readmission Rates within 30 Days Following Thoracic Oncology Surgery**

Maureen King, Papworth Hospital, UK

**P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS**

**P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS - PATIENTS' VOICE, PATIENTS INFORMATION**

**P2.08-001: Giving a Voice to Patients and Caregivers through the Lung Cancer Canada 'Faces of Lung Cancer' Survey**

Mark Doherty, Princess Margaret Cancer Centre, Canada

**P2.08-002: Online Patient Education in Advanced Lung Cancer: Effect on Patient/Caregiver Knowledge**

Elaine Hamarstrom, Medscape Education, USA

**P2.08-003: Quality of Life and Patient Reported Outcome Measures for Lung Cancer Patients; Treatment Outcomes, and Patient Management**

Maureen Rigney, Lung Cancer Alliance, USA

**P2.08-004: The Importance of Patient Recall within Cancer Survivorship Care for Improved Post-Treatment Surveillance in Lung Cancer Survivors**

Leah Backhus, Stanford University, USA

**P2.08-005: Treating Cachexia-Anorexia in Lung Cancer Patients: Understanding the Patient Perspective on Novel Treatment Approaches**

Upal Basu Roy, LUNGeivity Foundation, USA

**P2.08-006: Attempts to Improve the Patient Literacy in Japan**

Tetsuya Yamaoka, Nikkei Business Publications, Inc., Japan

**P2.08-007: Listen Advocate Voice - Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society**

Toshiyuki Sawa, Gifu Municipal Hospital, Japan

**P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS - OTHER**

**P2.08-008: Regional Clinical Pathway for Lung Cancer in Kumamoto University Hospital**

Takeshi Mori, Kumamoto University Hospital, Japan

**P2.08-009: Need for Consistent Language around Biomarker Testing in the Diagnosis and Treatment of Lung Cancer**

Andrea Ferris, LUNGeivity Foundation, USA

**P2.08-010: The Reach and Adoption of a Multidisciplinary Thoracic Oncology Program within a U.S. Community Healthcare System**

Fedora Rugless, Baptist Cancer Center, USA

**P2.08-011: Fashion Forward: Stigma Busting in Style in Egypt**

Esraa Elsayed, CanSurvive, Egypt

**P2.08-012: Evaluation of Lung Cancer Support Group Participation: Preliminary Results**

Maureen Rigney, Lung Cancer Alliance, USA

**P2.08-013: Integrated Complementary 'Energy' Therapy Improves Patient Experience of a Lung Cancer Diagnosis**

Patricia Swann, East and North Herts NHS Trust, UK

**P2.08-014: Lung Cancer Awareness and Barriers to Primary Care in Ireland**

Aoife McNamara, Irish Cancer Society, Ireland

**P2.08-015: Promoting Lung Cancer Awareness in Ireland - Balancing Traditional and Digital Platforms**

Aoife McNamara, Irish Cancer Society, Ireland

**WEDNESDAY, DECEMBER 7, 2016****P3.01 BIOLOGY/PATHOLOGY**

MORPHOLOGY

FUNCTIONAL BIOLOGY IN LUNG CANCER

MODELS OF LUNG CANCER

STEM CELLS IN LUNG CANCER

APOPTOSIS IN LUNG CANCER

P3.01-001 - P3.01-033

P3.01-034 - P3.01-051

P3.01-052 - P3.01-054

P3.01-055 - P3.01-062

P3.01-063 - P3.01-064

**P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

ALK

ALK BIOMARKERS

ALK CLINICAL

ROS1

MISCELLANEOUS

P3.02a-001 - P3.02a-004

P3.02a-005 - P3.02a-011

P3.02a-012 - P3.02a-028

P3.02a-029 - P3.02a-031

P3.02a-032 - P3.02a-036

**P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

EGFR

EGFR BIOMARKERS

EGFR CLINICAL

EGFR RES

P3.02b-001 - P3.02b-005

P3.02b-006 - P3.02b-043

P3.02b-044 - P3.02b-093

P3.02b-094 - P3.02b-127

**P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

TARGETED THERAPY

IT

IT BIOMARKERS

IT CLINICAL

P3.02c-001 - P3.02c-025

P3.02c-026 - P3.02c-057

P3.02c-058 - P3.02c-090

P3.02c-091 - P3.02c-102

**P3.03 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC**

MALIGNANCIES

MESOTHELIOMA TRANSLATIONAL

MESOTHELIOMA CLINICAL

P3.03-001 - P3.03-027

P3.03-028 - P3.03-063

**P3.04 SURGERY**

MISCELLANEOUS I

MISCELLANEOUS II

P3.04-001 - P3.04-028

P3.04-029 - P3.04-047

**P3.05 PALLIATIVE CARE/ETHICS**

SYMPTOMS, THERAPEUTIC INTERVENTIONS

QOL, OTHERS

P3.05-001 - P3.05-009

P3.05-010 - P3.05-020

**P3.06 TRIAL DESIGN/STATISTICS**

CLINICAL STUDIES

OTHERS

P3.06-001 - P3.06-004

P3.06-005 - P3.06-009

**P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH**

THERAPY AND ECONOMICS

OTHER- GEOGRAPHICAL DIFFERENCES

P3.07-001 - P3.07-010

P3.07-011 - P3.07-022

## **Wednesday, December 7, 2016**

Poster Setup Time: Wednesday, December 7, 08:30 - 10:15

Poster Takedown Time: Wednesday, December 7, 15:45 - 18:00

(Posters not taken down by 18:00 will be discarded by management)

### **POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME)**

Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.

Wednesday, December 7, 14:30 - 15:45 (Hall B - Poster Area)

### **P3.01 BIOLOGY/PATHOLOGY**

#### **P3.01 BIOLOGY/PATHOLOGY - MORPHOLOGY**

**P3.01-001: Cancer Cell Invasion Driven by Extracellular Matrix Remodeling is Dependent on the Properties of Cancer-Associated Fibroblasts**

Shinya Neri, Kyoto University Graduate School of Medicine, Japan

**P3.01-002: The Clinical Impact of Spread through Air Spaces (STAS) in Surgically Resected pStage I Lung Squamous Cell Carcinoma**

Naoki Yanagawa, Yamagata Prefectural Central Hospital, Japan

**P3.01-003: Thyroid Transcription Factor-1 (TTF-1) Expression for Intraoperative Diagnosis Using the Rapid-Immunohistochemistry (IHC) in Lung Tumors**

Hayato Konno, Akita University Graduate School of Medicine, Japan

**P3.01-004: Exceptional Evolution of Benign Metastasizing Leiomyomas of the Lung**

Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

**P3.01-005: 9 Year's in Oncopathology at a Latin American Country: Demographic and Pathology Characterization of Lung Cancer at National Cancer Institute**

Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

**P3.01-006: Prognostic Impact of Tumor Spread through Air Spaces in Limited Resection for pStage I Lung Cancer**

Kyohei Masai, National Cancer Center Hospital, Japan

**P3.01-007: A Pulmonary Glomus Tumor**

Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

**P3.01-008: Clinicopathological and Immunohistochemical Features in Lung Invasive Mucinous Adenocarcinoma According to Computed Tomography Findings**

Yuji Nojima, Kawasaki Medical School, Japan

**P3.01-009: A Prospective Study of 'Spread through a Knife Surface' (STAKS) in Non-Small Cell Lung Cancer Resection Specimens**

Hans Blaauwgeers, Onze Lieve Vrouwe Gasthuis, Netherlands

**P3.01-010: Primary Giant Cell Carcinomas of the Lung: Study of Seven Cases**

Lourdes Gutierrez Sanz, Hospital Universitario Puerta de Hierro, Spain

**P3.01-011: Clinopathological Profile and Role of Immunohistochemistry in the Diagnosis of Primary Lung Cancer - A Prospective Study from Eastern India**

Pritinanda Mishra, All India Institute of Medical Sciences, India

**P3.01-012: P40 in Metastatic Pulmonary Trophoblastic Tumour: Potential Diagnostic Pitfall with Pulmonary Squamous Cell Carcinoma**

Deepali Jain, All India Institute of Medical Sciences, India

**P3.01-013: Case Report of Melanotic Schwannoma: A Challenging Diagnosis Made Clear through Genetic Testing**

Sue Wang, University of California San Francisco, USA

**P3.01-014: Differential Gene Expression of Lung Adenocarcinoma Histology Subtypes According to the IASLC/ATS/ERS Classification**

Oscar Arrieta, National Cancer Institute, Mexico

**P3.01-015: Prognostic Impact of Histologic Invasion Factors in Pulmonary Adenocarcinoma, with Particular Focus on the Pattern of Architectural Remodeling**

Masaya Yotsukura, National Cancer Center Hospital, Japan

**P3.01-016: Factors Influencing the Concordance of Histological Subtype Diagnosis by Biopsy and Resected Specimens of Lung Adenocarcinoma**

Reiko Matsuzawa, National Cancer Center Hospital East, Japan

**P3.01-017: Primary Lung Adenocarcinomas with Enteric Differentiation: A Retrospective Analysis**

Laura Bonanno, Istituto Oncologico Veneto, Italy

**P3.01-018: Reproducibility in Classification of Small Lung Adenocarcinomas: An International Interobserver Study**

Mari Mino-Kenudson, Massachusetts General Hospital, USA

**P3.01-019: Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer**

Roya Navab, Princess Margaret Hospital and Ontario Cancer Institute, Canada

**P3.01-020: Evolving Trends in Lung Cancer Pathology**

Karen Ege Olsen, Odense University Hospital, Denmark

**P3.01-021: Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumour Nodules**

Andrew Nicholson, Royal Brompton and Harefield NHS Foundation Trust and National heart and Lung Institute, UK

**P3.01-022: Impact of Histologic Subtype and Spread through Air Spaces (STAS) in Stage III (N2) Lung Adenocarcinoma**

Yuriko Terada, The University of Tokyo, Japan

**P3.01-023: Quality Assessment of Resampling Specimens in Primary Lung Cancers with Acquired Resistance to the Initial Therapy**

Masashi Mikubo, Aichi Cancer Center Hospital, Japan

**P3.01-024: Drastic Morphological and Molecular Differences between Lymph Node Micrometastatic Tumors and Macrometastatic Tumors of Lung Adenocarcinoma**  
Nao Aramaki, Tokyo Medical University, Japan

**P3.01-025: Primary Pulmonary Sarcomas: An Entity Lost in Misdiagnosis**  
Kavneet Kaur, All India Institute of Medical Sciences, India

**P3.01-026: Clinical and Pathological Reappraisal of Primary Lung Carciner with Lymphoepithelioma-Like Carcinoma Morphology**  
Yasufumi Goda, Kyoto University, Japan

**P3.01-027: 3D Telomere Nuclear Organization to Distinguish Multiple Synchronous Lung Adenocarcinoma from Metastatic Lung Adenocarcinoma**  
Nathalie Bastien, Quebec Heart and Lung Institute, Canada

**P3.01-028: Comparison of Touch Imprint Cytology and Section Histopathology in the Diagnostic of the Small Peripheral Lung Tumors**  
Masatoshi Kakihana, Tokyo Medical University, Japan

**P3.01-029: Cases Demonstrating Spread Through Air Spaces (STAS) Reflects Invasive Growth and Not an Artifact**  
Shaohua Lu, Memorial Sloan Kettering Cancer Center, USA

**P3.01-030: Correlation of Preoperative CT Characteristics and Histologic Patterns of Pulmonary Adenocarcinoma**  
Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China

**P3.01-031: Impact of a Novel Lung Gross Dissection Method on Intrapulmonary Lymph Node Yield**  
G Spencer, Trumbull Laboratories, USA

**P3.01-032: PELP1 Expression in Molecularly Classified Lung Adenocarcinomas**  
Charuhas Deshpande, University of Pennsylvania, USA

**P3.01-033: Changes in the Tumor Microenvironment during Lymphatic Metastasis of Lung Squamous Cell Carcinoma**  
Shinnosuke Ikemura, Tokyo Dental Collage Ichikawa General Hospital, Japan

### **P3.01 BIOLOGY/PATHOLOGY - FUNCTIONAL BIOLOGY IN LUNG CANCER**

**P3.01-034: Migration and Epithelial to Mesenchymal Transition of Lung Cancer Can Be Targeted via Translation Initiation Factors eIF4E and eIF4G1**  
Oshrat Attar-Schneider, Meir Medical Center, Israel

**P3.01-035: Nicotine Enhances Hepatocyte Growth Factor-Mediated Lung Cancer Cell Migration**  
Remi Yoneyama, Tokyo Medical University, Japan

**P3.01-036: Eukaryotic Translation Initiation Factors impact Non Small Cell Lung Cancer**  
Nadine Gantenbein, Medical University of Graz, Austria

**P3.01-037: The Role of HIF3A Polymorphism in Lung Cancer Patients**  
Andika Putra, Faculty of Medicine, Universitas Indonesia-Persahabatan Hospital, Indonesia

**P3.01-038: STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma**

Chiara Lazzari, Istituto Europeo di Oncologia - IEO, Italy

**P3.01-039: JAK2 Participates in Lung Cancer Cells Proliferation, Migration and Invasion**

Yun Fan, Zhejiang Cancer Hospital, China

**P3.01-040: Difference of Graphene Oxide-Induced Autophagy between Adenocarcinoma and Macrophage Cell Line**

Jong Wook Shin, Chung-Ang University Hospital, South Korea

**P3.01-041: Anti-Cancer Effect of Hyperoxia on Human Lung Cancer Cells through Oxidative Stress Mediated ERK Signaling**

Jin Young Mo, The Catholic University of Korea, South Korea

**P3.01-042: Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells**

Anne-Marie Baird, St. James's Hospital & Queensland University of Technology, Ireland

**P3.01-043: Inhibition of Ornithine Decarboxylase Facilitates Pegylated Arginase Treatment in Lung Adenocarcinoma Xenograft Models**

James Chung-Man Ho, The University of Hong Kong, Hong Kong

**P3.01-044: Splicing Variant of Estrogen Receptor Alpha is Associated with Pathological Invasiveness in Smoking Independent Lung Cancer**

Ayumi Suzuki, Nagoya City University Graduate School of Medical Sciences, Japan

**P3.01-045: Sex Differences in CXCR4-Dependent Motility of NSCLC Cells**

D. Gwyn Bebb, University of Calgary, Canada

**P3.01-046: Klotho Regulates Epithelial-Mesenchymal Transition in Lung Squamous Cell Carcinoma**

Takayuki Ibi, Nippon Medical School Hospital, Japan

**P3.01-047: Food for Thought: Should We Analyze a Cancer Cell as a Biological Mechanism or as a Biological Computer?**

Zarko Vrbica, University of Dubrovnik, Croatia

**P3.01-048: Cigarette Smoking is Associated with Epithelio-Mesenchymal Transition in Human Adenocarcinoma**

Toshi Menju, Kyoto University Graduate School of Medicine, Japan

**P3.01-049: ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets**

Katey Enfield, BC Cancer Research Centre, Canada

**P3.01-050: Isolation and Characterization of Lymphatic Endothelial Cells from Neoplastic and Normal Human Lung**

Giulia Mazzaschi, University of Parma, Italy

**P3.01-051: Analysis of Molecular Aberrations Associated with COPD in Patients with Lung Cancer**

Tomas Tokar, University Health Network, Canada

**P3.01 BIOLOGY/PATHOLOGY - MODELS OF LUNG CANCER**



**P3.01-052: DNA Adductomics to Identify the Role of Inflammation in NNK-Induced Lung Carcinogenesis**

Silvia Balbo, Masonic Cancer Center, USA

**P3.01-053: Mouse Models of Primary Lung Cancer - A Thorough Evaluation**

Jae-Hwi Jang, University Hospital Zürich, Switzerland

**P3.01-054: Antagonism of a Novel Kinase, MAP3K19, By Specific Small Molecule Inhibitors Blocks Human Primary NSCLC Tumor Growth in Murine Xenograft Models**

Stefen Boehme, Axikin Pharmaceuticals, Inc., USA

**P3.01 BIOLOGY/PATHOLOGY - STEM CELLS IN LUNG CANCER**

**P3.01-055: In vitro Construction of Lung Cancer Organoids from Induced Lung Cancer Stem Like Cells**

Hiroyuki Ogawa, Kobe University Hospital, Japan

**P3.01-056: Association of Angiogenesis, EMT and Stem Cell Characteristics Using Hypoxic Stress in Lung Cancer**

ChanKwon Park, The Catholic University of Korea, South Korea

**P3.01-057: TGF- $\beta$  Induced EMT and Stemness Characteristics in Lung Cancer**

Seung Joon Kim, The Catholic University of Korea, South Korea

**P3.01-058: Demethylation of CXCR4 and Stemness Acquisition in Lung Cancer**

Seung Joon Kim, The Catholic University of Korea, South Korea

**P3.01-059: A Stem-Cell Oriented Phylogeny of Non-Small Cell Lung Cancers**

Robert Downey, Memorial Sloan Kettering Cancer Center, USA

**P3.01-060: Aptamers as a Tool to Detect Lung Cancer Stem Cells**

Isis Nascimento, University of São Paulo, Brazil

**P3.01-061: Prognostic Significance of Stem Cell-Related Marker Expression and Its Correlation with Histologic Subtypes in Lung Adenocarcinoma**

Hyojin Kim, Seoul National University Bundang Hospital, South Korea

**P3.01-062: Profiling DNA Methylation and Gene Expression on Cancer Stemness Reprogramming in Lung Adenocarcinoma**

Sheng-Fang Su, Academia Sinica, Taiwan

**P3.01 BIOLOGY/PATHOLOGY - APOPTOSIS IN LUNG CANCER**

**P3.01-063: XIAP Inhibits Mature Smac Induced Apoptosis by Degrading It through Ubiquitination in NSCLC**

Sida Qin, The First Affiliated Hospital of Xi'an Jiaotong University, China

**P3.01-064: The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells**

Kenneth O'Byrne, Queensland University of Technology, Australia

**P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

**P3.02a      ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK**

**P3.02a-001: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC**

Leora Horn, Vanderbilt University, USA

**P3.02a-002: Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor**

Likun Chen, Sun Yat-Sen University Cancer Center, China

**P3.02a-003: ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicentre Study of 732 Cases**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P3.02a-004: NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14**

Christos Chouaid, CHI Créteil, France

**P3.02a      ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK BIOMARKERS**

**P3.02a-005: The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor**

Tae Tanaka, Kurashiki Central Hospital, Japan

**P3.02a-006: Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer**

Mark Awad, Dana-Farber Cancer Institute, USA

**P3.02a-007: Monitoring for and Characteristics of Crizotinib Progression: A Chart Review of ALK+ Non-Small Cell Lung Cancer Patients**

Gero Struebbe, Novartis Pharmaceuticals Corporation, USA

**P3.02a-008: EML4-ALK in Plasma Exosomes from a Cohort of NSCLC Patients**

Kay Brinkmann, Exosome Diagnostics GmbH, Germany

**P3.02a-009: TPX-0005: A Multi-Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer**

J. Jean Cui, TP Therapeutics, Inc., USA

**P3.02a-010: Evaluation of Aberrant ALK Expression in Lung Cancer by RT-PCR and Comparison with FISH and Immunohistochemistry**

Mirella Giordano, University of Pisa, Italy

**P3.02a-011: Analysis of ALK Status in Peripheral Blood to Predict the Clinical Activity of Alk Inhibitors and Assess Prognosis in Patients with Lung Cancer**

Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P3.02a      ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ALK CLINICAL**

**P3.02a-012: Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy**

Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

**P3.02a-013: Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial**

Marcello Tiseo, University Hospital of Parma, Italy

**P3.02a-014: Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)**

Elizabeth Masters, Pfizer Oncology, USA

**P3.02a-015: Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis**

Daniel Shao-Weng Tan, National Cancer Center, Singapore

**P3.02a-016: Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)**

James Chih-Hsin Yang, National Taiwan University, Taiwan

**P3.02a-017: Indirect Naive Comparison of Post-Crizotinib Treatments for ALK+ Non-Small-Cell Lung Cancer (NSCLC)**

Karen Reckamp, City of Hope Comprehensive Cancer Center, USA

**P3.02a-018: Efficacy of Pemetrexed Based Chemotherapy Compared with Non-Pemetrexed Based Chemotherapy in Advanced, ALK-Positive NSCLC**

Jaemin Jo, Seoul National University Bundang Hospital, South Korea

**P3.02a-019: Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice**

Craig Reynolds, McKesson Specialty Health/The US Oncology Network, USA

**P3.02a-020: Clinical Failure to Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancers**

Jin Kang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P3.02a-021: Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC**

Xiangchan Hong, Sun Yat-Sen University Cancer Center, China

**P3.02a-022: Experiences of Patients Receiving Treatment with Ceritinib to Treat ALK+ Non-Small Cell Lung Cancer: A Qualitative Study**

Kenneth Culver, Novartis, USA

**P3.02a-023: Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study**

Gero Struebbe, Novartis Pharmaceuticals Corporation, USA

**P3.02a-024: Response to Crizotinib in a Lung Adenocarcinoma Patient Harboring EML4-ALK Translocation with Adnexal Metastasis**

Wenxian Wang, Zhejiang Cancer Hospital, China

**P3.02a-025: PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)**

Daniel Shao-Weng Tan, National Cancer Centre Singapore, Singapore

**P3.02a-026: Crizotinib in Clinical Practice and in Clinical Trials - How Much the Results Differ?**

Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

**P3.02a-027: A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK-Positive Lung Cancer Patients**

Kazutoshi Komiya, Saga University, Japan

**P3.02a-028: Anaplastic Lymphoma Kinase Fusion Oncogene Positive Non-Small Cell Lung Cancer - The Experience of an Institution**

Sérgio Azevedo, Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal, Portugal

**P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - ROS1**

**P3.02a-029: Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P3.02a-030: ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next-Generation Genotyping from ctDNA**

Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P3.02a-031: Non-Small Cell Lung Cancer Targeted Therapy in Case of ROS1 Rearrangement**

Elena Reutova, Russian Cancer Research Center, Russia

**P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - MISCELLANEOUS**

**P3.02a-032: Multicenter Trial of Nintedanib in Combination with Docetaxel in Metastatic Lung Adenocarcinoma: Expertise in the Real-Life Setting**

Jeronimo Rodriguez Cid, Instituto Nacional de Enfermedades Respiratorias, Mexico

**P3.02a-033: The Humanistic Burden Associated with Caring for Advanced NSCLC Patients in Europe - A Real World Survey of Caregivers**

Oana Chirita, Bristol-Myers Squibb, UK

**P3.02a-034: Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial**

Julien Mazieres, CHU de Toulouse Hôpital Larrey, France

**P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

**P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR**

**P3.02a-035: Can Airway Stenting Avoid Suffocation Deaths Caused by Malignant Airway Obstruction?**

Naofumi Miyahara, Fukuoka University Hospital, Japan

**P3.02a-036: Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC**

Rafal Dziadziuszko, Medical University of Gdansk, Poland

**P3.02b-001: Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC**

Hatim Husain, UC San Diego Moores Cancer Center, USA

**P3.02b-002: Treatment Outcome Comparison between Exon 19 and 21 EGFR Mutations after Second-Line TKIs in Advanced NSCLC Patients**

Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

**P3.02b-003: Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumour and Serum Biomarkers**

Enriqueta Felip, Vall d'Hebron University Hospital, Spain

**P3.02b-004: EGFR Mutation in Squamous Cell Advanced NSCLC in Persahabatan Hospital, Jakarta Indonesia**

Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

**P3.02b-005: Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results**

Byoung Chul Cho, Yonsei University Medical Center, South Korea

**P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR BIOMARKERS**

**P3.02b-006: Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients**

Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

**P3.02b-007: Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung**

Alok Goel, Tata Memorial Hospital, India

**P3.02b-008: Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital-PCR in Plasma cftDNA**

Vienna Ludovini, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

**P3.02b-009: Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status**

Chiara Lazzari, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, Italy

**P3.02b-010: Urine Detection of EGFR T790M Mutation in Non-Small-Cell Lung Cancer: An Outcomes and Total Cost of Care Analysis**

Jacob Sands, Lahey Hospital & Medical Center, USA

**P3.02b-011: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma**

Xiaozheng Kang, Peking University Cancer Hospital and Institute, China

**P3.02b-012: Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series**

David Berz, Beverly Hills Cancer Center, USA

**P3.02b-013: Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation**

Pascal Dô, Baclesse, France

**P3.02b-014: Monitoring of T790M Mutation in Serum for Prediction of Response to Third Generation Inhibitors**

Teresa Morán, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Spain

**P3.02b-015: Impact of Metastatic Status on the Prognosis of Patients Treated with First Generation EGFR-TKIs**

Yoshihiko Taniguchi, National Hospital Organization Kinki-chuo Chest Medical Center, Japan

**P3.02b-016: An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations**

Ee Ke, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

**P3.02b-017: Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC**

Chanchai Charonpongsuntorn, Ramathibodi Hospital, Thailand

**P3.02b-018: Detection of Epidermal Growth Factor Receptor Mutations in Circulating Cell-Free DNA versus Tumor Biopsy**

In-Jae Oh, Chonnam National University Hwasun Hospital, South Korea

**P3.02b-019: TTF-1 Expression as a Predictor of Response to EGFR-TKIs in Patients with Lung Adenocarcinoma**

Kostas Syrigos, Medical School, University of Athens, Greece

**P3.02b-020: Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution**

Roxana Tudor, University of Calgary, Canada

**P3.02b-021: Comparing T790M Identification across Testing Strategies in Advanced EGFR NSCLC: A Diagnostic Outcomes and Cost Analysis**

Carolyn Bodnar, AstraZeneca, UK

**P3.02b-022: Early Experience of Detecting EGFR Activating Mutations in Cell Free DNA Using Droplet Digital PCR**

Moushumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

**P3.02b-023: Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice**

Bernd Tischer, Kantar Health, Germany

**P3.02b-024: Dynamics of EGFR Mutational Load in Urine and Plasma Correlates with Treatment Response in Advanced NSCLC**

Jhanelle Gray, Moffitt Cancer Center, USA

**P3.02b-025: Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung Adenocarcinoma**

Filiz Oezkan, Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Germany

**P3.02b-026: Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients**

Norikazu Matsuo, Kurume University School of Medicine, Japan

**P3.02b-027: Detection of EGFR Mutations in Plasma of Lung Adenocarcinoma Patients Using Real-Time PCR and Mass Spectrometry**

Rossella Bruno, University of Pisa, Italy

**P3.02b-028: Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts**

Erin Stewart, University of Toronto, Canada

**P3.02b-029: Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients**

Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

**P3.02b-030: Single Institution Experience with EGFR Gene Mutation Analysis and Treatment of EGFR Positive Patients in the Years 2010 to 2015**

Ondřej Venclíček, University Hospital Brno, Czech Republic

**P3.02b-031: T790M: A Favorable Mutation?**

Hong Jian, Shanghai Chest Hospital, China

**P3.02b-032: Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC**

Anna Buder, Medical University of Vienna, Austria

**P3.02b-033: Filter Paper as Specimen Storage and Transport Medium of EGFR Mutation Testing Collected from Lung Cancer Patients in Remote Areas of Indonesia**

Najmiatul Masykura, Stem-cell and Cancer Institute, Indonesia

**P3.02b-034: Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients**

Elisabetta Macerola, University of Pisa, Italy

**P3.02b-035: Cell Free Tumor DNA to Monitor Response to Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer**

Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

**P3.02b-036: The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients**

Toshiki Ebisudani, Kameda Medical Center, Japan

**P3.02b-037: Does Tissue EGFR Mutation Status Predict Treatment Response and Mortality in Adenocarcinoma Lung?**

Anant Mohan, All India Institute of Medical Sciences, India

**P3.02b-038: Molecular Dynamics Simulation of EFGR L844V Mutant Sensitive to AZD9291 in Non-Small Cell Lung Cancer**

Vahideh Assadollahi, Student Research Committee, Kurdistan University of Medical Sciences, Iran

**P3.02b-039: Analysis of Prognostic Factor for Afatinib Treated Patients with EGFR Mutation Positive NSCLC**

Masafumi Sata, Kanagawa Cancer Center, Japan

**P3.02b-040: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance**

Wenxian Wang, Zhejiang Cancer Hospital, China

**P3.02b-041: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib**

Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P3.02b-042: Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib**

Aaron Lisberg, UCLA Medical Center, USA

**P3.02b-043: Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma**

Cleo Keppens, KULeuven, Belgium

**P3.02b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR CLINICAL**

**P3.02b-044: Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged  $\geq 75$  Years: Subgroup Analysis of LUX-Lung 7**

Ken O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

**P3.02b-045: Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study**

Luis Paz-Arez, Hospital Universitario 12 de Octubre, Spain

**P3.02b-046: Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)**

Sanjay Popat, Royal Marsden Hospital, UK

**P3.02b-047: Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer**

Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón-Dexeus, Spain

**P3.02b-048: Oral Vinorelbine Monotherapy in Patients with EGFR+ NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study**

Dariusz Kowalski, The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Poland

**P3.02b-049: EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis**

Elaine Hamarstrom, Medscape Education, USA

**P3.02b-050: A Phase I/II Study of Erlotinib, Carboplatin, Pemetrexed and Bevacizumab for Advanced Non-Squamous NSCLC Harboring EGFR Mutation**

Takashi Yokoi, Kansai Medical University, Japan

**P3.02b-051: Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study**

Simon Baldacci, CHU Lille, Univ. Lille, France



**P3.02b-052: Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403**

Sarah Goldberg, Yale School of Medicine, USA

**P3.02b-053: A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data**

Kwai Han Yoo, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

**P3.02b-054: EGFR Mutation Profile in Newly Diagnosed Lung Adenocarcinoma in Persahabatan Hospital, Jakarta-Indonesia**

Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

**P3.02b-055: Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC**

Vikas Talreja, Tata Memorial Hospital, India

**P3.02b-056: Survival in EGFR Mutated Advanced Lung Cancer Adenocarcinoma Patients - A National Study**

Erik Jakobsen, Odense University Hospital, Denmark

**P3.02b-057: Network Meta-Analysis of First-Line and Maintenance Regimens in EGFR Mutated Advanced Non-Small-Cell Lung Cancer (NSCLC)**

Gilberto De Lima Lopes, Grupo Oncoclinicas, Brazil

**P3.02b-058: Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial**

Arun Chandrasekharan, Tata Memorial Hospital, India

**P3.02b-059: The Role of Epidermal Growth Factor Receptor in the Onset of Skeletal Related Events in Non-Small Cell Lung Cancer**

Shu-Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P3.02b-060: Comparative Analysis of the Efficacy of Three 1st/2nd Generation EGFR-TKIs for EGFR Mutated NSCLC in Clinical Practice**

Kentaro Ito, Matsusaka Municipal Hospital, Japan

**P3.02b-061: A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations**

Christina Baik, University of Washington, Seattle Cancer Care Alliance, USA

**P3.02b-062: Safety of Nectinumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**

Benjamin Besse, Gustave Roussy, France

**P3.02b-063: Analysis of Survival in EGFR-Mutation-Positive Advanced Non-Small-Cell Lung Cancer Patients with Miliary Pulmonary Metastasis**

Kageaki Watanabe, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

**P3.02b-064: Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center**

Pascal Dô, Baclesse, France

**P3.02b-065: Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer**  
Nikhil Pande, Tata Memorial Hospital, India

**P3.02b-066: Phase II Trial of the C-Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy**  
Paul Paik, Memorial Sloan Kettering Cancer Center, USA

**P3.02b-067: A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer**  
Hiroyuki Minemura, Fukushima Medical University, Japan

**P3.02b-068: Outcomes of Patients with Advanced EGFR Mutation Positive Adenocarcinoma of Lung Treated with Gefitinib in Northern Ireland 2010-2016**  
Michael-John Devlin, Northern Ireland Cancer Centre, UK

**P3.02b-069: To Assess Efficacy of First Line TKIs in EGFR Mutant Advanced NSCLC Patients from North India**  
Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, India

**P3.02b-070: NSCLC with Detectable EGFR Mutation: Institutional Experience**  
Jose Minatta, Hospital Italiano, Argentina

**P3.02b-071: First-Line Gefitinib for EGFR-Mutated Lung Adenocarcinoma Patients with Bone Metastases - A Single Institution Experience**  
Davorin Radosavljevic, Institute for Oncology and Radiology of Serbia, Serbia

**P3.02b-072: A Multicenter Phase II Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy**  
Tae Kyu Lim, Veterans Health Service Medical Center, South Korea

**P3.02b-073: A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR)**  
Hiroaki Akamatsu, Wakayama Medical University, Japan

**P3.02b-074: Brain Radiotherapy with EGFR-TKI Plays an Important Role in 181 EGFR Mutant Non-Small Cell Lung Cancer Patients with Brain Metastasis**  
Wenxian Wang, Zhejiang Cancer Hospital, China

**P3.02b-075: Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients**  
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.02b-076: Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases**  
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.02b-077: Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC**  
Edgardo Santos, Lynn Cancer Institute, USA

**P3.02b-078: Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases**  
Myung-Ju Ahn, Samsung Medical Center, South Korea

**P3.02b-079: Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non-Small Cell Lung Cancer and Brain Metastases**

Yun Fan, Zhejiang Cancer Hospital, China

**P3.02b-080: Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer**

Silvia Novello, University of Turin, Italy

**P3.02b-081: Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis**

Ramon Andrade De Mello, University of Algarve, Portugal

**P3.02b-082: Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21**

Jana Skrickova, University Hospital and Medical Faculty Brno, Czech Republic

**P3.02b-083: Potential Usage of Afanitib in the Treatment of Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations**

Taishi Harada, Fukuchiyama City Hospital, Japan

**P3.02b-084: Rational Combinations to Improve Outcome for EGFR-TKIs in NSCLCs with EGFR Mutations**

Barbara Helfrich, University of Colorado Anschutz Medical Center, USA

**P3.02b-085: The Combination Therapy of S-1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease**

Lu Yang, Peking Union Medical College, China

**P3.02b-086: ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results**

Makoto Nishio, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan

**P3.02b-087: Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PEM with Erlotinib and Bev for Non-SQ NSCLC Harboring EGFR Mutations**

Akihiro Tamiya, National Hospital Organization Kinki-chuo Chest Medical Center, Japan

**P3.02b-088: TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations**

Inês Guerreiro, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Portugal

**P3.02b-089: Treatment of NSCLC Patients with Malignant Pleural Effusion Harboring Exon 19 and 21 EGFR Mutations after First-Line and Second-Line TKIs**

Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

**P3.02b-090: Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India**

Kumar Prabhash, Tata Memorial Centre, India

**P3.02b-091: Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation**

Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.02b-092: Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose**  
Raja Mudad, University of Miami, USA

**P3.02b-093: Zoledronic Acid Enhances the Effects of Icotinib on Non-Small Cell Lung Cancer Patients with Bone Metastases**  
Wenxian Wang, Zhejiang Cancer Hospital, China

**P3.02b**      **ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - EGFR RES**

**P3.02b-094: Rebiopsy Post Progression in EGFR Mutated Lung Cancer**  
Arun Chandrasekharan, Tata Memorial Hospital, India

**P3.02b-095: Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs**  
Yi-Chen Zhang, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

**P3.02b-096: Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results**  
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

**P3.02b-097: Experience of Re-Biopsy (Biopsy at Progression) of EGFR Mutant Non-Small Cell Lung Cancer Patients in Japan: A Retrospective Study**  
Kaname Nosaki, Department of Thoracic Oncology, National Kyushu Cancer Center, Japan

**P3.02b-098: Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors**  
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P3.02b-099: Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study**  
Junning Cao, Fudan University Shanghai Cancer Center, China

**P3.02b-100: Comparison of Three T790M Testing Methods for the Detection of Non-Small Cell Lung Cancer after Tyrosine Kinase Inhibitor Failure**  
Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P3.02b-101: EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib**  
Maximilian Hochmair, Otto Wagner Hospital, Austria

**P3.02b-102: Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients**  
Jordi Remon, Gustave Roussy, France

**P3.02b-103: Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing**  
Jessica Lin, Massachusetts General Hospital, USA

**P3.02b-104: Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure**  
Xuefei Li, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.02b-105: Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing**

Ying Jin, Zhejiang Cancer Hospital, China

**P3.02b-106: Local Experience of Osimertinib Use; Retrospective Review Based on Plasma EGFR Using ddPCR Technique**

Jacky Li, Queen Elizabeth Hospital, Hong Kong

**P3.02b-107: Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment**

Marisol Arroyo Hernandez, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico

**P3.02b-108: Assessment of Clinical Usability of a cfDNA-Based Assay Detecting EGFR T790M Mutation in EGFR-TKI Refractory NSCLC Patients**

Masaki Hanibuchi, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

**P3.02b-109: Molecular Profiling of EGFR-Positive NSCLC with Secondary T790M Resistance Mutation and Tertiary Transformation into Small-Cell Lung Cancer**

Martin Faehling, Klinikum Esslingen, Germany

**P3.02b-110: ROS1 Translocation as a Bystander Mutation in T790M EGFR Mutated NSCLC**

Jan Stratmann, Universitätsklinik Frankfurt am Main, Germany

**P3.02b-111: Can We Avoid Using Chemotherapy in Managing Acquired Resistance of EGFR-Mutated NSCLC?**

Thongbliew Prempee, Chularat 3 Hospital, Thailand

**P3.02b-112: Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy**

Yoo-Duk Choi, Chonnam National University Hwasun Hospital, South Korea

**P3.02b-113: Clinical Course of NSCLC Patients with EGFR Mutation Undergoing Rebiopsy and Osimertinib Therapy**

Kenichiro Hirai, Fukushima Medical University, Japan

**P3.02b-114: Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience**

Marko Jakopovic, University Hospital Centre Zagreb, Croatia

**P3.02b-115: Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib**

Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

**P3.02b-116: Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI**

Zhong-Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

**P3.02b-117: Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)**

Daniel Shao-Weng Tan, National Cancer Centre Singapore, Singapore

**P3.02b-118: Potential Mechanism Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to EGFR-TKIs**

Jie Wang, Cancer Hospital Chinese Academy of Medical Sciences, China

**P3.02b-119: YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC**

Min Hee Hong, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, South Korea

**P3.02b-120: EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib**

Yoshihisa Kobayashi, Kindai University Faculty of Medicine, Japan

**P3.02b-121: Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features**

Kazuhiko Shien, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

**P3.02b-122: Characterization of Afatinib Resistant Lung Cancer Cells (PC9/Afa) and Reversal of Resistance by T790M Specific Tyrosine Kinase Inhibitors**

Anya Maan-Yuh Lin, Institute of Pharmacology, National Yang-Ming University, Taiwan

**P3.02b-123: Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance**

Shirong Zhang, Hangzhou First People's Hospital, Nanjing Medical University, China

**P3.02b-124: Efficacy of Osimertinib in Patients with Non-Small-Cell Lung Cancer (NSCLC) and Pleural Effusion**

Saki Manabe, Kanagawa Cancer Center, Japan

**P3.02b-125: Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer**

Oscar Arrieta, National Cancer Institute, Mexico

**P3.02b-126: Clinical Activity of Olmutinib (HM61713) Used on a Compassionate IND Basis for Patients with Lung Adenocarcinoma (LADC) in Korea**

Jin Soo Lee, National Cancer Center, South Korea

**P3.02b-127: NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14**

Jean Bernard Auliac, Hopital Quesnay, France

**P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

**P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - TARGETED THERAPY**

**P3.02c-001: Phase I Study of Salazosulfapyridine Targeting Cancer Stem Cells in Combination with CDDP and Pemetrexed for Chemo-Naïve Advanced Non-Sq NSCLC**

Kohei Otsubo, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan

**P3.02c-002: Mannosylated Poly (Propylene Imine) Dendrimer Mediated Lung Delivery of Anticancer Bioactive**

Mani Bhargava, ICFAI University, India

**P3.02c-003: TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC**

Matthew Krebs, The University of Manchester and The Christie NHS Foundation Trust, UK

**P3.02c-004: SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth via Modulating Both Autophagy and Apoptosis Pathways**

Conghua Xie, Zhongnan Hospital of Wuhan University, China

**P3.02c-005: MET Exon 14 Skipping in Quintuple-Negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) Lung Adenocarcinoma**

Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

**P3.02c-006: EGFR and HER3 Inhibition - A Novel Therapy for Invasive Mucinous Non-Small Cell Lung Cancer Harboring an NRG1 Fusion Gene**

Wolfgang Jacob, Roche Diagnostics GmbH, Germany

**P3.02c-007: Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer**

Anne Steino, DelMar Pharmaceuticals, Inc, Canada

**P3.02c-008: A MET Inhibitor in the Treatment of Metastatic Non Small Cell Lung Cancer with MET Amplification**

Junling Li, Cancer Institute & Hospital, Peking Union Medical College/Chinese Academy of Medical Science, China

**P3.02c-009: Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model**

Vera Capelozzi, Faculdade de Medicina da USP, Brazil

**P3.02c-010: Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC**

Gillian Moore, Trinity College Dublin/St. James's Hospital, Ireland

**P3.02c-011: A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors**

Alexander Spira, Virginia Cancer Specialists, USA

**P3.02c-012: Apatinib, a New Small Molecular VEGFR2 Inhibitor, Suppresses the Activity of Lung Cancer Stem Cells**

Caiyun Zhong, Nanjing Medical University, China

**P3.02c-013: Combination Therapy of Oncolytic Herpes Simplex Virus Type 1 with Erlotinib in a Human Lung Cancer Xenograft Model**

Yoshinori Sakata, Tokyo Medical University, Japan

**P3.02c-014: Patients with Recurrence after Resection of Lung Cancer Are Good Candidates for the beyond over Progressive Disease Application of Bevacizumab**

Tatsuya Yoshimasu, Wakayama Medical University, Japan

**P3.02c-015: Phase II Trial of S-1/Cisplatin Combined with Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: TCOG LC-1202**

Yusuke Okuma, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Japan

**P3.02c-016: Efficacy of Bevacizumab Combined with Chemotherapy in Lung Adenocarcinoma-Induced Malignant Pleural Effusion**

Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

**P3.02c-017: '2nd Line' RET-Inhibition in a Female Patient with Non-KIF5B RET-Translocation**

Tobias Overbeck, Goettingen University, Germany

**P3.02c-018: Could COX-2 Inhibitors Enhance the Outcomes of Chemotherapeutic Agents in Lung Cancer?**

Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

**P3.02c-019: The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes**

Gordana Drpa, Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, Croatia

**P3.02c-020: More Than 3 Years Long-Term Maintenance Treatment of Bevacizumab for Advanced-Stage NSCLC: A Report of Three Cases**

Hongxia Li, Beijing Chest Hospital, Capital MedBeijing Chest Hospital, Capital Medical University, China

**P3.02c-021: PD 0332991, a Selective Cyclin D Kinase 4/6 Inhibitor, Sensitizes Lung Cancer Cells to Killing by EGFR TKIs**

Jun Chen, Tianjin Medical University General Hospital, China

**P3.02c-022: Anticancer Activity of Sorafenib in Combined Treatment with Betulin in Human Non-Small Cell Lung Cancer Cell Lines**

Justyna Kutkowska, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Science, Poland

**P3.02c-023: Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P3.02c-024: Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling**

Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

**P3.02c-025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer**

Feng Ying Wu, Shanghai Pulmonary Hospital, Tongji University, China

**P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - IT**

**P3.02c-026: Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153**

David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, USA



**P3.02c-027: Phase I and PK Study of the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Subset**  
Martin Edelman, University of Maryland, USA

**P3.02c-028: Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)**  
Stephen Bagley, University of Pennsylvania, USA

**P3.02c-029: Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab**  
Stephen Bagley, University of Pennsylvania, USA

**P3.02c-030: Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)**  
Edward Garon, David Geffen School of Medicine at UCLA/Translational Research in Oncology- US Network, USA

**P3.02c-031: Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients**  
Jihene Lahmar, Gustave Roussy, France

**P3.02c-032: Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients**  
Myriam Delaunay, CHU larrey, France

**P3.02c-033: Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer**  
Antony Mersiades, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

**P3.02c-034: A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC)**  
Jesus Corral, Virgen del Rocio Hospital, Spain

**P3.02c-035: Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor**  
Myung-Ju Ahn, Samsung Medical Center, South Korea

**P3.02c-036: Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab**  
Carlo Genova, San Martino Hospital - National Institute for Cancer Research, Italy

**P3.02c-037: Clinical Safety of Combinational Therapy of Immune Checkpoint Inhibitors and Viscum Album L. in Patients with Advanced or Metastasized Cancer**  
Anja Thronicke, Forschungsinstitut Havelhöhe gGmbH am Krankenhaus Havelhöhe, Germany

**P3.02c-038: First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program**  
Frederico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Italy

**P3.02c-039: Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer**  
Giovanni Rossi, San Martino Hospital - National Institute for Cancer Research, Italy

**P3.02c-040: Checkmate 384: A Phase 3B/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)**

Ronald Harris, Broome Oncology and US Oncology Research, USA

**P3.02c-041: IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC**

Stephen Liu, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, USA

**P3.02c-042: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients**

Filippo De Marinis, European Institute of Oncology, Italy

**P3.02c-043: Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge**

Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

**P3.02c-044: Nivolumab-Response in a Patient with Advanced Squamous NSCLC Occurring Simultaneously with SIAD**

Parvis Sadjadian, Johannes Wesling Medical Center Minden. UKRUB, University of Bochum, Germany

**P3.02c-045: Experience with Nivolumab in Compassionate Use in Non-Small Lung Carcinoma Patients Who Have Progressed to One or More Prior Lines of Chemotherapy**

Maria Marin Alcalá, Corporació Sanitària Parc Taulí, Spain

**P3.02c-046: Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC**

Charles Rudin, Memorial Sloan Kettering Cancer Center, USA

**P3.02c-047: Local Experience in an Expanded Access Program of Nivolumab in Advanced Non-Small Cell Lung Cancer in Brazil**

Luiz H. Araujo, Instituto COI de Educação e Pesquisa (ICOI) and Núcleo de Oncologia Torácica (NOT), Brazil

**P3.02c-048: A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC**

Roy Decker, Yale School of Medicine, USA

**P3.02c-049: Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer**

Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.02c-050: IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC**

Heather Wakelee, Stanford University School of Medicine, USA

**P3.02c-051: A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Baviximab to Docetaxel**

Rachel Sanborn, Providence Portland Medical Center, USA

**P3.02c-052: Electronic Nose: An Early Response Biomarker for Anti-PD1 Therapy in Patients with NSCLC**

Mirte Muller, The Netherlands Cancer Institute, Netherlands

**P3.02c-053: Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)**

Sameh Daher, Chaim Sheba Medical Center, Israel

**P3.02c-054: Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab**

Federica Biello, San Martino Hospital - National Institute for Cancer Research, Italy

**P3.02c-055: Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies**

Andrew Yam, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

**P3.02c-056: Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC)**

Jonathan W. Goldman, David Geffen School of Medicine at the University of California, USA

**P3.02c-057: Viroimmunotherapy with Vesicular Stomatitis Virus Expressing Interferon- $\beta$  (Vsv-IFN $\beta$ ) in a Murine Model of NSCLC**

Manish Patel, University of Minnesota, USA

**P3.02c ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - IT BIOMARKERS**

**P3.02c-058: In-Depth Molecular Characterization of T Cell Clonal Expansion Induced by Anti-PD1 Therapy in NSCLC**

Jyoti Patel, University of Chicago, USA

**P3.02c-059: CD70 Immune Checkpoint Ligand is Associated with Epithelial-To-Mesenchymal Transition in Non-Small Cell Lung Cancer**

Sandra Ortiz-Cuaran, INSERM U1052, CNRS UMR 5286. Cancer Research Center of Lyon, France

**P3.02c-060: Dual Positive PD-L1 and CD8<sup>+</sup> TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity**

Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P3.02c-061: Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer**

Koung Jin Suh, Seoul National University Bundang Hospital, South Korea

**P3.02c-062: Anti-Lung Cancer Effect of CD8<sup>+</sup> T Cells Transduced Retroviral Vector Encoding WT1-Specific TCRs and siRNAs Targeting Endogenous TCRs**

Jun An, The Third Affiliated Hospital, Sun Yat-Sen University, China

**P3.02c-063: Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non-Small-Cell Lung Cancer (NSCLC)**

AM Martinez De Castro, Vall d'Hebron Institute of Oncology/Vall d'Hebron University Hospital, Spain

**P3.02c-064: Higher PD-L1 Expression Correlates with Solid and High Grade Lung Adenocarcinomas: Implications for Immunotherapy Selection**

Ross Miller, Houston Methodist Hospital, USA

**P3.02c-065: Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients**

Laura Mezquita, Gustave Roussy, France

**P3.02c-066: HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients**

Laura Mezquita, Gustave Roussy, France

**P3.02c-067: Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer**

Veena Singh, Biocept, USA

**P3.02c-068: Immunotherapy against Non Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting**

Chiara Bennati, Medical Oncology, Santa Maria della Misericordia Hospital, Italy

**P3.02c-069: Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)**

Stephen Bagley, University of Pennsylvania, USA

**P3.02c-070: Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model**

J. Peter Koo, Yale Cancer Center, Yale School of Medicine, USA

**P3.02c-071: Spatially Selective Depletion of Regulatory T Cells with near Infrared Photoimmunotherapy for Syngeneic Lewis Lung Carcinoma**

Kazuhide Sato, Nagoya University, Japan

**P3.02c-072: Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer**

Carlo Genova, San Martino Hospital - National Institute for Cancer Research, Italy

**P3.02c-073: Evidence Suggesting a Dichotomous "Present vs absent" Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC)**

David Stewart, University of Ottawa, Canada

**P3.02c-074: Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer**

Francesco Grossi, IRCCS San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Italy

**P3.02c-075: Could Blood Levels of Lymphocytes and Eosinophils Help Us to Identify the Efficacy or Toxicity of Immunotherapy?**

Pilar Garrido, University Hospital Ramon y Cajal, Spain

**P3.02c-076: Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer**

Alona Zer, Princess Margaret Cancer Centre, Canada

**P3.02c-077: Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab**

Erika Rijavec, San Martino Hospital - National Institute for Cancer Research, Italy

**P3.02c-078: The Utilization of Pre-Treatment Neutrophil to Lymphocyte Ratio as a Predictive Marker for Efficacy of Immunotherapy in Non Small Cell Lung Cancer**

Isabel Preeshagul, North Shore Long Island Jewish/ Northwell Health, USA

**P3.02c-079: Immunotherapy in Non Small Cell Lung Cancer (NSCLC): Biomarkers Associated with Early Death**

Ana Gomez, University Hospital Ramon y Cajal, Spain

**P3.02c-080: The Beneficial Effect of Platelet Binding to Monocytes on the Clinical Response to Checkpoint Inhibitors**

Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

**P3.02c-081: Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab**

Diana Saravia, University of Miami Miller School of Medicine, USA

**P3.02c-082: Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma**

Zhengbo Song, Zhejiang Cancer Hospital, China

**P3.02c-083: Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center**

Aaron Lisberg, UCLA Medical Center, USA

**P3.02c-084: Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients**

Javier Garde-Noguera, Hospital Arnau de Vilanova, Spain

**P3.02c-085: Neutrophil/Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti-PD1 Therapy**

Domenico Galetta, Medical Oncology Unit, Clinical Cancer Centre "Giovanni Paolo II", Italy

**P3.02c-086: Genomic Heterogeneity in Tumors Demonstrating a Mixed Response to Nivolumab for Stage IV Squamous Cell Carcinoma of the Lung**

Michael Menefee, Mayo Clinic, USA

**P3.02c-087: The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters**

Sacha Mignon, Vrije Universiteit Brussel, Belgium

**P3.02c-088: Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)**

Scott Gettinger, Yale School of Medicine, USA

**P3.02c-089: ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non-Small Cell Lung Cancer Patients in Routine Clinical Practice**

Christos Chouaid, GRC OncoEst Creteil, France

**P3.02c-090: The Role of ERCC-1 Polymorphisms as Predictive Biomarker of Response to Nivolumab in Advanced NSCLC**

Marco Aiello, A.O.U. Policlinico Vittorio Emanuele, Italy

**P3.02c**      **ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY - IT**

## CLINICAL

**P3.02c-091: Final Phase Ib Results of RActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC**

Alexandros Papachristofilou, Universitätsspital Basel, Switzerland

**P3.02c-092: Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from the Italian Cohort of Expanded Access Programme (EAP)**

Marcello Tiseo, University Hospital of Parma, Italy

**P3.02c-093: A Prospective, Randomized, Multicenter, Phase III Study, Comparing rHTPO with rhIL-11 Treating CIT (NCT02344979)**

Shun Lu, Shanghai Chest Hospital, Shanghai Jiaotong University, China

**P3.02c-094: Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases**

Annamaria Catino, National Cancer Research Centre, Istituto Tumori "Giovanni Paolo II" Bari, Italy, Italy

**P3.02c-095: Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non Small Cell Lung Cancer Patients**

Lucio Crinò, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

**P3.02c-096: Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)**

Francesco Grossi, National Institute for Cancer Research, Italy

**P3.02c-097: Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer**

Sho Watanabe, National Cancer Center Hospital, Japan

**P3.02c-098: An Observational Study of the Efficacy and Safety of Nivolumab in Patients with Advanced NSCLC. A Galician Lung Cancer Group**

Rosario García Campelo, Complejo Universitario de a Coruna, Spain

**P3.02c-099: A Retrospective Study of the Efficacy and Safety of Nivolumab in Our Clinical Practice: A Single Institutional Experience**

Tadashi Sakaguchi, Matsusaka Municipal Hospital, Japan

**P3.02c-100: Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)**

Miguel Sotelo, Hospital Universitario Infanta Cristina, Spain

**P3.02c-101: Immunotherapy with Nivolumab in NSCLC Patients: One Centre Preliminary Results**

Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

**P3.02c-102: Safety and Tolerability of Abemaciclib Combined with LY3023414 or with Pembrolizumab in Patients with Stage IV NSCLC**

Jonathan W. Goldman, UCLA Medical Center, USA

## **P3.01 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES**

**P3.01 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - MESOTHELIOMA TRANSLATIONAL**

**P3.03-001: Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells**

Mayura Meerang, University Hospital Zürich, Switzerland

**P3.03-002: Inducible Changes in Cell Morphology and Gene Expression Reflecting the Histological Subtypes of Mesothelioma**

Karin Schelch, Medical University of Vienna, Austria

**P3.03-003: Mesothelium Covering Pleural Plaque Is Not Primarily Involved in Asbestos-Induced Mesothelial Carcinogenesis in Human**

Yuichi Koda, Respiratory, Japan

**P3.03-004: Genome-Wide Copy Number Aberrations in Mesothelioma and Its Correlation with Tumour Microenvironment including PD-L1 Expression**

Bibhusal Thapa, Olivia Newton John Cancer Research Institute, Australia

**P3.03-005: Inhibition of PRMT5 is Synthetic Lethal in Mesotheliomas Harboring MTAP Loss**

Annabel Sharkey, University of Leicester, UK

**P3.03-006: Optical Control of Growth Factor Receptors to Advance Signal Transduction Research and Drug Screening**

Michael Grusch, Medical University of Vienna, Austria

**P3.03-007: miR-137 Acts as a Tumour Suppressor via the Down-Regulation of YB-1 in Malignant Pleural Mesothelioma**

Thomas Johnson, Asbestos Diseases Research Institute, Australia

**P3.03-008: Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma**

Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia

**P3.03-009: Role of microRNAs as Biomarkers of Malignant Mesothelioma in Patients with Pleural Effusion**

Alessandro Palleschi, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Italy

**P3.03-010: Activation of p53 in Malignant Mesothelioma**

Chuong Hoang, National Cancer Institute, USA

**P3.03-011: Downregulated Expression of miR-30d Contributes to Pleural Malignant Mesothelioma Progression**

Lijin Zhu, Zhejiang Academy of Medical Sciences, China

**P3.03-012: Tumor-Infiltrating Lymphocytes, PDL-1, BAP-1, VEGFR-2 and IGF-1R Expression in Malignant Pleural Mesothelioma**

Luca Ampollini, Thoracic Surgery, University Hospital of Parma, Italy

**P3.03-013: BAP1 Immunostaining and FISH Analysis of p16 Help Making Distinction among Subtypes of Mesothelioma**

Kenzo Hiroshima, Tokyo Women's Medical University, Japan

**P3.03-014: Tumor Subtype-Specific Cells-Of-Origin of Malignant Pleural Mesothelioma**

Hilda De Vries, Netherlands Cancer Institute, Netherlands

**P3.03-015: BAP1 is Inactivated by Copy Number Loss, Mutation, and/or Loss of Expression in More Than 70% Malignant Peritoneal Mesotheliomas**

Noémie Leblay, International Agency for Research on Cancer, France

**P3.03-016: Association between the Stainability of the Neurofibromatosis Type 2 Gene-Related Protein Merlin and the Tumor Properties of Mesotheliomas**

Kozo Kuribayashi, Hyogo College of Medicine, Japan

**P3.03-017: Fluorescent in situ Hybridization Analysis of MET Gene Status in Malignant Mesothelioma**

Antonella Vigani, ASL5 Spezzino, Italy

**P3.03-018: Suppression of Tumor Growth by Pegylated Arginase in Malignant Pleural Mesothelioma**

James Chung-Man Ho, The University of Hong Kong, Hong Kong

**P3.03-019: Molecular Characterization of Malignant Pleural Mesothelioma (MPM) by next Generation Sequencing**

Alejandro Navarro, Vall d'Hebron Institute of Oncology/Vall d'Hebron University Hospital, Spain

**P3.03-020: Cytotoxicology Assessment of MWCNT on MeT-5A Cells**

Li Ju, Zhejiang Academy Of Medical Sciences, China

**P3.03-021: When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?**

Steven Gray, LabMed Directorate, Ireland

**P3.03-022: Serum CEA, VEGF and MMP-7 in Patients with Malignant Pleural Effusion. A Prospective Study with Logistic Regression Analysis of Accuracy**

Franco Lumachi, University of Padua, School of Medicine, Italy

**P3.03-023: High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma from Turkey**

Salih Emri, Hacettepe University, School of Medicine, Turkey

**P3.03-024: Malignant Pleural Mesothelioma: Gene Expression Profiling of the Main Histological Subtypes**

Greta Ali, University Hospital of Pisa, Italy

**P3.03-025: Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma**

Muhammad Alamgeer, Monash Cancer Centre, Australia

**P3.03-026: Orotate Phosphoribosyltransferase is Overexpressed in Malignant Pleural Mesothelioma: Dramatically Responds One Case in High OPRT Expression**

Yoichiro Hamamoto, National Hospital Organization Disaster Medical Center, Japan

**P3.03-027: Growth Factor and Inflammatory Signaling Pathway Interactions Influence Outcomes Following Multimodality Therapy for Mesothelioma**

Keith Cengel, University of Pennsylvania, USA

**P3.01           MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES - MESOTHELIOMA CLINICAL**



**P3.03-028: Nivolumab for Advanced Malignant Pleural Mesothelioma outside of Clinical Trials: A Single Institution Experience**

Jun Zhang, Baylor College of Medicine, USA

**P3.03-029: EPP Followed by Hemithoracic IMRT - A Multicenter Study on Behalf of the Italian Association for Radiation Oncology Lung Cancer Study Group**

Marco Trovo, CRO -Aviano, Italy

**P3.03-030: Cisplatin with Pemetrexed or Gemcitabine in Prolonged Infusion for Inoperable Mesothelioma: A Phase II Randomized Trial**

Danijela Strbac, Institute of Oncology, Slovenia

**P3.03-031: Definitive Radiation Therapy is Associated with Improved Survival in Non-Metastatic Malignant Pleural Mesothelioma**

Kenneth Rosenzweig, Mount Sinai, USA

**P3.03-032: PET/CT for Patients with Very Early Clinical Stage of Malignant Pleural Mesothelioma: When Can PET/CT Detect Tumor Growth of T0/T1a Mesothelioma?**

Yoshiki Negi, Hyogo College of Medicine, Japan

**P3.03-033: The Influence of Geographic and Socioeconomic Factors on Prognosis and Treatment Provision in Malignant Pleural Mesothelioma**

Anthony Linton, Asbestos Diseases Research Institute, Australia

**P3.03-034: Comprehensive Immunophenotyping of the Blood and Pleural Fluid from Patients with Malignant Pleural Mesothelioma by Flow Cytometry**

Tobias Peikert, Mayo Clinic, USA

**P3.03-035: Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens**

Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

**P3.03-036: Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)**

Herbert Pang, The University of Hong Kong, China

**P3.03-037: Impact of Sarcomatoid Component in Patients with Biphasic Mesothelioma: Review of 118 Patients**

Andrea Bille, Guy's and St Thomas' NHS Foundation Trust, UK

**P3.03-038: Improving Quality of Care and Outcomes for Patients Diagnosed with Pleural Mesothelioma in England**

Susan Harden, Royal College of Physicians of London, UK

**P3.03-039: Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy**

Hakan Akgun, Eskisehir Osmangazi University, Turkey

**P3.03-040: Long Term Outcomes Following IMRT for Mesothelioma Post EPP and Unresectable**

Aaron Allen, Davidoff Center, Israel

**P3.03-041: FAS/FASL Genetic Polymorphisms Impact on Clinical Outcome of Malignant Pleural Mesothelioma**

Ahmed Salem, Faculty of Pharmacy, Ain Shams University, Egypt

**P3.03-042: Study Comparing Volume and TNM in Predicting Clinical Outcome in Malignant Pleural Mesothelioma**

Marina Garassino, Fondazione IRCCS- Istituto Nazionale dei Tumori, Italy

**P3.03-043: Trimodality Therapy with Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma**

Kazunori Okabe, Yamaguchi Ube Medical Center, Japan

**P3.03-044: Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?**

Isabelle Opitz, University Hospital Zürich, Switzerland

**P3.03-045: Treatment of Malignant Pleural Mesothelioma beyond First-Line among Hispanics (MeSO-CLICaP)**

Luis Corrales, Hospital San Juan de Dios (San José, Costa Rica), Costa Rica

**P3.03-046: Prognostic Fibrinogen/Leucocyte Score at Diagnosis Predicts Survival and Benefit from Multimodality Treatment in MPM**

Thomas Klikovits, Medical University Vienna, Austria

**P3.03-047: Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma**

Nobukazu Fujimoto, Okayama Rosai Hospital, Japan

**P3.03-048: Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma among Hispanics (MeSO-CLICaP)**

Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

**P3.03-049: Optimisation of Malignant Mesothelioma Registration at the Belgian Cancer Registry**

Jan Van Meerbeeck, University Hospital of Antwerp, Belgium

**P3.03-050: Prognostic and Predictive Factors Affecting Course of Disease and Survival in Malignant Pleural Mesothelioma**

Angela De Palma, University of Bari "Aldo Moro", Italy

**P3.03-051: Establishment of Consultation System for Mesothelioma Diagnosis Using Remote Medicine by Internet**

Kouki Inai, Pathological Diagnostic Center, Inc., Japan

**P3.03-052: Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma**

Salih Emri, Hacettepe University, School of Medicine, Turkey

**P3.03-053: Malignant Mesothelioma in Iranian Patients: A Study from National Institute of Tuberculosis and Lung Disease**

Sharareh Seifi, National Institute of Tuberculosis and Lung Disease (NRITLD), Iran

**P3.03-054: Review and Descriptive Analysis of 140 Patients Diagnosed with Malignant Mesothelioma at Consorci Sanitari Parc Tauli**

Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

**P3.03-055: Results of Second-Line Chemotherapy in Pleural Mesothelioma: A Single-Centre, Retrospective Study**

Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

**P3.03-056: Retrospective Study Comparing Two Frontline Chemotherapy Schemes in Unresectable Malignant Mesothelioma**

Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Tauli, Spain

**P3.03-057: Granulocyte Colony-Stimulating Factor-Producing Malignant Pleural Mesothelioma: Report of Two Cases**

Eisuke Matsuda, Saiseikai Imabari Hospital, Japan

**P3.03-058: A Retrospective Evaluation of 64 Hospitalised Malignant Pleural Mesothelioma (MPM) Patients**

Aida Ustamujic, Clinic for Lung Disease and TB Podhrastovi, Clinical Center University of Sarajevo, Bosnia and Herzegovina

**P3.03-059: Diaphragmatic and Pericardial Reconstruction by Heterologous Pericardial Patch after Extrapleural Pneumonectomy for Mesothelioma**

Domenico Galetta, European Institute of Oncology, Italy

**P3.03-060: Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO-CLICaP)**

Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

**P3.03-061: Burden of Disease and Management of Mesothelioma in France: A National Cohort Analysis**

Christos Chouaid, GRC OncoEst Creteil, France

**P3.03-062: Response to Pembrolizumab in a Malignant Pleural Mesothelioma with Sarcomatoid Histology: A Case Report**

Vera Wienhausen-Wilke, Klinikum Esslingen, Germany

**P3.03-063: Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer**

Sylvia Lee, University of Washington, Seattle Cancer Care Alliance, USA

**P3.04 SURGERY**

**P3.04 SURGERY - MISCELLANEOUS I**

**P3.04-001: Near-Infrared Fluorescent Identification of Lymphatic Flow in Non-Small Cell Lung Cancer**  
Andrey Akopov, Pavlov First State Medical University, Russia

**P3.04-002: Reducing the Amount of Resection after Induction Photodynamic and Chemotherapy in Inoperable Non-Small Cell Lung Cancer**

Andrey Akopov, Pavlov First State Medical University, Russia

**P3.04-003: Incidence and Outcome of Female Patients with Previous Breast Cancer Undergoing Curative Resection for Lung Cancer**

Sabrina Tahon, Medical University Vienna, Austria

**P3.04-004: The Risk Factor of the Thrombus Formation in Pulmonary Vein Stump after Left Upper Lobectomy for Lung Cancer**

Reiko Shimizu, Shizuoka Cancer Center, Japan

**P3.04-005: Evaluation of Noninvasive Lung Adenocarcinoma Using 3D-CT Imaging**

Katsuyuki Suzuki, Yamagata Prefectural Central Hospital, Japan

**P3.04-006: The Effect of Preoperative Multi-Disciplinary Support Commenced at Outpatient Clinic on Lung Cancer Patients**

Masafumi Kataoka, Okayama Saiseikai General Hospital, Japan

**P3.04-007: Detection of Brain Metastasis in Resected Lung Cancer with the New Postoperative Follow-Up Program**

Rie Nakahara, Tochigi Cancer Center, Japan

**P3.04-008: CATS: Computed Tomography-Assisted Thoracoscopic Surgery - A Novel Approach in Patients with Deep Intrapulmonary Lesions of Unknown Dignity**

Peter Hohenberger, Mannheim University Medical Center, Germany

**P3.04-009: Photodynamic Therapy (PDT) Turns 21: Indications, Applications and Outcomes for NSCLC**

Patrick Ross, Main Line Health System, USA

**P3.04-010: Changes of Right Lung Volume after Right Upper Lobectomy for Lung Cancer**

Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P3.04-011: Salvage Surgery for Isolated Local Recurrence after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small Cell Lung Cancer**

Hiroshi Date, Kyoto University Graduate School of Medicine, Japan

**P3.04-012: Bronchial Sutures in Anatomic Pulmonary Resections: The Clinical Experience of 865 Cases**

Aleksei Aksarin, Surgut District Clinical Hospital, Russia

**P3.04-013: The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma**

Morgan Cox, Duke University, USA

**P3.04-014: Surgical Outcome and Diagnosis of cN1 Lung Cancers after Introducing PET/CT**

Satoshi Shiono, Yamagata Prefectural Central Hospital, Japan

**P3.04-015: Usefulness of Carotid Ultrasonography for Postoperative Cerebrovascular Complication Prevention in Patients with Lung Cancer**

Sadanori Takeo, National Kyusyu Medical Center, Japan

**P3.04-016: Surgical Implications of the New Lung Adenocarcinoma Classification - Usefulness for Selecting Cases Undergoing Sublobar Resection**

Akira Shimamoto, Mie University Graduate School of Medicine, Japan

**P3.04-017: Wedge Resection for Clinical-n0 Non-Small Cell Lung Cancer**

Hiroaki Tsunetzuka, Kyoto Prefectural University of Medicine, Japan

**P3.04-018: Recurrence Dynamic of Completely Resected Non-Small Cell Lung Cancer in Perspective of Follow-Up Surveillance**

In Kyu Park, Seoul National University Hospital, South Korea

**P3.04-019: Nodal Upstaging in cN0 Lung Cancer is More Influenced by Tumor Size Than the Surgical Approach**

Florian Augustin, Medical University Innsbruck, Austria

**P3.04-020: Segmentectomy in Patients with Pulmonary Malignancies Using 3D-CT Reconstruction and Bronchovascular Separation**

Oleg Pikin, Hertzen Research Institute of Oncology, Russia

**P3.04-021: Readmission Rate is Not Increased with Shortened Hospital Stay after Lung Cancer Surgery**

Kei Yarimizu, Yamagata Prefectural Central Hospital, Japan

**P3.04-022: Unexpected Residual Carcinoma in the Bronchial Stump after Surgery for Lung Cancer**

Yohei Kameda, Kanagawa Cardiovascular and Respiratory Center, Japan

**P3.04-023: Perioperative Management of Antiplatelet Therapy in Patients with Coronary Stent Who Need Thoracic Surgery**

Shunki Hirayama, Juntendo University School of Medicine, Japan

**P3.04-024: Long-Term Outcome of Sublobar Resection versus Lobectomy for Stage I and II Non-Small Cell Lung Cancer**

Su Kyung Hwang, Asan Medical Center, University of Ulsan College of Medicine, South Korea

**P3.04-025: Repeated Lung Resection of Ipsilateral Lung Cancer That is Detected after Segmentectomy for Primary Lung Cancer**

Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, Japan

**P3.04-026: A Simultaneous Surgical Strategy for Patients with Lung Cancer and Severe Cardiac Diseases Requiring Surgical Treatment**

Jae Jun Jung, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

**P3.04-027: Feasibility of Lung Cancer Surgery for the Patient with Previous History of Coronary Artery Bypass Grafting**

Yutaro Koike, Juntendo University Hospital, Japan

**P3.04-028: The Left Upper Division Sacrifice for Bronchoplasty for an Adenoid Cystic Carcinoma of the Left Main Bronchus**

Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

**P3.04 SURGERY - MISCELLANEOUS II**

**P3.04-029: A Prospective Randomized Trial of Perioperative Administration of Neutrophil Elastase Inhibitor in Patients with Interstitial Pneumonias**

Mariko Fukui, Juntendo University School of Medicine, Japan

**P3.04-030: Examination of the Relevance of Prolonged Air Leakage after Pulmonary Resection for Lung Cancer and Factors Affecting Delayed Wound Healing**

Koshi Nagano, Bell-Land General Hospital, Japan

**P3.04-031: Intermittent Chest Tube Clamping May Shorten Chest Tube Duration and Postoperative Hospital Stay of Lung Cancer Surgery**

Shi Yan, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

**P3.04-032: Sternal Reconstruction with a Custom-Made Titanium Neosternum after Resection of a Solitary Breast Cancer Metastasis**

Ihsan Alloubi, CHU Oujda, Morocco

**P3.04-033: Digital Drainage System Reduces Chest Tube Duration and Hospitalization after Anatomic Pulmonary Resections for Malignancies**

Ricardo Terra, Instituto do Câncer do Estado de São Paulo - ICESP, Brazil

**P3.04-034: Differences between Pleurodesis Using Talc and Silver Nitrate at Different Times of Pleural Disease in Mice**

Ricardo Terra, University of Sao Paulo Medical School, Brazil

**P3.04-035: Pleurodesis with a 50% Glucose Solution for Post-Operative Pneumothorax, after Curative Lung Cancer Resection**

Hiroyuki Sumitomo, Tokushima Municipal Hospital, Japan

**P3.04-036: Clinical Analysis of the Association between Lung Cancer and Connective Tissue Disease**

Kazuhiro Nii, Kagawa University, Japan

**P3.04-037: Rare Giant Malignant Tumors of the Chest: Reconstructive Challenge**

Krzysztof Kurowski, Hospital Universitario del Vinalopo, Spain

**P3.04-038: Pulmonary Resection for Metastatic Pancreaticobiliary Cancer: Can It Be Justified as a Treatment of Choice?**

Toshiki Okasaka, Nagoya University Graduate School of Medicine, Japan

**P3.04-039: Solitary Fibrous Tumor of the Pleura Associated with Gynecomastia: A Case Report**

Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

**P3.04-040: A Rare Case of Intrathoracic Mass: Intrathoracic Desmoid Tumor**

Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

**P3.04-041: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case**

Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

**P3.04-042: 2 Cases of Fast-Growing Emphysematous Bullae Following Lobectomy for Lung Cancer**

Hirofumi Suzuki, Saiseikai Suita Hospital, Japan

**P3.04-043: Minimally Invasive Small Incision, Muscle- and Rib-Sparing Thoracotomy (miMRST) for Multiple Sclerosing Pneumocytomas**

Jun Zhang, The First Hospital Of China Medical University, China

**P3.04-044: Surgical Management of Arteriovenous Malformations: Our Experience**

Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

**P3.04-045: Primary Lung Cancer Presenting as Pneumothorax**

Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

**P3.04-046: Cases of Surgical Resection of Post-Operative Lymph Node Recurrences from Primary Lung Cancer**

Ema Mitsui, Okayama Saiseikai General Hospital, Japan

**P3.04-047: The Incidence and Outcome of Hoarseness after Systematic Upper Mediastinal Nodal Dissection by Radical Surgery for Primary Lung Cancer**

Yoshifumi Sano, Ehime University Medical School, Japan

**P3.05 PALLIATIVE CARE/ETHICS**

**P3.05 PALLIATIVE CARE/ETHICS - SYMPTOMS, THERAPEUTIC INTERVENTIONS**

**P3.05-001: Psychological Intervention to Treat Distress and Suffering Experienced by People with Lung Cancer Nearing the End-Of-Life**

Mary Duffy, Peter MacCallum Cancer Centre, Australia

**P3.05-002: Malnutrition is an Independent Risk Factor on Survival on EGFR Mutated Patients Diagnosed with Non-Small Cell Lung Cancer**

Ana Gonzalez-Ling, Instituto Nacional de Cancerología, Mexico

**P3.05-003: Anxiety and Depression in Patients with EGFR+ NSCLC Receiving Treatment with TKIs**

Ana Gonzalez-Ling, Instituto Nacional de Cancerología, Mexico

**P3.05-004: Psycho-Social Function and Caregiver's Burden in Patients with Advanced Lung Cancer**

Annamaria Catino, Clinical Cancer Center "Giovanni Paolo II", Italy

**P3.05-005: Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer**

Lore Decoster, UZ Brussel, Belgium

**P3.05-006: Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnoea in Lung Cancer and Mesothelioma**

Anna Minchom, Royal Marsden Hospital NHS Foundation Trust, UK

**P3.05-007: Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC**

Mototsugu Shimokawa, National Kyushu Cancer Center, Japan

**P3.05-008: Mindfulness-Based Stress Reduction Added to Care as Usual for Lung Cancer Patients and Their Partners: A Randomized Controlled Trial**

Miep Van Der Drift, Radboud University Medical Centre, Netherlands

**P3.05-009: Medical Marijuana and Lung Cancer: Patients' Knowledge and Attitude towards Its Use**

Raja Mudad, University of Miami, USA

**P3.05 PALLIATIVE CARE/ETHICS - QOL, OTHERS**

**P3.05-010: Developing Tools for a Successful Thoracic Rapid Tissue Donation Program**

Andrea Shaffer, H Lee Moffitt Cancer Center and Research Institute, USA

**P3.05-011: Importance of Assessment of Malnutrition Risk in Lung Cancer Patients**

Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

**P3.05-012: Assessment of the Impact of Palliative Care on the Quality of Life in Advanced Non-Small Cell Lung Cancer Patients - A Longitudinal Study**

Fawaz Pullishery, Educare Institute of Dental Sciences, India

**P3.05-013: Development of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program**

Jamie Studts, University of Kentucky College of Medicine, USA

**P3.05-014: Evaluation of Hyponatraemia in Lung Cancer Patients: A U.K. Teaching Hospital Experience**

Joyce Thompson, Heart of England NHS Trust, UK

**P3.05-015: Sleep Quality and Fatigue in Patients with Lung Cancer**

Nudra Malik, Lahore college women university, Pakistan

**P3.05-016: Mitochondrial Pathway Mediated Apoptosis is Involved in Erlotinib-Induced Cytotoxicity in Hepatic Cells**

Xueqin Chen, Hangzhou First People's Hospital, China

**P3.05-017: Survivor Guilt: The Secret Burden of Lung Cancer Survivorship**

Kay Bayne, Lung Cancer Alliance, USA

**P3.05-018: Assessment of Skeletal Muscle Mass as a Predictive Factor for Chemotherapy Toxicity and TTP in Advanced NSCLC Patients with Cancer Cachexia**

Drazena Srdic, University Hospital Centre Zagreb, Croatia

**P3.05-019: Patients with Advanced Lung Cancer: What Do They Know, What Would They Like to Know, What Should They Know about Their Disease**

Elke Vandenbroucke, AZ Monica, Belgium

**P3.05-020: Patients' Perception of Rapid Onset Opioids**

Choonhee Son, Dong-A University Hospital, South Korea

**P3.06 TRIAL DESIGN/STATISTICS**

**P3.06 TRIAL DESIGN/STATISTICS - CLINICAL STUDIES**

**P3.06-001: Phase I/II Study to Evaluate Safety and Efficacy DCVAC/LuCa with 1st Line Chemotherapy +/- Immune Enhancers vs Chemotherapy, Stage IV NSCLC**

Libor Havel, Thomayer Hospital, Czech Republic

**P3.06-002: ATLANTIS Trial: Phase III Study of PM01183/Doxorubicin vs. CAV or Topotecan in SCLC after One Platinum-Containing Line**

Anna Farago, Massachusetts General Hospital, USA



**P3.06-003: SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomised Phase III Trial**

David Landau, Guy's and St Thomas' NHS Foundation Trust, UK

**P3.06-004: A Systematic Review of Outcome Reporting in Studies of Radical Radiotherapy and Chemoradiotherapy in Lung Cancer**

Sarah Cruickshank, University of Aberdeen, UK

**P3.06 TRIAL DESIGN/STATISTICS - OTHERS**

**P3.06-005: Blastomatoid Pulmonary Carcinosarcoma, Combined with Lepidic Adenocarcinoma**  
Yu-Deok Choi, Chonnam National University Medical School, South Korea

**P3.06-006: Endpoints in Reports on Clinical Trials for Advanced Lung Cancer**

Matjaz Zwitter, Institute of Oncology Ljubljana, Slovenia

**P3.06-007: The Consequence of Incomplete Follow-up in Hospital-based Survival Study as Compared with National Vital Status-based Results**

Jin Soo Lee, National Cancer Center, South Korea

**P3.06-008: Employing Remote Web Consenting and Social Media to Facilitate Enrollment to an International Trial on Young Lung Cancer**

Barbara Gitlitz, University of Southern California Keck School of Medicine, USA

**P3.06-009: Multiple Oral Presentations at Major International Conferences from a Single Clinical Trial Are Common**

Edward Garon, UCLA Medical Center, USA

**P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH**

**P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH - THERAPY AND ECONOMICS**

**P3.07-001: Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing**

Oliver Gautschi, Cantonal Hospital Luzern, Switzerland

**P3.07-002: Complications and Costs of Diagnostic and Post-Progression Biopsies among Patients with Non-Small Cell Lung Cancer (NSCLC)**

Ronan Kelly, Johns Hopkins University, USA

**P3.07-003: Effectiveness of Pemetrexed in Advanced Non-Squamous NSCLC and Estimation of Its Impact on Public Health in France**

Katherine Bellebaum Winfree, Eli Lilly and Company, USA

**P3.07-004: Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data**

Elizabeth Dudnik, Davidoff Cancer Center, Israel

**P3.07-005: US Healthcare without Payer Restrictions or Out-Of-Pocket Costs: Treatment of Advanced NSCLC in the Military Health System**

Matthew Peterson, San Antonio Military Medical Center, USA

**P3.07-006: Estimating Time Equivalents for Cancer Side Effects among Lung Cancer Survivors and Caregivers: A Discrete-Choice Experiment**

Andrea Ferris, LUNGeivity Foundation, USA

**P3.07-007: Compassionate Use Program for New Cancer Drugs in Israel - Shortcut for Reimbursement Approval**

Hiba Rechtes, Davidoff Cancer Center, Israel

**P3.07-008: METASTATIC NSCLC: Treatment Reality from 182 Cases of Lung Adenocarcinoma in a Brazilian Public Cancer Health Service**

Leonardo Lago, Hospital Sao Lucas da Pucrs, Brazil

**P3.07-009: Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan**

Bin-Chi Liao, National Taiwan University Hospital, Taiwan

**P3.07-010: Economic Evaluation of Gefitinib vs. Erlotinib for First Line in NSCLC EGFRm under the Perspective of Brazilian Health System**

Marcelo Custodio, AstraZeneca, Brazil

**P3.07 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH - OTHER- GEOGRAPHICAL DIFFERENCES**

**P3.07-011: Geographical Variation in the Use of Radiotherapy and Surgical Resection for Treatment of Non-Small Cell Lung Cancer in England**

Daniela Tataru, Public Health England, UK

**P3.07-012: Disparities in Guideline-Concordant Treatment for Node-positive Non-Small Cell Lung Cancer Following Surgery**

David Harpole, Duke University, USA

**P3.07-013: Determining EGFR and ALK Status in a Population-Based Cancer Registry: A Natural Language Processing Validation Study**

Bernardo Goulart, Fred Hutchinson Cancer Research Center, USA

**P3.07-014: Patient and Caregiver Experiences: Identifying Gaps in Access to High Quality Care for Lung Cancer Patients**

Jennifer King, Lung Cancer Alliance, USA

**P3.07-015: Patterns and Risk Factors of Patient Flows across Different Geographic Health Service Units for Lung Cancer Surgery**

Emanuela Taioli, Icahn School of Medicine at Mount Sinai, USA

**P3.07-016: Ontario's Episode-Based Funding Model Reveals Practice Variation in Adjuvant NSCLC Chemotherapy**

William Evans, Cancer Care Ontario, Canada

**P3.07-017: Joinpoint Regression Analysis of Lung Cancer Mortality, Turkey**

Sedat Altin, Erzincan University Faculty of Medicine, Turkey

**P3.07-018: New European Clinical Trial Regulation: What's Going On?**

Francesca Arizio, AOU San Luigi Gonzaga, Italy



**P3.07-019: AMDAT Lung, An Ideal Lung Cancer MDT Dataset**

Emily Stone, St Vincent's Hospital, Australia

**P3.07-020: Implementation of an International Value-Based Standard Set of Outcomes for Lung Cancer Patients in a Brazilian Center**

Clarissa Baldotto, Instituto COI de Educação e Pesquisa (COI) and Núcleo de Oncologia Torácica (NOT), Brazil

**P3.07-021: Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer**

Ellias Abreu Lima, Instituto Mário Penna, Brazil

**P3.07-022: Progress against Non-Small-Cell Lung Cancer (NSCLC) Compared to Other Solid Tumors**

Silvia Paddock, Rose Li and Associates, Inc., USA